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1. Introduction 
1.1 Developmental Origins of Health and Disease, DOHAD 
  The  DOHAD  hypothesis  proposes  the  idea  that  environmental  fetal  exposure  can  alter  the 
epigenome  of  that  individual,  resulting  in  an  altered  phenotype.  That  this  alteration  is  set  to  be 
advantageous for the environment the individual is exposed to during its life-time. 
1.1.1 Evidence for DOHAD 
Most  of  the  evidence  for  the  DOHAD  hypothesis  in  humans  comes  from  two  different  natural 
exposures.  The  two  seminal  studies  that  provide  data  to  support  the  DOHAD  hypothesis  are  the 
Hertfordshire cohort born between 1911 and 1930, and the Dutch Hunger Winter cohort who were born to 
mothers pregnant during the winter of 1944-1945.  
For the Hertfordshire cohort the first chief health visitor and lady inspector of midwives for the 
county of Hertfordshire, Ethel Margaret Burnside (Syddall 2005), instigated the collection of in-depth data 
about all the children born in Hertfordshire while she was practicing there. This data included the birth 
weight, body length and head circumference of each new born. This data was then stored and forgotten 
until it was rediscovered years later. Records of birth weight, body length and head circumference provided 
surrogate information on early life nutrition. All of the individuals who could be traced and who were still 
living in Hertfordshire were recontacted and correlations between growth restriction during pregnancy and 
development of chronic diseases in later life were established (Syddall 2005). Positive correlations were 
found between a low birth weight, surrogate measure for reduced fetal nutrition, risk of developing type II 
diabetes, increased blood pressure (Hales 1991), and risk of developing metabolic syndrome (McKeigue 
1998).  
The Hertfordshire cohort has been used to link the development of chronic diseases to early life 
exposures, however this study has had to use surrogate measures, birth weight in relation to crown/rump 
length, to estimate if a nutrition restriction has occurred. The actual diet that the mother was exposed to is 
not available.  
Another example of clear correlation between early life environmental exposures and risk of chronic 
disease in later life is an imposed nutritional restriction within a Dutch population who could not get food 
due to restrictions on movements during the Second World War. German occupation of the Dutch area that 
was affected lead to the formation of an allied response known as ‘Operation Market Garden’. Taking place 
over nine consecutive days (17-25 September 1944) airborne forces- Market, and ground forces- Garden, 
stormed the area to try and remove the German forces. After the failure of this attempt, mainly blamed on     Chapter 1  Introduction 
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the weather, the amount of food available was severely decreased.  This was mainly due to the strike of the 
Dutch railway workers in an attempt to aid the Allied attack, but once the attack had failed the lack of 
transportation of food stuffs during this period caused massive shortages and many Dutch people starved to 
death during the following winter.   
This cohort is especially relevant as the individuals were known to have experienced famine during 
pregnancy and anthropomorphic surrogate measures for nutritional intake are not used. The effects seen 
therefore are those induced by direct nutritional reduction only. Studies of this cohort have found that those 
individuals  that  had  been  exposed  to  famine  during  gestation  had  decreased  glucose  tolerance  and 
increased insulin levels indicative of type II diabetes, which was independent of their current BMI, at both 50 
and  58  years  of  age  (Ravelli  1999;  Painter  2006).  Exposure  to  famine  has  also  been  linked  with  the 
development of obesity with women whose mothers were exposed to the Dutch Famine in early gestation 
showing  significantly  higher  BMI  by  7.4%  (95%  CI:  0.7%,  4.5%)  than  that  of  non-exposed  women. 
Interestingly this association was not found in those individuals whose mothers were exposed during either 
mid or late gestation or in men (Ravelli 1999). This implied that there are developmental windows that affect 
the offspring differently if the exposure is experienced at different times within development. Although 
effects have been seen in some papers, others have reported no transgenerational effects and some have 
been sex linked with the trait only being passed down from mother to daughter and not being seen in the 
sons (Painter 2006).   
Both of these cohorts provide evidence that development of many chronic diseases have a basis in 
early life. These findings have also been replicated in other cohorts throughout the world. This type of 
evidence has been found for ischemic heart disease in British, American, Indian, Swedish, Finish, Dutch, 
Icelandic  and Danish  populations  (Huxley 2007),  and  for  type  II diabetes  in Japanese, Indian, Icelandic, 
Swedish, Finnish, American, Dutch, Canadian, British and Chinese populations (Whincup 2008). Thus, the 
evidence to support the effect of early life in later development of chronic diseases in humans is substantial.  
1.1.2 The DOHAD Hypothesis 
Epidemiological evidence resulted in the proposal of the developmental origins of health and disease 
(DOHAD), or thrifty hypothesis (Hales 2001), that suggests that as an organism develops, its capacity for 
developmental plasticity decreases, but the effect of the environment increases, as seen in figure 1. This is a 
mechanism that allows the organism to adapt to the environment it should find itself being born into. This is 
an advantageous adaptation for the individual allowing it to utilise its environment effectively and reach 
reproductive age in peak condition. This can mean that the individual appears to have a normal phenotype 
but has actually adapted itself, and is at greater risk of developing diseases later in life.       Chapter 1  Introduction 
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This adaptive response allows the alterations to the phenotype of the organism within a single 
generation that then can  then be altered back if the environment reverts back for its offspring. These 
alterations are suspected to be epigenetic in nature as there is no alteration within the DNA sequence and 
natural selection as a result of random mutagenesis occurs over much longer time frames. Some of the most 
obvious visual examples of an adaptive response to environment are known within mammals that have a 
short life-span, such as the meadow vole, meaning that they have two or more litters of young during a 
single year. The environmental exposures here are thought to be day length and temperature. This then 
alters the epigenetic profile changing the phenotype of the young to produce either the summer or winter 
coat (Gluckman 2005). 
These adaptations are meant to be advantageous to the organism for example if there is a reduction 
in the availability of nutrition a small size coupled with a slower metabolism can help survival, however if 
there is an abundance of nutrition a larger size with increased metabolism would have advantages for 
reproduction (Bateson 2004). 
Problems  occur  when  the  environmental  exposure  during  development  does  not  match that  in 
which the organism encounters in its adult life. This mismatch in environments is thought to be the basis of 
increased risk of disease within these individuals (Godfrey 2007). 
 
Figure 1: Diagrammatic representation of the effect of the environment during development. As the age of the 
individual increases its developmental plasticity decreases, this is a natural developmental stage which prevents 
differentiated parts of the body altering themselves. While this happens, the effect of environmental exposure 
increases, this allows for the growing fetus to alter some of its phenotypes to become better adapted to the 
environment it will experience when outside the womb. This adaptive programming can cause an increase in the 
individuals’ disease risk if the environment it is adapted for is not the actual environment that it experiences during its 
lifetime. Reproduced from (Godfrey 2007).      Chapter 1  Introduction 
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Diseases known to be associated with increased risk from altered maternal environment such as 
under nutrition include decreased glucose tolerance, type II diabetes, coronary artery disease (Painter 2006) 
and obesity (Ravelli 1999). As an organism is developing its epigenetic profile has to adapt as each level of 
development is reached and then passed. It is at this time that the organism is most susceptible to any 
interference  that  may  affect  it  at  this  level.  This  does  not  mean  that  this  is  the  only  time  during  the 
organism’s life span that the epigenome will be altered but it is the most susceptible time for changes to 
occur. 
1.1.3 Animal Models of DOHAD 
Given that in humans studies, to establish the effects of environmental exposure during mothers or 
grandmothers  pregnancy  and  to  investigate  the  mechanisms  behind  these,  would  take  many  years,  a 
number of animal models for developmental programming effects have been developed (Nathanielsz 2006). 
In general these models alter the extent or content of nutrition that is allowed to reach the fetus across the 
placenta.  
Animal models allow for the direct effect of nutrition to be studied, as with the Dutch Hunger Winter 
cohort. The model of reduction of a single food group within the food source is more representative of a 
typical situation found within normal human situations.  The reduction of total nutrition, such as the Dutch 
Hunger Winter Famine, is more severe and requires unusual circumstances for exposure within a human 
population. 
Implementing a nutritional challenge can be done in several ways. One of these is placental ligation, 
where the blood flow is restricted from the placenta leaving less to reach the fetus, thus reducing the total 
nutrition it receives.  Another way is to alter the amount, or balance, of nutrients the mother is allowed 
during pregnancy. This could be altering the total calorific intake to the dam, total under-nutrition, or it 
could be that the normal animal food is replaced with another type that contains less of a certain food 
group, such as protein, and is then made up with another group to keep the overall diet isocalorific.  
As detailed later in this chapter, the timing of the challenge has an effect on the phenotype of the 
offspring.  This  is  due  developmental  windows.  Exposure  to  a  dietary  challenge  in  the  early  stages  of 
gestation can effect the organs of the fetus while an exposure seen in later gestation will not effect the 
organs as they are already formed but could effect the birth weight as the later period is involved with 
increasing the size of the fetus and not the development of the fetus. This is important to note with the 
Hertfordshire cohort as it used birth weight as a surrogate measure for fetal nutrition. Due to these effects, 
with nutritional challenges it is important to note the time and type of challenge that is given.     Chapter 1  Introduction 
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1.1.4 Offspring Effects 
1.1.4.1 Maternally Inherited Offspring Effects 
  Many studies have looked at the effect of the maternal line, usually through nutrition, as in the 
above examples. As there are no other human examples than those previously discussed, the following 
studies look at data from animal models. Most of these studies have utilised a rat model. Severe dietary 
challenges have  been used to  look  at different  aspects  of  nutrition  alteration in  the  development  and 
function  of  the  organs  and  tissues  found  to  be  associated  with  disease.  For  example,  an  increase  in 
vasoconstriction, but no change in vasodilation, was found in male rats whose dams were given a severe 
restriction of total nutrition in-take from conception until term, and then a high fat diet, with 45% of their 
energy in-take derived from fat, for the offspring until culled (Torrens 2008). These rats had endothelial 
dysfunction,  a  symptom  of  cardiovascular  disease  and  metabolic  syndrome.  This  study  involved  four 
different groups, those on control diet throughout, birth dams and offspring; those dams restricted nutrition 
during pregnancy but offspring on control; those dams on control diet and the offspring on a high fat diet 
from birth until culling, and those dams on restricted nutrition during pregnancy and then their offspring on 
the high fat diet from birth until culling.  Interestingly it was the two groups where the dams experienced 
nutrition restriction during their pregnancy that showed endothelial dysfunction showing that the level of 
maternal nutrition is as important as the high fat diet in these vascular alterations. 
  The reduction of methyl groups within the pregnant dams diet, essential for epigenetic changes such 
as  DNA  methylation  at  CpG  sites  to  be  made,  resulted  in  male  offspring  with  an  almost  40%  higher 
concentration of insulin within their system when compared with controls, indicating a shift towards type II 
diabetes (Maloney 2011). This diet was given to dams from three weeks prior to conception and for the first 
five  days  of  gestation.  When  plasma  homocysteine  levels,  a  source  of  methyl  groups  that  is  provided 
endogenously, were checked, those rat dams that had been fed a methyl-deficient diet had increased levels. 
This  could  be  due  to  the  dam  trying  to  make  up  for  the  loss  of  methyl  groups  within  the  diet  by 
supplementing with her own during this period (Maloney 2011) . 
The utilisation of models involving the reduction of one source of essential food is fairly common 
place within the literature, with one of the most common being a reduction in protein. This also acts as a 
methyl-donor source. The effects of different levels of reduction within this food group have been studied in 
several different organs. Gressens et al. (1997) used a 75% reduction of protein, which was supplemented 
within  the  diet  to  produce  an  isocalorific  result  between  the  control  and  treatment  group  rats,  from 
confirmation of pregnancy until 2 weeks of gestation to look at the development of the brain in the resulting 
offspring. They found that there was no change in the overall rat brain weight; however the development of 
the brain was altered, smaller cortical thickness, in the animals on the low protein diet. This difference only     Chapter 1  Introduction 
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occurred at 2 weeks postpartum and all the animals’ brains were similar at the next observed time point 
indicating some sort of catch up growth within the treatment animals (Gressens 1997). 
  A smaller reduction of protein, around 50% but keeping an isocalorific total diet, in mice was given 
to three different groups (Chen 2009). Reduced protein was given from conception until the end of lactation 
for  one  group,  from  conception  until  birth  for  another,  and  the  final  group  was  on  the  control  diet 
throughout. The first group describes a diet where the offspring experience low protein diet throughout its 
early life, mothers pregnancy and then after until weaning, the second experiences a low protein diet and 
then a normal diet allowing a period of catch-up growth which was not present in the first group. This had an 
effect on the life-span of the offspring with the first group have a shorter life than those in the second group. 
When compared to control, the first group had improved insulin sensitivity, showed lower organ weights, 
e.g. heart and liver, and had smaller body weights up to three weeks of age.  
The same level of dietary restriction, 50% maternal protein, has been used in several rat studies, 
although the exposure has been made over different time periods. When this diet was given for two weeks 
before conception until term, the offspring from the protein restricted group had increased blood pressure 
and levels of glucocorticoid enzymes within their brain and liver, and had decreased binding capacity of type 
II glucocorticoid receptors (Langley-Evans 1995). It was postulated within this paper that the reduction in the 
binding capacity of these receptors could be the reason behind the increase in blood pressure within these 
individuals. Other studies have started dams on a 50% protein restricted diet from conception until term. 
One study found a decrease in the level of methylation of both the PPARα and GR promoters of the male 
offspring from the protein restricted dam group. This was found to persist through to the F2 generation as 
well (Burdge 2007). The same diet run over the same time frame showed hypertension within the male 
offspring but not in the female offspring (Woods 2003). 
Interestingly several of these studies looked at the effect of maternal nutrition on both female and 
male offspring, however most effects are seen within the male offspring. This could suggest a sex linked 
effect.  
1.1.4.2 Paternally Inherited Offspring Effects 
Fewer studies have been undertaken examining the effect of paternal programming. In humans the 
male line seems to affect the offspring differently in some organs depending on the sex of the offspring. A 
study by Pembrey et al. looked at the effect of smoking on the BMI of the male’s offspring. It shows that if 
the male started smoking early in life, before the age of 11 years, their sons, but not their daughters had an 
increased BMI at the age of 9 (Pembrey 2006). More recently, Arshad et al. (2011) studying a longitudinal     Chapter 1  Introduction 
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birth cohort from the Isle of Wight found that for childhood asthma, maternal asthma was significant in girls, 
but not in boys, while paternal asthma was associated with asthma in boys, but not in girls  (Arshad 2011). 
  Animal  models  have  also  been  utilised  to  examine  at  the  effect  of  altered  diet  on  male  line 
inheritance. In the rat, effects of a high fat diet have been studied. Males were exposed to the high-fat diet 
from 4 weeks of age until 13 weeks, when they were mated to the females who remained on a control diet. 
This dietary exposure altered the phenotype of the fathers making them fat, with an increase in their glucose 
tolerance and insulin resistance indicating type II diabetes development. The daughters of these males were 
shown to have increased glucose tolerance but a decrease in their insulin production, due to dysfunction of 
the beta cells. This indicates a shift in their metabolism towards both type I, reduced insulin production, and 
type II, glucose tolerance, diabetes (Ng 2010). 
  A mouse model was also used to look at the male effect on metabolic systems. The diet that is used 
in this study is of more interest as it involves a reduction of approximately 50% in protein content. Male mice 
were randomly allocated to each diet which was introduced after weaning, around 21 days, and continued 
until 9-12 weeks of age when males were mated with females who had remained on the control diet. Both 
male and female offspring had altered gene expression of genes in the cholesterol and lipid metabolism 
pathways in liver tissue. However the number of animals in each group was small and the effect may not 
have been due to the reduction in protein but by an increase in sucrose that was also present in the diet. The 
methylation levels within the parental (F0) sperm were examined and found to be different dependent on 
the litter from which they came, but were not different dependent on the dietary exposure (Carone 2010). 
1.1.4.3 Transgenerational Effects 
The effect of epigenetics has been observed over more than just a single generation. For example, in 
humans, transgenerational effects have been observed where the initial environmental exposure occurred in 
F0 generation and was still present in F2. In this study F0 exposures such as poor nutrition or smoking during 
the slow growth period of the F0 generation, resulted in effects on life expectancy and growth through the 
male line and female line in the F2 generation, although there had been no further exposure (Pembrey 2006; 
Kaati 2007). 
Studies of human cohorts have also provided evidence of transgenerational effects of environmental 
exposure  on  chronic  disease  risk.  Kaati  and  colleagues  studied  a  Swedish  cohort  of  descendants  of  a 
population from northern Sweden where food availability within the population could be established from 
harvest records. In this cohort, sex dependent effects of poor food availability were evident, with their 
grandmothers’ nutrition affecting their granddaughters’ length of life and the grandfathers’ affects their 
grandsons’. In general terms if there was a poor period of food availability before puberty then the F2,     Chapter 1  Introduction 
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granddaughters and sons, had an increased risk of death at a younger age, i.e. an increased mortality risk 
ratio (Kaati 2007). This study shows that there are risk factors from nutrition that can be effective through 
both the female and male lines and that this can be seen transgenerationally. 
From studies it appears that the female line can affect the offspring for several generations, while 
the  male  line  only  appears  to  effect  the  next  generation.  The  reason  for  this  could  be  due  to  the 
development  of  the  sperm.  As  mentioned  above  the  female  ova  are  laid  down  during  their  mother’s 
conception and their gestation, leaving markers from this period. The male sperm is developed as the male 
hits puberty. This means that the environment that the male experiences during gestation is not present and 
so will have little or no effect when compared with that of the female line.     
1.1.5 Mechanisms of DOHAD 
As previously mentioned, organisms are predicted to be able to change their phenotype between one 
generation and the next. This led to the proposal that these changes were due to epigenetic alterations. 
These epigenetic changes are not permanent and do not alter the DNA sequence. They are usually caused by 
additions of chemical groups to key residues within regulatory sections of a gene, or of a histone protein 
causing it to coil or relax allowing transcription factors to copy the genes around that histone.  
Changes within a gene promoter or enhancer region will usually result in a reduction of expression of 
the gene, however this is not always the case and some epigenetic markers increase the expression of the 
gene they are attached to. These changes occur naturally during development allowing for different genes to 
be switched on and off as required. They are essential for the organism’s development.  
The term epigenetics refers to changes in phenotype or an organism at either the molecular (e.g. 
gene  expression),  cellular  or  physiological  level  (e.g.  appearance)  that  are  heritable  mitotically  and/or 
mieotically. These changes are caused by chemical group additions to the DNA, or changes in the way DNA is 
packed within the nucleus (chromatin structure), rather than changes in the actual DNA sequence. The term 
was created (Waddington 1956) to describe how a developing embryo’s genetic information would interact 
with the environment to determine development (Dolinoy 2006). This mechanism could account for part of 
the missing heritability within the genome. Epigenetic effects are reversible and so can be switched on and 
off  depending  on  the  needs  of  the  cell  at  that  point  in  time.  Epigenetic  mechanisms  involve  post-
translational modification of histones, e.g. acetylation and methylation, methylation of DNA bases and the 
production of non-coding microRNAs.  
The addition of methylation or acetylation residues to the histone subunits alters their configuration 
and secondary structure allowing change between an open chromatin structure, euchromatin, and a closed 
chromatin  structure,  heterochromatin.  This  alteration  in  structure  changes  accessibility  of  the  DNA  to     Chapter 1  Introduction 
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transcription factors that regulate mRNA transcription, and hence gene expression. Methylation of DNA 
bases tends to occur at CpG sites in the genome. The combination of the cytosine residue (C) followed by the 
phosphate link (p) then a guanine residue (G) is needed for the binding of a methyl group to the cytosine 
residue. Methylation of the DNA can prevent or alter the number of transcription factors binding to the DNA.  
There are areas of the genome that contain many CpG sites following each other. These areas are known as 
CpG islands and are usually associated with the promoters of genes. The addition of a methyl group to the 
DNA  does  not  automatically  mean  that  those  genes  associated  with  that  promoter  region  have  their 
expression reduced or stopped; it can also produce an increase in the expression of that gene.  
1.1.5.1   Histones 
  To help protect and regulate DNA within the nucleus the DNA strand of bases are kept in tight 
structural hold. The first level of organisation of this structure is a double helix which holds the two stands of 
a single chromosome together. This double helix coil is then wrapped around structures known as histones. 
Histones are a complex of eight subunits of protein that form a ring shape (Strahl 2000). When the DNA is 
unwound from these proteins transcription can occur as the required apparatus can only get to the DNA 
once it has been unwound.  This enable the cell to keep the DNA organised in as compact a structure as 
possible. Histone subunits undergo a number of post-translational modifications including acetylation and 
methylation  at  specific  residues  in  tails  that  protrude  from  the  nucleosome  core.  Collectively,  these 
combinations  of  post-translational  modification  are  referred  to  as  the  ‘histone  code’,  and  through  the 
recognition of this code by a range of chromatin remodelling proteins, regulate chromatin confirmation, and 
hence gene expression. 
1.1.5.1.1 Histone Acetylation  
  Histone acetylation is the addition of an acetyl group to the chromatin that holds the DNA coiled 
around the histones. This is mediated by enzymes known as histone acetyltransferase (HAT)  (Ito  K  2005). 
Histone acetylation generally favours an open chromatin configuration allowing gene transcription.  
1.1.5.1.2 Histone Methylation 
This is similar to acetylation except that a methyl group is added to one of the chromatin proteins. The 
enzyme used to do this is known as Histone methyl transferase (Strahl 2000). There are several enzymes that 
can reverse this methylation step (Swiqut 2007). 
1.1.5.1.3 Histone Deacetylase, HDACs 
  Histone deacetylase’s (HDAC’s) are enzymes which remove acetyl residues from the histones. The 
addition of acetyl residues to specific residues on the N-terminal tails of histones generally favours a closed     Chapter 1  Introduction 
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chromatin configuration preventing gene transcription. Given this, HDAC enzymes are critical to control gene 
expression within the cells.  There are several classes of HDACs, class I includes HDACs 1, 2, 3 and 8, class II 
includes HDACs 4, 5, 6, 7, 9 and 10, class III includes SIRT 1, 2, 3, 4, 5, 6 and 7 and class IV includes HDAC 11 
(De Ruijter 2003; Senqupta 2004; Dokmonovic 2007). 
 
Figure 2: Action of HDAC and HAT enzymes on the configuration of chromatin. Reproduced from(Barnes 2006). 
1.1.5.2  Micro-RNAs 
Non-coding microRNAs are short lengths of messenger RNA, around 20 base pairs in length, which 
do not code for any protein. These short non-coding RNAs bind to specific combinations of nucleotides often 
found in the 3’ UTRs of messenger RNAs to prevent or reduce translation of the RNA into the nascent protein 
(Tate 1993; Peterson 2004; Makeyev 2008). 
1.1.5.3   DNA Methylation 
DNA methylation is the addition of methyl groups to cytosine bases in the DNA. This is done by an 
enzyme known as DNA methyltransferase (DNMT) of which there are three subtypes. These are DNMT1, 
DNMT2 (now  known as  TRDWT1) and  DNMT3,  with family members  DNMT3A,  DNMT3B  and DNMT3L. 
(Langer  2004)  DNMT1,  3A  and  3B  methylate  DNA  in  mammalian  cells  to  establish  regulation  of  gene 
expression, DNMT3L is thought to methylate with the result of effecting maternal imprinting. DNMT2 (or 
TRDWT1) does not methylate DNA (Goll 2006). 
Methyltransferases are used normally in the cell to regulate transcription. The addition of these groups 
prevents transcription from occurring and reduces the expression of the gene into which they have attached. 
Addition of methyl groups usually occurs in CpG islands in the promoters of genes. CpG islands are areas of 
DNA rich in both cytosine and guanine bases, and make up more than 50% of the genome. These areas are 
usually between 300-3,000 bases long. This interference may not totally prevent transcription of the gene     Chapter 1  Introduction 
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but can lower the total level of the resultant protein within the affected tissues. Other enzymes, such as DNA 
demethylase (Bhattacharya 1999), in the cell can be used to reverse this effect by removing the methyl 
group. It is the effect of the disease which alters the natural balance of these two sets of antagonistic 
enzymes and results in the phenotype displayed by the disease. The methylation status of the genome can 
be  affected  by  diet,  environment,  naturally  occurring  mutations  and  pre-existing  inherited  methylation 
patterns (Jirtle 2007). 
Methylation  patterns  can  also  be  inherited  from  either  parent  as  well  as  being  affected  by 
environmental  cues.  Another  example  of  methylation  is  imprinting.  This  form  of  methylation  is  non-
Mendelian but is parent of origin dependent and does involve inherited patterns. It involves the alteration of 
gene expression to ensure correct levels are found in the offspring, such as on the X-chromosome (Jirtle 
2007).     Chapter 1  Introduction 
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1.2  Asthma 
Asthma is a respiratory disease that causes reversible airway inflammation when in the presence of 
a certain stimuli. It is a complex disease that involves many different genes and their interaction with the 
environment. There are several forms of asthma: childhood asthma that begins in childhood and the patient 
grows out of it over time, persistent asthma where the disease is diagnosed during childhood and persisted 
during that individual’s life, and adult onset asthma (McLean 2011). 
1.2.1 Clinical Symptoms 
An individual may exhibit no symptoms when there is no stimulus. However once the individual has 
been exposed to that stimulus, whatever it may be, symptoms become apparent. The clinical symptoms 
include wheezing, coughing, shortness of breath and tightness in the chest. Not all of these symptoms may 
occur at the same time, and some may never occur.  
Wheezing  can  be  heard  using  a  stethoscope  with  each  breath.  It  can  be  difficult  to  tell  if  the 
wheezing is due to asthma, or resulting from a respiratory infection. Persistent wheezing is usually not due 
to an infection. Coughing is common as the airways of asthma sufferers tend to produce more mucus than 
normal airways. Shortness of breath and tightness in the chest could also be from respiratory infection but 
are common in asthma as the lungs become inflamed. 
Asthma can be triggered by many different types of stimuli and it is these many, and varied, causes 
that make treating asthma difficult. Some causes of asthma are listed in table 1. 
Table 1: Causes of asthma exacerbations. 
Cause  Aspects of cause that are triggers. 
Allergens  Most  asthma  exacerbations  occur  in  response  to  allergic  reactions  to 
common allergens. These include: 
Furry and feathered animals that release dander, small skin particles, that 
can  result  in  irritation  to  the  airways.  Salvia  and  urine  can  also  cause 
problems 
Mould and Fungi: spores released from these organisms. 
Pollen: especially from plants such as trees and grass 
House-dust Mite: specifically their droppings which can build-up in carpets, 
bedding, soft furnishings and soft toys 
Food: allergy can develop for many foods including cow’s milk, eggs, fish, 
nuts and yeast, as well as some colourings and preservatives. 
Air Pollutants  This is mainly from car exhaust fumes 
Cold and Viral 
infections 
This is one of the most common cause of asthma exacerbations  
Emotions  Any emotion that increases the breathing rate, such as stress or extreme 
laughter, can increase the risk of inhaling a stimulus  
Exercise  Exercise also increases the breathing rate 
Hormones  Usually only around the time of puberty and in females     Chapter 1  Introduction 
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Medicines  These are mostly anti-inflammatory drugs, such as ibuprofen   
Smoking  Many of the toxins in cigarette smoke can cause irritation to the lungs and 
result in asthma exacerbations 
Weather  Exposure to a cold environment can cause irritation to the airways 
 
1.2.2 Diagnosis 
The  presence  of  asthma  symptoms  does  not  mean  that  the  individual  has  asthma  and  so  a 
physician’s diagnosis is important. While there is no definitive biochemical or physiological test that can 
diagnose asthma, physicians will diagnose based on reported symptoms, spirometery, evidence of bronchial 
hyperresponsiveness and response to treatment. It is difficult to diagnose asthma in very young children as 
there is no clearly defined way to differentiate between wheeze, caused by infection, and wheeze caused by 
asthma.  
1.2.2.1 Spirometry  
Spirometry is used to measure lung function. To measure lung function, an individual takes a large 
breath in and expels forcefully through a tube connected to a spirometer. The first second gives the forced 
expiratory volume in one second (FEV1). This can give an indication of an obstructive pattern within the 
airways as the peak will be lower and the amount of breath left for the long exhale will be larger if airways 
obstruction is present. The long continuation of the breath gives an estimate for FVC (Forced Vital Capacity). 
This is the total amount of air able to be forcefully released from the lungs. If the individual has a poor 
volume for the FEV1 but is able to continue the long breath afterwards this is an indication of a restricted 
pattern, most commonly associated with asthma. A ratio for the two measurements is usually also taken 
FEV1/FVC (Forced Expiratory Volume in one second/Forced Vital Capacity) although this is mostly used in the 
diagnosis of COPD (Chronic Obstructive Pulmonary Disease) (Pellegrino 2005). 
The results have to be normalised for patient age, sex, height and weight as these all contribute to 
the FEV1. It is also important to identify the ethnic ancestry of the patient as the expected values are 
different depending on descent. For example total lung capacity, vital capacity and residual volume are 
around 12% lower in a black population than in a Caucasian one (Lanese 1978). 
Spirometric results give an indication of the type of lung function problem as well as the severity of 
the condition. Figure 3 shows the spirometric results from different types of lung function complication, with 
the accompanying lung function measures in the table 2.      Chapter 1  Introduction 
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Figure 3: Spirometry result curves; for A) Obstructive, B) Normal, C) Restrictive and D) Mixed lung function 
complications. Reproduced from (Pellegrino 2005) 
Table 2: Spirometry result values; for A) Obstructive, B) Normal, C) Restrictive and D) Mixed lung function 
complications. Reproduced from (Pellegrino 2005) 
Lung  Function 
complication 
FEV1 % 
(Forced  Expiratory 
Volume  in  one 
second) 
FEV1/FVC % 
(Forced  Expiratory 
Volume  in  one 
second/  Forced 
Vital Capacity) 
PEF % 
(Peak  Expiratory 
Flow) 
TLC % 
(Total  Lung 
Capacity) 
A Obstructive  38  46  48  101 
B Normal  57  73  43  96 
C Restrictive  66  80  79  62 
D Mixed  64  64  82  72 
 
  The obstructive lung function results show a decrease in the FEV1 and FEV1/FVC ratio values, of 38% 
and 46% respectively. This is due to the reduction in flexibility of the airways reducing the volume of air that 
can escape in the first second of the test and increasing the time it takes to evacuate the total volume of air. 
An example of an obstructive lung disease is Chronic Obstructive Pulmonary Disease (see section 1.3). 
  The normal lung function results show that usually half the predicted value of air is released in the 
first second, the FEV1/FVC ratio is above 70% with around 43% of the peak expiratory flow and almost all of 
the total lung capacity percentage.  
  The restrictive results show a high percentage for the FEV1 and ratio values but a lower total lung 
capacity value. This is due to the small airways being involved. The first expiratory blast is not affected but 
the long breath is usually not able to be completed. An example of a restrictive lung disease is asthma  
The mixed results show a low FEV1/FVC value and a reduced TLC value.     Chapter 1  Introduction 
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Spirometry is a well known and often used method to help diagnose both different forms of lung 
disease as well as the severity of that disease, especially in the case of obstructive disorders. If an individual 
has  normal  parameter  for  their  spirometry  results  but  has  had  symptoms  for  a  long  period  of  time  a 
methacholine challenge may be used to help with diagnosis.  
1.2.2.2 Methacholine Challenge 
One of the most commonly used diagnostic tests or asthma is a methacholine challenge, also known 
as a provocation test. This uses inhaled methacholine, an acetylcholine mimetic, as an agent to constrict the 
bronchi (Beckett 1992). This drug is diluted to form a concentration gradient going from no drug up to a 
possible value of 32mg/ml (Crapo 2000). Once the individuals FEV1 (Forced Expiratory Volume in one second) 
has fallen by 20% of their normal flow the test is stopped and bronchodilators are administered until the 
FEV1  value  has  normalised.  It  is  the  concentration  of  methacholine  that  is  required  to  reach  this  20% 
reduction that gives an indication of asthma for that individual as most asthmatics tend to show enhance 
constriction in response to methacholine  challenge, this is termed bronchial hyperresponsiveness (BHR) 
(Birnbaum 2007).  Bronchial hyper-reactivity testing can also be carried out using alternative constrictor 
agents such as histamine and adenosine. 
1.2.3 Treatment 
  There are three main groups of drugs that are used for asthma treatment, all of which are aimed at 
relieving the narrowing of the airways by inflammatory infiltrates, as seen in figure 4. These are I) inhaled 
glucocorticoids, II) β-agonists and III) cysteinyl-leukotriene inhibitors (Drazen 2000). 
 
Figure 4: Normal and asthmatic bronchi, showing the narrowing of the lumen of the airway caused by inflammatory 
infiltrates, remodelling and increased mucus production. Reproduced from (AllreferHealth 2009)     Chapter 1  Introduction 
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Inhaled glucocorticoids have multiple mechanisms of action and are the mainstay of current asthma 
therapies. They are naturally occurring molecules that have two main functions with in the body. The first is 
a  reduction  in  pro-inflammatory  mediators  and  the  second  is  an  increase  in  the  production  of  anti-
inflammatory mediators. The glucocorticoid proteins bind to their receptors which dimerise and translocate 
to the nucleus, where they bind to specific response elements in gene promoters, enhancing transcription of 
genes encoding anti-inflammatory proteins and inhibiting transcription of pro-inflammatory mediators  
Glucocorticoids have a very narrow therapeutic index as they are toxic to the body. This means that 
there  are  several  side-effects  that  occur  with  their  use.  These  include  immunosuppression,  insulin 
resistance, osteoporosis, glaucoma and cataracts. Hence most glucocorticoids are delivered topically to the 
airways through the use of inhaler devices. However there are some asthmatics that do not respond to 
glucocorticoids. These individuals are known as glucocorticoid resistant and require other types of treatment 
for their asthma medication. (Kamada 1996) 
  Β2-agonists are effective bronchodilators that bind to β2 adrenergic receptors that are expressed in 
the airways and cause the smooth muscle to relax by increasing the intracellular level of cAMP. There are 
two main types of β2-agonists, long-acting and short-acting. Long-acting β2 agonists usually last up to 12 
hours after they have been given and are used as a preventative medication. They are prescribed for the 
long term control of symptoms within persistent asthma, nocturnal asthma and to help prevent exercise-
induced asthma. Short-acting β2-agonists have a much shorter half-life and only work for up to an hour after 
administration. They work in the same way as the long-acting form and are used as rescue medication for 
sudden bronchoconstriction.  
  Cysteinyl-leukotriene  inhibitors  are  used  in  asthma  treatment  as  they  prevent  the  action  of 
leuoktrienes that are one of the main pro-inflammatory mediators. These lipids are released from leukocytes 
at sites of inflammation. They stimulate the production of molecules that cause micro-vascular leakage, 
allowing eosinophils into the airways and increasing the inflammatory response as well as being potent 
bronchoconstrictors (Ducharme 2004)  . 
1.2.4 Prevalence 
The prevalence of a disease gives an idea of the number of patients within a given population that 
have that disease at a given time. Respiratory diseases are one of the largest disease groups in the UK. In 
2004 around 1,942 out of every 10,000 males and 2,516/10,000 females had a respiratory disease. It is the 
second most common cause of emergency admissions in the UK. In the UK the prevalence of asthma in 2004 
for males was 409/10,000 people and 484/10,000 for females. There were around 1.381 deaths caused by 
asthma in 2004 (British Thoracic Society 2007).     Chapter 1  Introduction 
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Around one third of the UK population have experienced wheeze in the last year. Asthma diagnosis 
is higher in children (21%) than in adults (15%). Recent wheeze and diagnosed asthma have increased since 
1960 and have given the UK the highest asthma prevalence in the world. Hospital admissions for asthma 
made up 12% of the total admissions in 2004/2005, and around 10% of doctor consultation visits (British 
Thoracic Society 2007). 
1.2.5 Pathogenesis 
Asthma may be classified as atopic (extrinsic) or non-atopic (intrinsic), based on whether symptoms 
are precipitated  by  allergens (atopic)  or not (non-atopic).  Atopic  inflammation  results from  specific  IgE 
mediated immune responses to allergens. Atopy can also cause other allergic conditions such as eczema, hay 
fever and allergic conjunctivitis. While the majority of asthmatics are atopic, some individuals exhibit non-
atopic asthma. This results in the same clinical symptoms as atopic asthma but is often induced by factors 
such as anxiety, stress, exercise, cold air, dry air, hyperventilation, smoke, viruses or other irritants such as 
occupational exposures. 
There are two stages of inflammation in asthma, the early-phase and the late-phase. The early-
phase reaction involves cells, such as mast cells, that have IgE antibodies bound to the high affinity IgE 
Receptor (FceR1) on their surface. Upon an encounter with an allergen and subsequent cross-linking of IgE 
receptors,  pro-inflammatory  markers  are  released,  such  as  histamine,  eicosanoids  and  reactive  oxygen 
species. These molecules induce the contraction of the smooth muscle around the airways, an increase in 
mucus secretion and induce vasodilation. (Bousquet 2000) 
The late-phase reaction occurs between 6 and 9 hours after the initial encounter. This involves the 
recruitment  to  the  airways,  and  activation  of,  eosinophils,  CD4+  T  cells,  basophils,  neutrophils  and 
macrophages.  The  recruitment  of  these  cells  from  the  blood  is  facilitated  by  increased  expression  of 
adhesion molecules due to the action of inflammatory cytokines. The up-regulation of adhesion molecules 
(CD11a,  CD11b,  CD18,  VLA-4,  ICAM-1  and  VCAM-1)  is  all  critical  for  the  induction  of  an  inflammatory 
response. (Elias 1999) 
Asthma reactions are dependent on CD4
+ T lymphocytes that have been skewed to a Th2 phenotype. 
It is the Th2 cytokines, IL-4, IL-5, IL-9 and IL-13; that drive asthma pathogenesis. IL-4 skews the T cells 
towards a Th2 phenotype and results in an increase in serum IgE through inducing isotype switching in B-
cells, IL-5, granulocyte-macrophage colony stimulating factor and IL-9 are involved in the production of 
eosinophils.  IL-13,  like  IL-4,  also  promotes  switching  of  B-cells  to  an  IgE  producing  phenotype  and  is 
responsible for the change in the airways towards hyperresponsiveness and mucus metaplasia all of which 
results in airway remodelling (Wills-Karp 2004).     Chapter 1  Introduction 
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1.2.6 Remodelling 
The severity and chronicity of inflammatory episodes lead to remodelling of the airways. This is 
because the airways  become  damaged and  inflammatory  cells  infiltrate  to  repair  the  damage  that  has 
occurred. In the case of asthma these instances of damage are often close together and the first set of 
inflammatory mediators has not been dispersed before the next set arrives. This build-up of inflammatory 
mediators causes the remodelling seen in the asthmatic airway. The protective effect works through two 
ways, one is to regenerate the tissue that has been damaged and the other is to replace that that has been 
too damaged to repair, this leads to the formation of scar tissue. This remodelling causes thickening around 
the airways altering their structure (Vignola 2000). 
Remodelling within the airway involves an increase in the number of goblet cells, which increases 
mucus production, causing the coughing symptom of the diseases as the individual tries to clear it.  The 
number of epithelial cells also increases and this is not site specific for injury, but throughout the luminal 
surface area.  This forms a thicker layer of epithelial cells making the lumen smaller (Törmänen 2005). This 
reduces the airflow and increases the airway surface tension making it more likely to collapse (Bousquet 
2000). 
The amount of smooth muscle around the bronchi is also seen to increase in airways of asthmatic 
patients and results from both hyper- and hypoplasia of the smooth muscle cells. This feature of airway 
remodelling is not usually seen in either chronic bronchitis or chronic obstructive pulmonary disease. This 
increase  in  muscle  mass  around  the  airways  could  be  due  to  inflammatory  mediators  driving  cell 
proliferation, or purely by the increase in the work undertaken by these muscle cells as they constrict the 
bronchi.  The  increase  in  smooth  muscle  cells  during  bronchoconstriction  results  in  increased  airway 
resistance. Computer models have predicted that within asthmatic airways these muscle cells only have to 
shorten  by  40%  to  completely  close  the  airway  lumen  (Bousquet  2000).  Within  normal  lungs  airway 
resistance reaches a plateau but continues to increase in asthmatic lungs as the airways close. This links in 
with spirometery FEV1 readings where the value for this levels off in normal lungs but continues to decrease 
in asthmatic lungs (Vignola 2003). 
The extra-cellular matrix is the area between the cells that compose the airway. It consists of fibrous 
proteins, such as collagen and elastin, structural and adhesive proteins, such as fibronectin and laminin, as 
well as a hydrated polysaccharide gel (Bousquet 2000). It is the composition of this that greatly alters airway 
structure and strength. 
Thickening of the basement membrane is also seen in asthma remodelling. This membrane is made 
up to two layers, the basal lamina and the lamina reticularis. It is the lamina reticularis that is thickened 
within asthma (Bousquet 2000). This can be seen even in the early stages of asthma. This thickening occurs     Chapter 1  Introduction 
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due to the deposition of immunoglobulins and collagen. Both collagen-I and collagen-III, increases within the 
extra-cellular matrix around the bronchi.   
 Remodelling involves the small airways first and progresses to affect the larger airways and has 
been linked with changes in vasculature.  
Within an asthmatic lung the vessels are larger which increases the thickness of the airway wall. This 
is due to high levels of inflammatory mediators, such as prostaglandins and adenosine, as well as cytokines 
and growth factors. The presence of these molecules drives expression of the vessel growth gene VEGF. The 
inner diameter of vessels increases as well coinciding with an increase in proliferating endothelial cells.  
1.2.7 Genetic Basis of Asthma 
Familial and twin studies suggest that there are strong underlying genetic factors which cause those 
individuals with asthma to be susceptible (Hemminki 2007). It has been suggested that approximately 60% of 
asthma risk is genetically based and the other 40% due to environmental exposures (Duffy 1990).  Asthma 
has been found to run in families, with an increased risk of the offspring developing asthma if it is present 
within  the  family  already  (Burke  2003).  However  the  overall  effect  of  non-asthmatic  older  siblings  is 
protective for younger children as they have a higher rate of exposure to external allergens (Leadbitter 
1999). It has also been noted that the risk of developing asthma is increased for males when compared with 
females (Kay 2001). This may suggest that one or more asthma susceptibility genes could be sex linked.  
Many studies have been undertaken that have looked into the genes associated with asthma. There 
are  two  main  genetic  study  types:  1)  hypothesis  based  candidate  gene  studies,  and  2)  hypothesis 
independent studies, such as genomewide linkage studies in families and more recently  Genome Wide 
Association Studies (GWAS). 
Candidate gene studies select a gene whose protein is known to play a role in one of the processes 
involved within the disease. Genetic variation, usually Single Nucleotide polymorphisms (SNPs), within the 
gene encoding the protein,  which may affect gene expression or protein function, is then assessed for 
association with the disease or related phenotypes. There have been many genes shown to be associated 
with asthma utilising this approach including genes involved in regulation of atopic immune responses, 
oxidant stress and tissue repair mechanisms. (Holloway 2010) 
While candidate gene studies increase understanding about individual susceptibility to disease, in 
general they do not provide more information on disease pathogenesis as by definition, the protein encoded 
was already known or suspected to be involved in the disease to be selected as a candidate for genetic 
analysis. In contrast, hypothesis independent genomewide approaches have the potential to identify novel 
genes that encode unknown proteins that play a role in disease pathogenesis. For example, in asthma,     Chapter 1  Introduction 
20 
 
gemonewide linkage analysis in family based samples has identified several novel genes e.g. ADAM33 and 
PCDH1 as having a role in asthma pathogenesis.  
The gene encoding a disintegrin metalloproteinase 33 (ADAM33) was the first gene to be identified 
for asthma using positional cloning (van Eerdewegh 2002) and has been associated with the development of 
smooth muscle around the airways. It has also been implicated in remodelling and associated with asthma 
(Ober 2006; Vercelli 2008). Links have also been made with development of COPD in Asian populations 
(Sadeghnejad 2009; Xiao 2010), and protocadherin-1 (PCDH) (Koppelmann 2009) genes as being associated 
with asthma. 
PCDH is a membrane bound protein that is found at all cell-cell boundaries. It is involved in neural 
cell adhesion and so may play an important role in the development of the neuronal system. The protein 
itself includes an extra-cellular region that contains seven cadherin-like domains, a transmembrane region 
and a C terminal cytoplasmic region. Any cells that express this protein are prone to aggregation activity. 
This  protein  has  been  linked  with  bronchial  hyperresponsiveness  in  Asthmatics  from  several  Caucasian 
populations (Koppelmann 2009). 
GWAS studies utilise hundreds of thousands of SNPs across the genome to test for association with 
the phenotype in question. Recent GWAS studies in asthma have identified a number of novel genes of 
unknown  function  as  being  associated  with  asthma  susceptibility.  For  example,  the  first  novel  asthma 
susceptibility locus to be identified by GWAS contains the orosomucoid 1-like 3 (ORMDL3) and Gasdermin-
like (GSDML) genes on chromosome 17q12-21 (Moffatt 2007). In this study, 317,000 SNPs in 994 subjects 
with childhood on-set asthma and 1243 non-asthmatic controls were genotyped. Subsequent studies in 
ethnically diverse populations have replicated the association between variation in the chromosome 17q21 
region (mainly rs7216389) and childhood asthma (Holloway 2010).     Chapter 1  Introduction 
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1.3 Chronic Obstructive Pulmonary Disease, (COPD) 
Chronic Obstructive Pulmonary Disease (COPD) is an irreversible inflammatory disease of the lungs 
that is typically late onset with most COPD occurring after 40 years of age. COPD is becoming a leading cause 
of morbidity and mortality in the UK. At present it is the 5
th biggest killer in both the UK and world wide 
(National Statistics 2006). However it is estimated that it will become the 3
rd most common cause of death in 
the  UK  in  2020  (Murray  1997).  COPD  is  diagnosed  as  a  restrictive  deficit  in  lung  function  that  is  not 
reversible. The GOLD (the Global initiative for chronic Obstructive Lung Disease.) defines COPD as ‘a disease 
state characterised by airflow limitation that is not fully reversible. The airflow limitation is usually both 
progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or 
gasses’  (Pauwels 2001). There are a number of pathophysiological processes that can lead to a diagnosis of 
COPD including chronic bronchitis, remodelling of small airways and fibrosis, and emphysema. 
1.3.1 Clinical Symptoms 
  The very early stages of COPD are usually undetectable by the individual. Mild (GOLD stage I) COPD 
has a diagnostic criteria in terms of reduced lung function, but generally patients experience no symptoms. 
Typically, the first symptoms exhibited by patients with moderate COPD (GOLD stage II) include shortness of 
breath when completing every day tasks. This is usually attributed to age and smoking, as smoking is the 
strongest risk factor for development of COPD. Patients with moderate COPD have reduced lung function 
and the symptoms become much more noticeable. There may also be instances of coughing, congestion and 
wheeze. The ability to complete everyday tasks is drastically effected and exacerbations begin to occur. The 
final  stage  of  COPD (Severe,  GOLD  stage III/IV)  often  requires  supplementary  oxygen  therapy, and any 
exacerbations that occur can be fatal.  
The reason behind the breathlessness is the inability of the lungs to efficiently remove the air that is 
already present before the next breath is taken. As seen in figure 5, a normal lung will expand during a 
period of exercise with the amount of gas exchanged increased. A COPD lung increases the amount of air 
coming in but is unable to increase the volume going back out. This means that the overall gas exchange is 
nowhere near the volume of that seen in the normal lung. A limit to the amount of gas volume alters the 
partial pressure of each gas and reduces the efficiency of gas exchange from the lung to the blood reducing 
the amount of oxygen available to the body. This leaves the individual breathless.  
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Figure 5: Spirometery readings with exercise. As exercise continues the normal lung increases its gas exchange volume 
by having more gas taken in as well as by removing more gas in the exhale. The COPD lung is able to increase the 
volume of gas in but not the volume that is released. This reduces the efficiency of the gas exchange and leaves the 
individual breathless. Reproduced from(Jones 2011). 
1.3.2 Diagnosis 
  COPD is difficult to diagnose as its symptoms are also common signs of ageing, however the number 
of people being diagnosed with COPD in the UK is on the increase, in part, due to the improved methods of 
diagnosis (Tinkleman 2007). The most common way of diagnosing COPD is by spirometery, with FEV1/FVC to 
be below that of 70% or 0.7. The values for this ratio are measured by spirometery readings as described in 
section 1.2.2.1. This disease shows an obstructive pattern, as seen in figure 6. The individual is unable to 
expel the normal volume of air in the first second of the challenge, making the initial peak less, and the 
volume being expelled is higher for longer over the rest of the test due to this. 
 
Figure 6: Stylised spirometery trace comparing a normal lung with a COPD lung.  
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Once this ratio is known the individual is given a severity rating as dictated by the global initiative for 
chronic obstructive lung disease (GOLD) standard. A ratio of less than 0.7 where the FEV1 is more than or 
equal to 80% of that predicted is considered as mild (class I), if the FEV1 is between 50 and 79% of that 
predicted it is considered moderate (class II), between 30 and 49% severe (class III) and if the FEV1 is less 
than 29%, or less than 50 % but with chronic respiratory failure, the individual is considered to be very 
severe (class IV). Figure 7 shows a normal healthy lung on the left and a smoking, COPD patient’s, lung on 
the right. The COPD lung is black due to the deposits left behind from smoking. 
 
Figure 7: Normal healthy lung compared with COPD, smoking lung. The normal healthy lung on the left with a larger 
overall size and pink healthy tissue, the COPD lung on the right is smaller and the black discolouration is caused through 
smoking, the biggest risk factor for COPD. Reproduced from(mylot 2005). 
Under-diagnosis of COPD is thought to be very common. It is estimated that around only 25% of 
COPD cases are diagnosed (Manfreda 1989; Lundback 1991; Viegi 1991). This is due to a lack of physicians’ 
awareness of the symptoms and factors involved in COPD, as well as a possible perception that the condition 
was self-inflicted. The use of spirometers as a diagnostic tool is low and the education available on COPD is 
minimal. The patients themselves are also a factor as they believe that the symptoms are just a result of 
their age and life style and do not push for an actual diagnosis (Jones 2011). A study by Tinkleman et al. 
(2007) indicated that introducing screening of smokers over the age of 40 the number of cases of diagnosed 
COPD could increase by 10-20% (Tinkleman 2007). 
1.3.3 Treatment 
  There is no treatment that has been shown to stop the progression of decline in lung function as this 
is a natural process. This means that only the symptoms of the disease can be treated. It is important to note 
that  although  corticosteroids  can  be  used  to  treat  asthmatic  inflammation  they  do  not  work  for 
inflammation in COPD, this aspect of the disease will be discussed further in section 1.3.9. However the     Chapter 1  Introduction 
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biggest risk factor in COPD is smoking and this increases the rate of lung function decline. The best way to 
reduce the rate of reduction is to stop smoking. A study by Kohansal et al. showed that in healthy individuals 
that had never smoked lung growth peaked earlier in women than in men and those women also had a 
slower rate of decline. Smoking was found to increase the rate of decline and the susceptibility of individuals 
to smoking varied (Kohansal 2009). The only help that can be given to individuals suffering from this disease 
is to treat symptoms.  
 
Figure 8: Rate of lung function decline is reduced by stopping smoking. The graph above goes from peak lung function, 
at 25 years, to 75 years, and shows the effect smoking, and the cessation of smoking has on the decline of an 
individuals lung function. Reproduced from(Jones 2011). 
Treatment of the symptoms depends on the severity of the disease classified by the GOLD standard. 
If classified as mild (class I) the only treatment is to stop known risk factors, such as smoking, and having an 
annual flu vaccination to help prevent exacerbations. Moderate COPD (class II) sufferers are advised to take 
the  same  precautions  as  class  I  with  the  added  treatment  of  bronchodilators  as  needed.  These 
bronchodilators work in two different ways, long-acting β2 adrenergic receptor agonists, (e.g. salmeterol and 
formoterol)  help  to  relieve  airway  narrowing  of  the  airways  through  their  β2  stimulation,  relaxing  the 
smooth muscle surrounding the airways. Long-acting muscarinic antagonists (e.g. tiotropum) work on the 
cholinergic  tone  of  the  airways  reducing  the  contraction  of  airway  smooth  muscle  aiding  reduction  in 
hyperinflation.  
Long-acting β2 agonists are known to improve symptoms and reduce the need for rescue medication 
(Ramirez-Venegas 1997; Mahler 1999; Campbell 2005; Derom 2007). It is also known that formoterol has a 
faster onset of action then salmeterol (Cote 2009), however if the patient is taking a standard daily dose this 
has no effect. As the disease progresses the prescribed dose of twice daily is given to act as a base line 
treatment to prevent exacerbations.     Chapter 1  Introduction 
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There is only one long-acting muscarinic antagonist commonly used in COPD treatment, tiotropium.  
This drug is the one most commonly used as a maintenance drug as it is only used once a day and has a 24 
hour effect resulting in bronchodilation (Briggs 2005; van Noord 2005; Wedzicha 2008; Brusasco 2011). The 
use of both a long-acting β2 agonist and a long-acting muscarinic antagonist has been found to be more 
effective than either type on in own (van Noord 2005; Cazzola 2009; Singh 2011). 
If classified as severe (class III), inhaled corticosteroids are added to the treatment plan in response 
to exacerbations. The final level of severity, very severe (class IV), includes all the treatments for the lesser 
degrees of severity as well as long term oxygen for respiratory failure and the consideration of surgical 
intervention.  
Treatment with oxygen therapy increases the partial pressure of oxygen within the lungs, meaning 
that more is passed from them into the blood system and then on to the rest of the body. By this stage of 
the disease the individual needs this increase in oxygen as they would suffocate otherwise. This is known as 
chronic respiratory failure. 
  Surgical intervention involves  the  removal of sections  of  the  lung  where the elastase  has  been 
destroyed. The alveoli in these areas are larger and have no elastic recoil and so air is not pushed back out of 
the lungs. This means that the efficiency of gas exchange is reduced and less oxygen enters the blood 
stream. By removing the affected tissue, the over all efficiency within the lung increases allowing better gas 
exchange within the lung which provides more oxygen for the body.  
1.3.4 Incidence 
In the UK the incidence of COPD was estimated to be between 25,000-30,000/ million in 2007 (Blanc 
2007). This figure has increased recently due to better methods of detection. Once the initial diagnosis has 
been made the severity of the condition is assessed and given a score using a predetermined scale. One of 
the biggest concerns with COPD is the level of under diagnosis. The reasons behind this have been detailed 
in section 1.3.2.  
Interestingly a study by Marco, 2007, found that the incidence of COPD in a population of young 
adults, 20-44 years old, was 2.8 cases/1,000/year (de Marco 2007 ). This figure was derived from data whose 
source was the European Community Respiratory Health Survey II.  
1.3.5 Prevalence 
A global estimate of COPD prevalence has been given as 9-10% in individuals over the age of 40 
years (Halbert 2006). In the UK the prevalence of COPD was thought to be around 1.5 million but a study on 
a sample population resulted in a much higher figure with 13.% of individuals over 35 having COPD (Shahab 
2006). This equates to 3.4-3.8 million people nationally. A study from China gave a prevalence of 8.2% within     Chapter 1  Introduction 
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its population of over 40 years (Zhong 2007), and a Danish population study found their prevalence of COPD 
to be 12% between the ages of 45 and 84 years (Hansen 2008). Within the USA morbidity from COPD is 
estimated at 4% making it the 4
th leading cause of death (Hurd 2000). The prevalence of COPD is different in 
different countries as shown in figure 9. The increase in the number of individuals with this disease is partly 
due to better health care increasing the mean age of the population as well as a better understanding of the 
disease as it becomes more common.  
 
Figure 9: Differences in deaths caused by COPD, from several different countries for individuals between 35-70 years 
of age. This figure was based on data from the World Health statistics (WHO). Reproduced from(Hurd 2000). 
1.3.6 Pathogenesis 
  The biggest cause of COPD is the oxidative stress that the lungs endure from the free radicals that 
are present in tobacco smoke and other exposures such as particulate air pollution. These lead to the release 
of cytokines that cause inflammation which leads to remodelling. Changes in the structure of the lung in 
COPD occur in two main areas. Firstly, in the small airways, inflammation drives goblet cell metaplasia, 
smooth muscle hyperplasia, and subepithelial fibrosis, resulting in narrowing of the airways, limiting airflow 
and is termed chronic bronchitis (Saetta 1994). Breathing out becomes harder for the individual as the 
pressure within the chest causes the airways to collapse instead of expand. This leads to hyperinflation of 
the lungs.  
Airway fibrosis is the thickening of the wall of the airway (figure 10). The reduction in contractibility 
within  the  airway,  caused  by  fibrosis,  impedes  the  body’s  natural  reaction  to  harmful  stimuli  and 
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In  the  alveoli,  the  inflammatory  response  causes  destruction  of  the  lung,  a  process  known  as 
emphysema. Emphysema is a pathological diagnosis defined by permanent enlargement of airspaces distal 
to the terminal bronchioles. This causes a significant decline in the alveolar surface area available for gas 
exchange. In addition, loss of alveoli leads to airflow limitation by both a decrease in elastic recoil, and 
airway narrowing as a result of the loss of the alveolar supporting structure. This reduces the ability of the 
lungs to push out air on the exhale, as there is no elastic recoil when lungs relax, resulting in a decrease in 
vital capacity as well as a decrease in FEV1.  Emphysema is due to alterations in the deposition of the matrix 
around the alveolar tissue. Less elastin is present reducing the lungs elastic recoil effect, and this destruction 
of the alveoli is due to the action of proteases, such as neutrophil elastase. Damage to the small airways 
structure  and  those  that  support  the  alveoli  means  that  airways  are  prone  to  collapse  as  the  patient 
breathes out and limits their ability to push air out due to reduction in elastic recoil of the alveoli. This is not 
reversible and the only option for severe emphysema is surgery (Geddes 2000). 
 
Figure 10: Normal airways compared with those with bronchitis and emphysema. The normal bronchi exhibit wide 
airways with large alveolar having a maximum surface area, bronchitis shows the thickening around the airways, 
fibrosis, and emphysema shows the decrease in surface area of the alveolar due to the breakdown in structure. 
The rate of decline in lung function is normally at a steady rate until an exacerbation occurs. An 
exacerbation  results  from  an  inflammatory  reaction  to  exogenous  stimuli,  that  is  often,  in  contrast  to 
asthma, non-responsive to steroid treatment. The difference in steroid responsiveness between COPD and 
asthma exacerbations may be due to epigenetic influences that may be causal or develop due to COPD 
(Barnes 2006). These exacerbations cause a drop in lung function that is never regained and a steady rate of 
decline continues from this point after the exacerbation (Eaton 2009). 
1.3.7 Genetic Basis of COPD 
As  previously  mentioned,  the  highest  risk  factor  for  COPD  in  the  developed  world  is  smoking. 
However not all smokers develop COPD. This suggests that there is another underlying factor which causes 
those individuals with COPD to become susceptible to the disease. There is increasingly strong evidence that 
one such underlying risk factor for COPD is genetically based (Kueppers 1977; Silverman 1998; Gottlieb 
1999).     Chapter 1  Introduction 
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Many studies have been undertaken that have looked into the genes associated with COPD. As with 
asthma these studies are of two main types, candidate gene and hypothesis independent approaches. 
 COPD candidate gene studies have identified several genes that are associated with COPD. For 
example, association was found with susceptibility to COPD and genetic variants in the gene encoding matrix 
metalloproteinase-12, this protein had originally been chosen as a candidate gene as they are known to 
degrade extra cellular matrix. It has been linked with airway inflammation and remodelling, as seen in COPD 
disease progression (Molet 2005; Xie 2005). 
Using genomewide linkage studies in families has been more difficult for COPD due to the late stage 
of onset of the disease making recruitment of multigenerational families difficult. However, using early onset 
COPD (0 years of age), the Boston early onset COPD study identified the gene encoding serine protease 
inhibitor E2 (SERPINE2) (DeMeo 2006). This gene had been previously linked with respiratory disease as it, in 
balance with its antagonistic partners- serine proteases, regulates the lung extra cellular matrix. It has been 
proposed  that  an  imbalance  between  these  two  sets  of  proteins  can  alter  the  matrix  and  result  in 
degradation giving an emphysemic phenotype (Zhu 2007; Kim 2009; Kim 2011).  
GWAS studies have more recently identified several genes as being associated with COPD.  For 
example, using a GWAS approach Pillai et al. (2009) found genes such as the α-nicotine CHRNA3/5 receptor 
and hedgehog-interacting protein (HHIP) to be associated with FEV1.  
The identification of CHRNA3/5 as a COPD susceptibility gene highlights an important issue when 
studying the genetics of COPD. Most individuals are smokers, and so the genes identified could be associated 
with smoking and not COPD directly. HHIP is involved in development of the lung during embryogenesis and 
would not necessarily have been thought to be linked with the lung later in life, or disease state (Pillai 2009). 
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1.4 DOHAD and the Respiratory System. 
1.4.1 DOHAD and Lung Function 
  Respiratory diseases are classically defined by pulmonary lung function, and lung function is in turn 
dependent on in utero environment. From birth, lung function increases until around 22 years of age, where 
it  peaks  and  then  steadily  declines,  as  seen  in  figure  11.  Thus  lung  function  in  adulthood  is  in  part 
determined by lung development, as even with a normal rate of decline, lung function at a particular age is 
determined by peak lung function, which in turn is determined by lung development (Postma 2011) . 
 
Figure 11: Interpretation of the Fletcher-Peto diagram. 
  While there are no studies that have looked at the effect of maternal nutrition on lung function 
across  the  life  course  in  humans,  studies  have  correlated  early  life  exposure  measurements  with  lung 
function  measures cross-sectionally at a number of ages. By putting the data from all of these studies 
together the effect of lung function can be seen from birth up to the age of 65 years. Figure 12 shows how 
each of these studies fits into the overall age range for lung function.  
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Figure 12: Overview of studies looking at the lung function during different time periods. The dashed lines represent a 
study that has data from birth and then has no further data until the age given. 
  Figure 12 summarises a number of studies that have information from birth and lung function at one 
or more points later in life. A number of studies have correlated birth weight (as a surrogate marker of 
maternal nutrition) with respiratory phenotypes in later life. An increase in the risk of becoming hospitalised 
due to any respiratory illness was also found to be linked with a low birth weight (Barker 1991; Lopuhäa 
2000; Edwards 2003; Canoy 2007; Hancox 2009; Walter 2009). Each of these studies have looked at the 
effect of a low birth weight on lung function and at different ages during an individuals life, but there are no 
repeated measures of lung function throughout the life course. Therefore it is not possible to precisely 
identify how poor nutrition (as indicated by birth weight) leads to poor lung function in adulthood as it could 
be  poor  in  utero  growth  of  reduced  childhood  lung  growth  leading  to  a  lower  peak  lung  function,  or 
alternatively altering responses to postnatal exposures (e.g. smoking) giving rise to a faster rate of decline in 
lung function from the peak. 
  The key study highlighting the importance of in utero lung development of lung function across the 
life course is the study of Stern et al. (2007) that looked at the lung function of individuals at birth through to 
age 22 years. In this study, subjects who had poor lung function (infant Vmax(FRC) in the lowest quartile) 
also had lower values for FEV1/FVC (-5.2%, p<0.0001), FEF25-72 (-663 mL/s, p<0.0001), and FEV1 (-233mL, 
p=0.001) up to age 22, after adjustment for height, weight, age, and sex compared to those in the upper 
three quartiles combined. The magnitude and significance of this effect did not change after additional 
adjustment for wheeze, smoking, atopy, or parental asthma. This highlights that poor airway function at 
birth was predictive of poor lung function in adulthood (Stern 2007). 
1.4.2 Animal Models and DOHAD in the Respiratory System 
  As discussed in section 1.1.3, in order to provide causality for particular exposures or to investigate 
mechanisms behind the effects of exposures in developmental programming, it is necessary to utilise animal 
models. One of the closest models to a human lung is that of sheep in terms of timing of lung development 
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of gestation until term (147 days), leads to low birth weight compared to controls (Maritz 2004). Later tests, 
at the age of 8 weeks and 2 years postnatal, found that the treated sheep achieved the same body weight as 
the controls but that the structure of the lungs was altered. Restricted sheep had 28% less alveoli than 
controls and the lungs were 10% smaller in size. The alveolar walls were also found to be thicker. The result 
of these two structural changes meant that both the surface area of the lungs and lung elastic recoil were 
reduced. 
  Similar findings have been reported in rats. Two studies in rats, using differently timed 50% dietary 
restrictions with the dams, produced alterations in the lungs of the offspring. The first study started the 
dietary restriction at day 10 of gestation until term. These pups weighed less than the controls at 21 days of 
age but more at 9 months indicating some catch up growth. The lung weights were not different but the 
restricted group had a smaller number of alveoli and increased alveolar wall thickness (Karadag 2009). The 
second study involved a shorter exposure with dams given the restricted diet in the last trimester of their 
pregnancy. The offspring were found to have reduced volume fraction for air spaces, as well as a reduced 
surface area to volume ratio for the restricted group. The lung surfactant lipids were also reduced (Chen 
2004). These studies show that an alteration in the diet during gestation can alter the structure of the lungs 
as well as changing the environment within the lungs, such as the surfactants present.  
1.4.3 Development Origins in Asthma 
There is a range of evidence that supports the hypothesis that asthma susceptibility is, to a large 
extent, determined by developmental influences. These include epidemiological studies in humans as well as 
evidence from animal models 
1.4.3.1 Epidemiological Evidence for Developmental Origins of Asthma 
  As for the study of the role of developmental programming in many chronic diseases, most studies 
providing evidence for developmental programming in asthma rely on anthropomorphic measures, such as 
birth  weight;  head  circumference;  body  length  or  ponderal  index  as  surrogate  markers  of  maternal 
nutritional status. 
The matching up of these measures gives an indication of nutritional availability. If the birth weight 
is small but the other measures are larger this would indicate that the offspring should be larger and that 
body weight has been sacrificed to preserve brain/head development. It is important to have this set of 
measurements to be able to distinguish between small individuals and those experiencing in utero growth 
restriction.     Chapter 1  Introduction 
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Kurukulaaratchy et al. (2005) showed in a prospective birth cohort from the Isle of Wight that risk of 
early  transient  wheeze  was  increased  by  both  maternal  environmental  tobacco  smoke  exposure  in 
pregnancy (OR=1.58; 95% CI: 1.02-2.45), and low birth weight (3.65; 1.27-10.52) (Kurukulaaratchy 2003). 
However, this was not associated with persistent wheeze (asthma) at the age of 10. Leadbitter et al. (1999) 
studying a longitudinal cohort from New Zealand, found that after adjustment for other factors, recent 
asthma symptoms were positively associated with birth length (p=0.04) but not with head circumference. 
The adjusted odds ratio for asthma in the previous two years in infants with a birth length of 56cm or more 
was 6.4 (95% CI 2.0-19.8).Infants with a low birth weight of less than 3.0 kg had an odds ratio for reported 
asthma of 0.2 (95% CI 0.0-0.6). Associations between anthropomorphic measures and total IgE levels (as a 
marker of atopy) were also seen in this cohort. While the authors of this study acknowledge that precision of 
the findings is limited by the small numbers in the extreme categories of each birth parameter, the results 
are consistent with intrauterine programming of the developing respiratory and immune systems (Leadbitter 
1999). In support of the observations of Leadbitter et al. (1999), Shaheen et al. (1999) studying the 1970 
British Cohort Study, showed that the prevalence of asthma at 26 years fell with increasing birth weight 
(Shaheen 1999). More recently, Bierg et al. (2011) have shown that in a Dutch birth cohort, while low birth 
weight alone was not associated with increased risk of diagnosis of asthma at age 10, there was a strong 
interaction  of  low  birth  weight  and  prenatal-smoking  on  the  risk  of  physician-diagnosed  asthma.  They 
suggest that this observation indicates that airway inflammation from prenatal smoke exposure induces 
obstructive symptoms more easily in the underdeveloped airways of low birth weight children (Bjerg 2011). 
One marker of intrauterine growth restriction is a rapid weight gain after birth. Several studies have 
now shown that rapid weight gain after birth is associated with poor lung function and increased risk of 
asthma. Lucas et al. (2004) showed in infants from the Southampton women’s Survey (SWS) cohort that lung 
function in normal-term infants aged 5-14 weeks were not related to birth weight or infant feeding but fell 
by 3.2% per standard deviation increase in infant weight gain, suggesting that lower rates of fetal growth 
and higher rates of early infancy weight gain are associated with impaired lung development (Lucas 2004). 
Subsequently,  they  also  measured  birth  weight  and  length  and  conditional  fetal  head  and  abdominal 
circumference growth velocities calculated from antenatal ultrasound measurements, in a larger sample 
from the SWS cohort (n=1548). At 3 years of age, a rapid growth trajectory during 11-19 weeks gestation 
followed by late gestation growth faltering was associated with atopy, suggesting that influences affecting 
fetal growth may also alter immune development. A lower early fetal growth trajectory was also associated 
with non-atopic wheeze, possibly reflecting an association with smaller airways (Pike 2010). More recently 
reduced fetal growth in this cohort has also been associated with increased BHR at age 6 (Pike 2011).     Chapter 1  Introduction 
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In addition to anthropomorphic studies, most epidemiological studies have shown that the in utero 
period is critical for determining subsequent risk of asthma. Maternal exposure to a range of exposures 
including tobacco smoke (Haley 2011), paracetamol (Garcia-Marcos 2011), and house hold chemical use 
(Choi 2010) have all been associated  with increased asthma in the child. In relation to tobacco smoke 
exposure,  this  provides  some  evidence  that  these  exposures  may  even  act  to  increase  risk  of  asthma 
transgenerationally. In a study by Li et al. (2005) the risk of developing asthma, both start of symptoms and 
persistent, has been linked with maternal smoking during pregnancy, with an odds ratio of 1.5. However this 
risk  is  reduced  to  nothing  if  the  mother  stopped  smoking  before  she  became  pregnant.  Interestingly 
however, grand maternal smoking during the mother’s fetal period was associated with increased asthma 
risk in her grandchildren (Li 2005). 
1.4.3.2 Animal Model Evidence for Developmental Origins of Asthma 
Several  studies  have  now  examined  the  effect  of  maternal  environmental  exposure  during 
pregnancy on the induction of allergic lung inflammation in animals postnatally. Mice born to mothers 
exposed to cigarette smoke from three weeks prior to conception until birth show alterations in their lung 
following postnatal challenge with either house dust mite or inhaled PBS with remodelling of the airways 
with  increased  smooth muscle,  collagen  and  increased  goblet cells  with  the  house  dust  mite  exposure 
(Blacquiere 2009). However, this requires postnatal challenge as no differences were observed at baseline in 
lung  structure.  This  exposure  of  in  utero  cigarette  smoke  also  induced  increased  bronchial 
hyperresponsiveness to methacholine and increased numbers of neutrophils  and mast cells in the lung 
(Blacquiere 2009). 
In a seminal  study,  Hollingsworth  et al. (2008) exposed pregnant  mice to a diet rich in  methyl 
donors, such as Genistein (Hollingsworth 2008). An increase in methyl donors in the diet of mice dams (High 
Methyl Diet , HMD) enhanced the development and severity of allergic airway disease (increased airway 
hyperreactivity, lung lavage eosinophilia and IL-13, higher concentrations of serum IgE, OVA-specific IgE, and 
OVA-specific  IgG1  and  histologic  evidence  of  allergic  airways  disease)  in  the  F1  progeny  following 
sensitisation and challenge with the allergen ovalbumin in comparison to offspring or mother exposed to a 
low methyl donor diet (LMD). Furthermore, the effect of in utero dietary modification on the allergic airway 
phenotype was paternally transmitted to the F2 generation with more eosinophilic airway inflammation and 
higher concentrations of total serum IgE in F2 offspring of male F1 mice exposed in utero to a HMD. In this 
study, the authors also used a genomic approach to assess DNA methylation in lung tissue from F1 mice with 
severe  allergic  airway disease (lavage  eosinophils <75%) exposed  in utero  to  a  HMD  and  F1 mice with 
minimal  allergic  airway  disease  (lavage eosinophils  >25%)  exposed  in  utero  to  a  LMD.  This  showed  an 
increase in the level of methylation, particularly in the promoter of the RunX3 gene which translated through     Chapter 1  Introduction 
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to a decreased expression of the protein in lymphocytes and correlated with functional differences observed 
in lymphocyte function. This could be reversed by exposure of splenocytes in vitro to a demethylating agent 
(5-Azacytidine)  which  increased  mRNA  expression  and  protein  level  of  RunX3  were  both  increased 
(Hollingsworth 2008). 
1.4.4 Developmental Origins of COPD 
As for asthma, there is a range of evidence that supports the hypothesis that COPD susceptibility is, 
to a large extent, determined by developmental influences. These include epidemiological studies in humans 
as well as evidence from animal models 
1.4.4.1 Epidemiological Evidence for Developmental Origins of COPD 
Epidemiological studies have shown that susceptibility to COPD is associated with markers of fetal 
growth such as anthropometric measurements at birth (Barker 1991). As described above, fetal growth and 
duration of gestation influence lung development and the study by Stern et al. (2007) highlights that poor 
airway  function  in the newborn  period,  which  is  dependent  on  fetal lung development,  is a significant 
predictor of poor adult lung function, and potentially COPD (Stern 2007). Equally, poor adult lung function 
and increased risk of death from COPD are also associated with lower birth weight, again suggesting an 
effect of maternal undernutrition modulating in utero development (Barker 1991; Lopuhäa 2000; Edwards 
2003; Canoy 2007). 
In the study of the Hertfordshire cohort, Barker et al. (1991) showed that small birth weight (≤5.5 lb) 
carried an increased risk of developing COPD at age 60 (standard mortality ratio (SMR) of 131), where as a 
normal range birth weight (6.5-7.5 lb) did not carry this risk (SMR of 80). There are also implications for 
respiratory health, with those of a low birth weight (≤6.5 lb) having an increased risk (OR = 1.83) of suffering 
from bronchitis or pneumonia. There was also a correlation found between (FEV1) and birth weight but not 
(FVC). This links in with the development of the lungs as FEV1 components are present in the lung in utero, 
while FVC components develop after birth. In keeping with this rationale, FVC values were decreased if the 
individual suffered from respiratory infection during their childhood  (Barker 1991). This is characteristic of 
an obstructive disease. 
A study by Lopuhäa and colleagues found that of those mothers who experienced famine while 
pregnant, the highest correlation between exposure and development of COPD was during the early (1.5 
(0.9 to 2.6)) and mid trimesters (1.7 (1.1 to 2.6)). If the woman was exposed during the last trimester of her 
pregnancy there was no correlation with the development of COPD (0.9 (0.5 to 1.5). Exposure to famine in 
the early or mid trimester resulted in and increased risk of developing all types of respiratory complications,     Chapter 1  Introduction 
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such as infections in childhood. The level of IgE with these individuals was not altered and so a push towards 
atopic affects is not seen in this study (Lopuhäa 2000). 
1.4.4.2 Animal Model Evidence for Developmental Origins of COPD 
  There  are  no  studies  within  the  literature,  at  the  time  of  print,  which  has  investigated  the 
developmental origins of COPD within an animal model. 
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1.5 Animal Models 
Animal models are used as a surrogate for humans. This is due to ethical reasons as well as practical 
reasons. One of the biggest advantages of using an animal model is the complete control over the exposure, 
diet and/or challenge that the animal experiences. It is also possible to get the results faster as the life span 
of the model animal is usually much shorter than that of humans. As this study is interested in the effect on 
the lung development from maternal environmental exposure up to late adulthood, to encompass possible 
effects on risk of COPD, a human study looking at a single generation would be an investment of over 60 
years. With an animal model this time-span can be vastly reduced depending on the species used.  
1.5.1  How Appropriate are Animal Models 
It is important to compare the animal model being used back to the human model trying to be 
emulated. This is essential because if the animal model being used has no relevance to that seen in humans 
then there is no reason to be using that model. There are several animal models which have been used to 
help investigate the possible effect a certain treatment or environment may have upon the human system. 
These models vary depending on the area of interest of the study, which animal is closest to displaying the 
processes being looked at, or the effects, as seen in humans.  
If the study is looking at an effect relevant to all mammals then mice, rats, dogs or sheep may be 
used. For example  mice  can be used to model the effect of gene expression  when in the presence  of 
interfering RNAs. Sheep have been used as a model of human development to examine the effect of single 
and repeated doses of corticosteroids on lung function, arterial pressure and growth (Moss 2002). In another 
study (Bederson 1986) rats were used to refine the best way to examine the effect of middle cerebral artery 
occlusion as seen in human stroke victims. Rats are a common choice for animal experiments as they have a 
short life span, so breeding new generations takes less time, and they tend to have larger litters giving a 
good number of animals to increase the power of the study. There are a few disadvantages with using rats, 
the main one being that the rats are not fully developed at birth, unlike humans. A commonly used animal 
model that is fully developed at birth are sheep, not only are these animals fully developed at birth but they 
have large fetuses which allow investigation at earlier time points. 
The model used in each investigation has to relate to humans as well as being as economical as 
possible. The reason for economic choices in models may have to be considered in terms of number as well 
as overall cost. Will the study have more impact with a larger number of smaller animals, for example rats, 
than with a smaller number of larger animals, such as sheep? 
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As the level of human comparison increases within the animal model it become harder to obtain the 
ethical permission to carry out any investigations. The animals also increase in size and the complexity of 
care and treatment levels increase, increasing the cost. Therefore the animal that was chosen to model our 
maternal nutrient challenge was the Wistar rat. These rats have been used for many years as a model of 
human relevance. 
1.5.2  Comparison Between Wistar Rat and Human Lung development. 
Human lung development begins in the womb when the fetus makes breathing movements. The first 
three stages of lung development occur before birth while the last and longest stage occurs after birth, as 
seen in figure 13. The first stage is known as the Pseudoglandular stage. It occurs between the fifth and 
eighteenth week after fertilisation. During this phase the bronchiole tree is laid down and the premature 
airways become lined with cubic epithelium. The second stage is known as the Canalicular stage. It occurs 
between  the  sixteenth  and  twenty-seventh week  of  development.  During this  stage the epithelial  cells 
differentiate and the blood-air barrier is formed. The last stage before birth is known as the Saccular stage. It 
occurs from the twenty-fourth week until birth. During this stage the airspaces expand and lung surfactant is 
starting to be produced. Once born the lung starts to be used and the next stage of development occurs. 
This stage is known as alveolaristion. It occurs from birth up until the child is approximately five years old. 
This stage mainly consists of an increase in the foundation structure of the lung (Burri 1984). 
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Figure 13: Diagrammatic representation of the stages of human lung development. Lung development starts five 
weeks after fertilisation and continues until the child is around five years old. Over this period of time there are four 
defined stages. Each stage has to occur in order but the next stage can begin before the previous one has ended. 
Rat lung development follows a similar pattern as that of the human, as seen in figure 14. It starts at 
a similar stage with the lung having no alveoli before birth. There is not much change in the lung structure 
for the first four days after birth. During days four to seven proliferation occurs in the thick walled secondary 
alveolar septa. The surface area of the lung then continues to increase until about day thirteen. During this 
period,  around  day  ten,  respiratory  bronchioles  are  formed.  From  day  thirteen  until  the  lung  finishes 
development,  about  day  28,  the  secondary  septa  elongate  creating  an  increase  in  lung  volume  which 
coincides with a decrease in volume density (Powell 1980). 
 
Figure 14: Diagrammatic representation of the stages of rat lung development. Lung development starts three weeks 
after fertilisation and continues until the rat is around 20 days post partum. Over this period of time there are four 
defined stages. Each stage has to occur in order but the next stage can begin before the previous one has ended. 
  The average life span of a human is 80 years (Sowell 2003) with lung development taking 5.6 percent 
of  that  time.  The  average  life  span  for  the  Wistar  rat  is  about  three  years  (Goodrick  1982)  with  lung 
development taking 13.5 percent of that time. As can be seen the development of the rat lung takes up 
twice as long as the human lung development as a percentage of total life span. However when looking at     Chapter 1  Introduction 
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the stages of development, it is seen that some of the stages that occur before birth in the human, occur 
after birth in the rat. This raises significant considerations for utilisation of the rat as a model for human lung 
development. Firstly prenatal environmental exposures in the rat may not show effects on later stages of 
lung development that occur postnatally in the rat but prenatally in the humans. Secondly, changes in early 
postnatal environment may have greater effects on adult lung function in rats than in humans. Despite these 
limitations the stages of development that the lungs of both organisms mature through are similar. Use of 
the  Wistar  rat  as  a  model  for  human  development  is  well  established  and  has  been  used  to  model 
development programming of the lung previously (Chen 2004). 
1.5.3 Models of Intrauterine Growth Restriction Models, IUGR 
  As implied, intrauterine growth restriction models reduce, or restrict the growth of the fetus while in 
utero. There are several ways to induce this challenge to the offspring. The most common forms include 
placental ligation, total nutrient reduction, or a reduction in a specific food group within the diet, and 
standardisation of litter size. Some of these methods are used in conjunction with each other or as ways of 
standardising the protocol to refine challenge effects. 
  Placental ligation involves removal of the nutrients via ligation of the placenta. This method does not 
involve  any  alterations  to  the  mother’s  diet  and  results  in  total  restriction  of  nutrients  flowing  to  the 
offspring. Disadvantages of this method include increased stress levels to the mother, as she is often being 
handled, and being more labour intensive as the ligation requires an operation to be preformed on the 
pregnant rats. Wigglesworth (1974) used placental ligation by attaching a silk ligature to the lower end of the 
uterine horn restricting the growth of the fetuses that are closest to this horn. This was undertaken on day 
17 of the pregnancy and the rats were culled 4-5 days afterwards. By doing this in this way the control and 
IUGR animals were both exposed to the same external factors reducing the error between the two groups. 
This model results in up to 60% growth retardation of the IUGR fetuses, if they survived, at the extreme end 
of the scale, but were normally found to have between 15% and 30% reduction in growth when compared 
with the control animals (Wigglesworth 1974). 
A total reduction in the food intake by the mother also produces restricted growth in the offspring. 
This is undertaken by limiting the amount of food that the mother has access to. It is less labour intensive 
than the placental ligation technique but can only be used as a global reduction in the nutrients taken in by 
the mother. Ozaki et al. used total nutrient reduction of 30% on the rats from day 0, initially found to be 
pregnant, to day 18.  This study used 10 control rats and 11 restricted rats. It found that restricted rats had 
significantly increased blood pressure (p=<0.01) at age 60 days. The rats also showed adverse effects in their 
cardiovascular function (Ozaki 2001).     Chapter 1  Introduction 
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To try and refine the effect of a single compound in the development of an organism, the reduction 
of a single food group linked with that compound may be undertaken. This method involves replacement of 
the usual rat food chow with one that has an altered concentration of the tested food group. This method is 
less labour intensive than the placental ligation but costs are increased due to the altered diet that the rats 
eat. Kalenga et al. used the reduction of casein (12% and 8%) in the maternal diet during pregnancy. This 
study used 11 control rats and 23 IUGR rats. It found that this model resulted in the restricted rats having a 
reduced lung volume, although the lung parenchyma was mature, and the growth of the rats was retarded 
(Kalenga 1995). 
All  epidemiological  evidence  within  humans  has  been  based  on  growth  restriction  and  within 
animals, evidence comes from IUGR. This can lead to some confusion and can result in interchangeable 
terminology.  
There  is  a  lot  of  variability  within  the  models  described,  but  most  are  looking  at  unbalanced 
nutrition. This means that other studies, such an increased fat model, have been put into the same category, 
however these are not IUGR but over nutrition. 
1.5.4  Langley-Evans Model. 
An early study from 1983 initially proposed the dietary challenge of a low protein maternal diet. This 
study used four different percentages within the diet of protein (6, 8, 12 and 18%) (Resnick 1983). This study 
found  that  animals  from  a  low  protein  maternal  diet  showed  a  brain-sparing  phenotype  that  was  not 
reversed when the pups were cross fostered to foster mothers who had been given an increased protein 
diet, 25%, indicating that the alterations had occurred in utero. 
The Langley-Evans model, proposed almost ten years later, is used as the basis for this study. The 
first  description  of  these studies  was  published  in  1994  (Langley  1994).  In  a  subsequent  study  protein 
restricted rats showed a larger fetal and placental size at 20 weeks gestation, but there was no final effect on 
birth weight. No difference in total protein within the brain was seen at either 20 days gestation or at birth, 
however levels of glucocorticoid enzymes were altered with a lower concentration in the low protein rats for 
the three areas of the brain studied. Interestingly the receptors for each of these enzymes did not have an 
altered  concentration.  Although  the  measurements  were  done  by  proxy,  using  alterations  in  the 
concentration of resulting compounds (Langley-Evans 1995). Although the study used different time points 
for culling, 20 days into gestation; at birth; weaning and 7 weeks after birth, the dietary components used in 
the Langley-Evans study are the same that were used in the diet for this investigation. Exact details of the 
dietary components are listed in table 3. 
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Dietary Components  Control Diet (%)  Protein Restricted Diet (%) 
Casein  18  9 
Cornstarch  42.5  48.5 
Sucrose  21.3  24.3 
Corn Oil  10  10 
Cellulose Fibre  5  5 
AIN-76 mineral mix  2  2 
AIN-76 vitamin mix  0.5  0.5 
DL-Methionine  0.5  0.5 
Choline Chloride  0.2  0.2 
 
Table 3: Component break down of both Control and Protein restricted diets, for the duration of pregnancy of the 
Wistar rats. Reproduced from (Langley-Evans 1995). 
  One of the important things to note with this study is that the deficit in protein is counterbalanced 
by an increase in the carbohydrate content. Therefore any effects seen could be due to restricted protein or 
increased carbohydrate. 
1.5.5 Previous Studies Using Langley-Evans Model 
  Studies that have utilised the Langley-Evans dietary model have seen a decrease in the life span of 
those rats whose mothers were exposed to a low protein diet during their pregnancy. Interestingly this if the 
offspring were born small and did not experience a period of catch-up growth their life span was increased, 
however if the period of catch-up growth was present then their life span was reduced (Langley-Evans 2006). 
Those offspring exposed to a low protein maternal diet during pregnancy also showed a preference for fatty 
foods during their life span(Bellinger 2004; Engeham 2010). 
  Studies of individual tissues within these rats observed alterations in both liver and renal function. 
Hepatic gene promoters exhibited altered methylation giving rise to differing levels of gene expression, 
which  was  found  to  be  transgenerational,  in  F2  and  F3  generations  (Burdge  2007;  Hoile  2011).  These 
alterations could be counteracted by the supplementation of folic acid within the diet (Lillycrop 2010). A 
decrease in nephron number as well as an increase in blood pressure was found transgenerationally, F1 and 
F2, in male offspring (Harrison 2009). 
  Blood pressure has been extensively studied using this model. An increase in male offspring blood 
pressure  has  been  consistently  seen  with  this  diet  (Swali  2010),  and  this  has  also  been  found  to  be 
transgenerational, F2 (Torrens 2008). These alterations in blood pressure can be counter-acted by dietary 
supplementation with folate (Torrens 2006). A possible mechanism for this alteration in blood pressure was 
proposed by an increase in the expression level of prostaglandin E(2)coupled with impaired degradation 
(Sherman  1999).  Differences  in  bone  growth  were  also  observed  with  exposure  to  maternal  protein 
restriction (Mehta 2002).     Chapter 1  Introduction 
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  As  the  thrifty  hypothesis  has  proposed  differences  to  be  an  epigenetic  effect,  (Hales  2001)  as 
supported by altered hepatic gene promoter methylation, the levels of homocysteine were considered, but 
there  was  no  alteration  in  these  levels  found.  (Langley-Evans  2006)  It  was  also  suggested  that  any 
methylation changes would be gene specific and not genome-wide (Engeham 2010). 
1.5.6 Summary of animal model considerations for DOHAD Models 
To  summarise  this  section  Nathanielsz  highlighted  ten  main  principles  within  developmental 
programming that need to be considered (Nathanielsz 2006). These are presented below together with 
evidence  that  chronic  human  disease,  in  particular  respiratory  disease,  is  subject  to  the  effects  of 
developmental programming. 
1.  Critical periods of vulnerability: This has been exampled in the fact that exposure to famine 
within the Dutch Hunger Winter cohort has been linked with mortality from COPD if the exposure 
occurred during the early or mid-trimester of pregnancy but not late (Lopuhäa 2000). 
2.  Permanent effects: an example of this is given by increased glucose tolerance and insulin 
production  in  individuals  that  experienced  nutritional  restrictions  during  gestation  but  have  these 
diabetes symptoms at the age of 50 (Painter 2006). 
3.  Activity dependant: this aspect is looking at the use of organs by the fetus before it is born, 
such  as  fetal  breathing  movements.  Studies  in  sheep  have  shown  that  if  these  movements  are 
depressed for any reason then the lung does not mature as expected (Harding 1993). 
4.  Structural changes in important organs: a protein alteration within the diet caused different 
parts of rat brain to develop differently, altering the size and the ability of some receptors to bind their 
substrates (Langley-Evans 1995). 
5.  Key role for placenta: low placental weight increases risk of developing chronic heart failure 
later in life (Barker 2010). 
6.  Fetal compensation carries a price: rat dams fed a low protein diet during their pregnancy 
produced offspring that had lower birth weights than the control. However if the offspring were then 
fed a low protein diet until they were weaned their life-span was longer than those offspring given a 
normal diet for this period (Chen 2009). 
7.  Attempts after birth to reverse the consequences of programming may have their own 
unwanted consequences: this is a very similar point to the previous one, where any attempt at altering 
the consequences of programming can lead to deleterious outcomes in the long run. 
8.  Fetal cellular mechanisms often differ from adult ones: This is of particular note in studies 
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experiences  once  born.  This  is  due  to  the  concentration  changes  of  oxygen  presenting  each 
environment.  
9.  Effects  of  programming  may  pass  across  generations:  an  increased  risk  of  developing 
asthma was found to be linked to grand maternal smoking, during the gestation of the mother, for the 
grand children (Li 2005). 
10.  Different effects in males and females: after a low protein diet was given during pregnancy 
to rat dams, hypertrophy was seen in male but not female offspring (Woods 2003). 
 
Each of these points can alter the effect on the offspring and the following generations. One of the 
easiest factors that can be altered to produce a programming effect is nutrition. Several of the examples 
given previously have shown the effect of altered nutrition on the development of the lungs in both humans 
and animal models. These effects have been linked with development of respiratory disease throughout the 
individual’s life. 
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2. Materials 
2.1 Physiology and Morphometry   
All  reagents  were  stored  at  room  temperature,  unless  otherwise  stated.  All  chemicals  were 
molecular Biology or Biotechnology grade. 
Table 4 Reagents 
Reagent  Cat no:  Supplier 
Absolute Ethanol  51976  Sigma 
Calcium Chloride  262244w  BDH 
Choral Hydrate  C/4280/53  Fisher Scientific 
Eosin Yellow  HD1320  R A Lamb 
Formalin  00600E  Surgipath 
Haematoxylin  411161000  Acrōs Organics 
Paraffin Wax  08605E  Surgipath 
Pertex  178290  Histolab 
Potassium Alum  A/1840/60  Fisher Scientific 
Sodium Dodecyl Sulphate  S/P530NC/48  Fisher Biochemicals 
Sodium Hydroxide  S-8045  Sigma 
Sodium Iodate  S8379  Sigma 
10 x TBE Buffer  EC-860  National Diagnostics 
Xylene  X/0250/17  Fisher Scientific 
 
Table 5 Plastic Ware 
Plastic ware  Cat no:  Supplier 
Cover Slips (22 x 40mm)  MNJ-350-0605  Menzel-Glãser 
Universal Tubes  CW3900  Alpha Laboratories 
Petri Dishes  633102  Greiner Bio-one 
Plastic Cassette  M490-10  Simpat 
Slides  Colour frosted Ends  Knittel-Glöeser 
 
Table 6 Apparatus 
Apparatus  Serial no:  Location  Supplier 
Camera  Coolpix 4500  Lab 19, Level B, Link Block  Nickon 
Hypercentre Tissue Processor  unknown  Lab 21, level B, Link Block  R A Lamb 
Microscope  196862  Lab 19, Level B, Link Block  Leica 
Microtome  unknown  Lab 23, Level B, Link Block  Leitz 
Drying Oven  unknown  Lab 20, level B, Link Block  Leec 
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Table 7 Software 
Program  Version  Supplier  Web-link 
SPSS  14.0  SPSS Inc  www.spss.com 
 
Table 8 Miscellaneous  
Description  Supplier 
Scalpel & Blades  - 
Tube Clamp  - 
Tubing  - 
Sterile Tweezers  - 
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2.2  Bronchial Hyperresponsiveness 
All  reagents  were  stored  at  room  temperature,  unless  otherwise  stated.  All  chemicals  were 
molecular Biology or Biotechnology grade. 
Table 9 Reagents 
Reagent  Cat no:  Supplier 
Calcium Chloride  C7902  Sigma 
Potassium Chloride  P4504  Sigma 
Magnesium Sulphate  M1880  Sigma 
D-Glucose  G5767  Sigma 
EDTA  E1644  Sigma 
Potassium Phosphate  P5379  Sigma 
Sodium Bicarbonate  S8875  Sigma 
Carbachol (stock 1x10
-2M, kept at -20
oC)  C4384  Sigma 
U46619 (stock 1x10
-4M, kept at -20
oC)  T0516  Sigma 
Histamine (stock 1x10
-2M, kept at -20
oC)  H7125  Sigma 
Angiotensin (stock 1x10
-4M, kept at -20
oC)  A9525  Sigma 
Isoprenaline (stock 1x10
-2M, kept at -20
oC)  I5627  Sigma 
Papaverine (stock 1x10
-2M, kept at -20
oC)  P3510  Sigma 
Salbutamol (stock 1x10
-2M, kept at -20
oC)  S8260  Sigma 
BRL 37344 (stock 1x10
-4M, kept at -20
oC)  B169  Sigma 
Prazosin (stock 1x10
-2M, kept at -20
oC)  P6656  Sigma 
 
Table 10 Plastic ware 
Plastic ware  Cat no:  Supplier 
1.5ml Tubes  616201  Greiner Bio-one 
10ul Pipette Tips  771288  Greiner Bio-one 
100, 200, 1000ul Pipette Tips  772288/739288/740288  Greiner Bio-one 
1ml Syringe  300013  BD Plastipak 
20ml Syringe  300613  BD Plastipak 
Petri Dishes  633102  Greiner Bio-one 
 
Table 11 Apparatus 
Apparatus  Serial no:  Location  Supplier 
Microscope  -  Vascular Lab, Level C, IDS Building  Zeiss 
Lights  -  Vascular Lab, Level C, IDS Building  Zeiss 
Myograph   -  Vascular Lab, Level C, IDS Building  Danish Myo Techniologies 
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Table 12 Software 
Program  Version  Supplier  Web-link 
Chart  5.0  AD Instruments  www.adinstruments.com  
SPSS  14.0  SPSS Inc  www.spss.com 
 
 
Table 13 Miscellaneous 
Description  Supplier 
Scalpel & Blades  - 
Metal Spatulae  - 
Funnel  - 
Pins  - 
Philip Head Screw Driver (size 2.0)  - 
Dissection Scissors  - 
Small Sealable Plastic bag  - 
Wire (size 40µm)  - 
Forceps  - 
Writing Ink  - 
Sterile Tweezers  - 
 
PSS and KPSS solutions 1 Litre 
Reagent  PSS  PSS Concentrations (mM)  KPSS  KPSS Concentrations (mM) 
NaCl  6.954g  12  -  - 
KCl  0.350g  0.47  9.222g  12.37 
MgSO4  0.288g  0.2  0.288g  0.2 
NaHCO3  2.100g  0.25  2.100g  0.25 
KH2PO4  0.161g  0.134  0.161g  0.134 
D-Glucose  0.991  0.55  0.991g  0.55 
EDTA  0.008  0.00273  0.008g  0.00273 
CaCl2  2.5ml  2.5  2.5ml  2.5 
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2.3 Methylation and Gene Expression 
All  reagents  were  stored  at  room  temperature,  unless  otherwise  stated.  All  chemicals  were 
molecular Biology or Biotechnology grade. 
Table 14 Reagents 
Reagent  Cat no:  Supplier 
Absolute Ethanol  51976  Sigma 
DEPC Treated Water  N/A  N/A 
2 x qPCR Mastermix (PD)  Mastermix-R  Primerdesign ltd 
PCR Grade Water  04 909 631 001  Roche diagnostics, UK 
Iso-propanol  I-0398  Sigma 
Guanidine Hydrochloride  G-3272  Sigma 
Sodium Citrate  S-4641  Sigma 
Chloroform  BP1145-1  Fisher BioChemicals 
TRIzol Reagent  15596-026  Invitrogen 
Liquid Nitrogen  N/A  N/A 
 
Table 15 Plastic ware 
Plastic ware  Cat no:  Supplier 
ABgene 96 well V-Bottomed storage plates  AB-1058  ABgene, UK 
ABgene Thermo-Fast 384 Well Plates  TF-0384  ABgene, UK  
Universal Tubes  CW3900  Alpha Laboratories 
Matrix D Lysing Tubes  6913-100  Q-Bio Gene 
1.5ml Tubes  616201  Greiner Bio-one 
0.5ml Tubes  LT2172  Alpha Laboratories 
0.2ml Tubes  LW2130  Alpha Laboratories 
0.2ml Tube Strips  LW2500  Alpha Laboratories 
10ul Pipette Tips  771288  Greiner Bio-one 
100, 200, 1000ul Pipette Tips  772288/739288/740288  Greiner Bio-one 
Petri Dishes  633102  Greiner Bio-one 
2ml Screw Cap Tubes  CP5320WL  Alpha Laboratories 
25ml Glass Pastets  760180  Greiner Bio-One 
Pipette Filler  712912  Alpha Laboratories 
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Table 16 Commercial Laboratory Kits 
Kit   Cat no:  Supplier 
ImProm II™ - Reverse Transcription Kit  A3800  Promega, Southampton, UK 
SYBRgreen™ Core qPCR Mastermix Kit  RT-SN10-05  Eurogentec, SA 
DNAfree Kit  AM1906  Ambion, USA 
Methylamp
TM  Global  DNA  Methylation 
Quantificantion Ultra Kit 
P-1014  Epigenetek  
 
Table 17 Apparatus 
Apparatus  Serial no:  Location  Supplier 
ABgene Plate Heat-sealer  951/2563  Asthma Genetics Lab  ABgene, UK 
AB54-S Balance  1120133255  Asthma Genetics Lab  Mettler-Toledo, USA 
BioPulverizer  59014H (cat no)  Asthma Genetics Lab  BioSpec Inc, US 
Lightcycler480™ Real-time PCR 
Machine 
1230  Asthma Genetics Lab  Roche diagnostics, UK. 
Nano-drop Absorbance 
Spectrophotometer 
unknown  Lab 18, Human Genetics  Nano-drop technologies, USA 
MJ Research DNA Engine Tetrad 
Thermal cycler 
TD002380  Asthma Genetics Lab  BioRad, USA 
Labofuge 400 Plate Centrifuge  40340180  Asthma Genetics Lab  Heraeus, Germany 
Ribolyser  unknown  Brook Lab  Thermo Fisher Scientific Inc 
UV PCR Cabinet  MC 0239  Asthma Genetics Lab  Lab-Caire, UK 
M-240R Bench-top Centrifuge  0000138-02-00  Asthma Genetics Lab  BOECO, Germany 
Microplate Reader  L02186 
Lab  LF58,  F  level,  South 
Academic Block 
Molecular Devices 
Incubator  unknown  Asthma Genetics Lab  New Brunswick Scientific 
 
Table 18 Software  
Program  Version  Supplier  Web-link 
SPSS  14.0  SPSS Inc  www.spss.com 
Roche Lightcycler480 Relative 
Expression Module 
1.2 
Roche  Diagnosics, 
UK 
www.roche-applied-science.com 
Roche Lightcycler Basic Software  1.2 
Roche  Diagnosics, 
UK 
www.roche-applied-science.com 
SOFTmax PRO  3.0  Molecular devices  www.moleculardevices.com  
BLAST Search    NCBI  www.ncbi.nim.gov/blast/Blast.cgi 
Primer Express  2.0  Applied biosystems   
Universal Probe Assay Design  - 
Roche  Diagnosics, 
UK 
www.roche-applied-
science.com/sis/rtpcr/upl/index.jsp 
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Table 19 Miscellaneous  
Description  Supplier 
Foil  N/A 
ABgene Clear Seal Diamond Plate Seals  ABgene, UK 
ABgene Clear Seal Strong  ABgene, UK 
Scalpel & Blades  - 
Liquid Nitrogen Dewar  - 
Metal Spatulae  - 
Sterile Tweezers  - 
RNAzap  Ambion, USA 
RNAzap Wipes  Ambion, USA 
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3. Methods 
3.1 Southampton Maternal Protein Restriction Model (PR) 
To investigate the effects of maternal under nutrition on lung development, the Southampton model 
of maternal protein restriction (PR) was used. This diet employs a 50% reduction in the casein content (PR, 
9% casein) in the isocaloric diet of pregnant dams from the day of confirmation of pregnancy until delivery, 
with control dams (C) receiving an 18% casein diet. It is important to note that the dietary challenge in these 
rats is during the entire pregnancy which means that there is no specific developmental window being 
targeted.   
This diet is based on the Langley-Evans model of protein restriction and a detailed description was 
given in section 1.5.4. On confirmation of pregnancy, female Wistar rats were allocated to either the control 
or  protein  restricted  diet.  At  delivery  dams  and  pups  were  returned  to  standard  chow  and  litters 
standardised to 8. The Home Office project license number for this investigation is 70/6457. 
Lungs were harvested from male F1 offspring at the end of initial lung development (28 days), young 
adult age (35 days), adult age (75 days), adult age (120 days) and mature adult age (225 days). As can be 
seen in figure 14, there were 25 animals available in the F1 28 day old group, with 15 from the control diet 
and 10 from the protein restricted diet. These animals were studied for physiological and morphometric 
measures, as well as gene expression. There were 12 animals from the F1 35 day old age group, 6 from 
control and 6 from the protein restricted diet. 12 animals were also studied from the F1 75 day old age 
groups with 6 from the control and 6 from the protein restricted group. Both of these two groups were used 
for the BHR experiments only. There were 18 animals from the F1 120 day old age group, with 11 from the 
control diet and 7 from the protein restricted diet. These animals were studied for gene expression data 
only. There were 12 animals from the F1 225 day old age group, with 6 from the control diet and 6 from the 
protein restricted diet. These animals were collected for physiological and morphometric measures, as well 
as gene expression.       Chapter 3  Methods 
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Figure 15: Diagrammatic representation of the two rat diets and the F1 culling time points for this investigation. Rats 
were randomly allocated control or protein restricted diet once pregnancy had been confirmed. They remained on this 
diet until they gave birth when they were all given the control diet. Offspring from these rats were culled at days 28, 35, 
75, 120 and 225. 
A further generation (F2) was then bred from the females F1 offspring bred to control males, and 
lungs were harvested from male F2 offspring at the end of initial lung development (28 days), figure 16. 
There were 41 animals available in the F2 28 day old group, with 24 from the control diet and 17 from the 
protein restricted diet. These animals were studied for physiological and morphometric measures, as well as 
gene expression. 
 
Figure 16: Diagrammatic representation of the two rat diets and the F2 generation for this investigation. Rats were 
randomly allocated control or protein restricted diet once pregnancy had been confirmed. They remained on this diet 
until they gave birth when they were all given the control diet. Offspring from these mice were then mated and the 
resultant generation culled at day 28, with no further dietary challenge. This created the F2 generation. 
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The females from this group (F2) were then bred with control males to produce the F3 generation 
from which the lungs were harvested from the males at 21 days, figure 17. There were 21 animals available 
in the F3 21 day old group, with 16 from the control diet and 5 from the protein restricted diet. These 
animals were studied for physiological and morphometric measures, as well as gene expression. 
 
Figure 17: Diagrammatic representation of the two rat diets and the F3 generation for this investigation. Rats were 
randomly allocated control or protein restricted diet once pregnancy had been confirmed. They remained on this diet 
until they gave birth when they were all given the control diet. Offspring from these mice were then mated to produce 
the F2 generation. The F2 offspring were then mated and the resultant generation culled at day 21, with no further 
dietary challenge. This created the F3 generation. 
The rats were bred until the third generation as these individuals will have had no exposure to the 
dietary challenge. The F1 are obviously present inside the womb of the mother when the challenge is being 
administered. The eggs that will form the F2 generation are also present at this time and so will be exposed. 
The F3 however are not present in any form at the time of the challenge. This means that any difference that 
is found in this generation will have to be due to inherited epigenetic effects, as opposed to direct effects of 
the exposure.      Chapter 3  Methods 
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3.2 Physiology and Morphometry 
3.2.1 Lung Volumes. 
To assess lung volumes in F1 animals the left lung was removed and weighed to give the wet mass. A 
needle was then inserted into the primary bronchi of the lung and the valve opened to allow the formalin to 
fill the lung. Formalin was used as the fixing agent as its use in morphometric analysis of the lung is well 
established (Hayatdavoudi 1980; Tome 1990; Lang 1994). Following inflation the lung was again weighed and 
the volume of the fluid introduced into the lung was used to estimate the volume of the lung. The formalin 
was always introduced from the same height/pressure which was calculated as previously described (Weibel 
1966) and shown below: 
Lung fixing perfusion pressure: 
Perfusion pressure                        = 25 cm of H2O  (1.36 cm of H2O is equivalent to 1 mmHg)  
          = 18.4 mmHg   (1 mmHg is equivalent to 133 Pa) 
          = 2447.2 Pa 
Hydrostatic pressure [Pa]       P= rgh     where   g = gravity at 9.81 m/s
2 
             h = height [m] 
r = practical gravity of fluid (m ÷ v)      [kg/m
3] 
r for 10% formalin       = 1.03 g / ml 
          = 1030 kg/m
3     (water is 1000 kg/m
3) 
Therefore: 
2447.2  = 1030 × 9.81 × h 
 
h  = 2447.2 ÷ 10104.3 
h  = 0.242 m  
  = 24.2 cm 
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3.2.2  Tissue Preparation and Embedding 
  To ensure consistency, left lungs were removed and embedded for all animals. Paraffin wax was 
chosen for embedding as the gaps in the matrix are larger than those found in other embedding substances, 
such as GMA. This would allow for the potential utilisation of other stains e.g. trichrome staining, whose 
large dye molecules would be not able to access the tissue otherwise, as well as any immuno-staining that 
may be required during further investigation.  
The left lung was kept in formalin, 10 times more formalin as tissue, volume per volume, for 48 
hours, this was considered sufficient fixing time, as although the lung is a large piece of tissue, it had already 
been infused with formalin during estimation of lung volume (see section 3.1.4.1.1). The formalin was then 
removed and replaced with 70% ethanol solution for storage until embedding. Tissue was placed inside a 
plastic labelled cassette and then put into the reaction chamber of the Hypercentre tissue processor (R A 
Lamb). The tissue was bathed in 50% alcohol, 70% alcohol and 90% alcohol for 10 minutes each, followed by 
absolute alcohol for 50 minutes and then a mix of equal parts absolute alcohol and chloroform for a further 
10  minutes.  It was then  placed into  chloroform  for  20 minutes  before  being  put  into  the  melted wax 
chamber at 60
oC for 20 minutes. It was then left in the chamber overnight, at 37
oC under a gentle vacuum 
which helps the solution to penetrate the tissue and remove small air bubbles.  
Following the process above, the samples were placed in the wax bath. The correct base mould was 
chosen depending on the size of the tissue and a thin layer of wax was poured into it. It was kept on the 
warm spot on the machine (Hypercentre Tissue Processor, R A Lamb) until the sample had been removed 
from the cassette and orientated into the correct position in the mould with heated forceps. The mould was 
then put on the cold spot and the tissue sample held until the wax had set enough to hold the tissue. 
Following this, the mould was filled until three quarters full and then the labelled plastic top of the cassette 
was added to the top of the mould and both were completely filled with wax. The mould was left to set 
completely and then the wax embedded sample removed from the mould and stored until cut.  
3.2.3  Cutting and Haematoxylin and Eosin (H & E) Staining 
The paraffin block with the embedded lung was cut on a microtome (Leitz) in 5µm thick sections. To 
ensure that the beginning of the sectioning was random, which is essential for unbiased analysis, the first 
section taken was the first full section of the block that included tissue (Hyde 2007). Twenty sections were 
cut and mounted onto slides. Twenty sections were kept at this point as the whole lung had to be cut at one 
time and spare slides may be needed for further investigation. This made up layer A. One hundred 5µm 
sections were then cut and discarded. A new layer (layer B) of twenty sections was then cut. This was 
repeated until the whole lung had been cut through.  
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One slide from each layer was then stained using H & E (Brumley 1967; Holt 1988; Chen 2004).  
Haematoxylin solution preparation: 
Haematoxylin                 1g 
Distilled water (ROW)              1000mls 
Potassium Alum              50g 
Citric Acid                1g 
Chloral Hydrate               50g 
Sodium Iodate                0.2g 
 
Eosin Yellow solution preparation: 
Eosin Yellow                5g 
Calcium Chloride              1g 
Distilled water (ROW)              500mls 
Sections were dewaxed in xylene for two minutes and then hydrated through graded alcohols for 
five minutes. Sections were stained in Mayers haematoxylin for ten minutes and then left in gently running 
cold tap water for five minutes to ‘Blue’. Five minutes in 1% eosin solution followed which was then washed 
in gently running  cold  tap  water for  a further five  minutes.  Sections were  dehydrated through  graded 
alcohols and then cleared in Xylene before a cover slip was applied and the slide left to set before imaging.  
3.2.4  Stereology 
 
Figure 18: Overview of H and E images from the offspring rat lungs culled at 225 days old. These mature lungs show 
an offspring lung from the control in utero diet on the left and from the protein restricted diet on the right. These 
images were taken at x10 magnification. 
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To estimate the surface area of the lungs a volume density design was used based on Cavalieri’s 
principle.  The sections used were  transverse  uniform random.  This  means that  one  orientation  will  be 
chosen according to the design. For the measurements to be correct two other choices must be isotrophic 
(random). The first of these is achieved by starting the cutting of the sections at a random point (first full 
section of paraffin that contains tissue), the second is the placing of the grid onto the sample. The grid has to 
have one plane matching the vertical plane but it can then be randomly place onto the image in the other 
two directions, forward or back and left or right. All equations, method designs and grids have been taken 
from, or are based on, those referred to in ‘Unbiased Stereology’ (Howard 2005). 
 
Figure 19: Overview of the lung structures showing an airway with its different components. In the middle, at the top 
of the image, a vessel on the right and air spaces in the bottom left of the image. Any tissue which is not of interest is 
labelled as Neuropil. This image was taken at x10 magnification. 
3.2.4.1  Volume Fractionation 
  To estimate the volume of smooth muscle around the airway, point counting was used on an image 
taken at x10 magnification. This method gives a ratio of total volume to the volume of interest, in this case 
smooth muscle. The total number of points, from the randomly placed grid, which lie in the area of interest, 
e.g smooth muscle, and the number of points in the reference area, e.g. smooth muscle and the lumen and 
edge of the airway are counted. Because the final value is a ratio of the object of interest it does not matter 
it the airway lies at right angles to the section. The equation used for this estimation is: 
Volume density of area of interest = total number of points in the area of interest 
                                                          Total number of points in the area of reference 
 
The grid used to determine if there is an alteration in the composition of the lungs has to be the 
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component which is being measured. Selection of the correct grid was undertaken using the ‘nugget effect’ 
equation.  This  equation  gives  a  percentage  error  for  the  variance  of  an  area.  This  can  be  altered  by 
increasing the number of sections looked at or the number of sections cut from the original tissue. The 
nugget effect, which gives the error involved depending on how close the points are in the grid, can be 
altered by choosing a grid with either more or less points. One lung was chosen randomly and used to 
determine if this was an acceptable method to produce the required results. The first grid that was used 
tested was not correct as it had more than a 10% error in both the variance of area and the nugget effect. 
The second grid that was considered was used (see figure 20), as it produced an 8% error for the variance of 
area  and  a  0.5%  error  for  the  nugget  effect.  These  are  both  below  the  10%  error  that  is  considered 
acceptable with this method (Howard 2005). The rest of the lungs were then assessed following the same 
methods.  
 
Figure 20: An image analysed from the 225 day old rat offspring with the point counting grid overlaid on top as seen 
during analysis. As the cross has a thickness the same point on the cross is used as a reference point for the cross. In 
the analysis the top right point of the cross line overlay was used. Depending on where this cross lands on the image 
the point is counted as in that tissue of interest. This image was taken at x10 magnification. 
3.2.4.2  Surface Area 
To estimate the surface area of the alveoli in the lungs the Cavalieri’s principle was used at the same 
magnification but this time the points of intersection along an isotrophic line are used as the estimator, 
figure 21. The surface area is given by the number of points of intersections along this given line. This will 
give a surface area A
2 in a 3D unit of volume. The equation used for this estimation is: 
Surface area =   2 x total number of intersections with interface of interest 
(cycloid length/magnification) 
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Figure 21: An image analysed from the 225 day old rat offspring with the cycloid grid for estimation of surface area 
overlaid on top. One side of the line is used to record the intercepts as the line has a thickness. The left hand-side of 
the line was used in this analysis. This image was taken at x10 magnification. 
3.2.4.3  Alveolar Wall Thickness 
  To estimate the average thickness of the alveolar walls a grid, with lines at 45
° angles and points of 
intercept at 90° to those lines, figure 22, was placed randomly over the lung image taken at a magnification 
of x63. Where the intercept of the line landed on an alveolar wall the thickness of that wall was measured 
and a geometric mean was used to compare between the groups. 
 
Figure 22: image of the alveolar walls from a 225 day old rat lung with the J-image grid for estimation of alveolar wall 
thickness overlaid on top. Where the smaller intersecting lines land on an alveolar wall, the thickness of that wall is 
measured along the same line as the small intersecting line. An average of these measurements is used to compare 
between groups. This image was taken at x63 magnification.     Chapter 3  Methods 
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3.3 Bronchial hyperresponsiveness 
3.3.1 Dissection of Bronchi from Rat Lungs.  
Initially the lung is removed from the thoracic cavity into a resin dish, allowing for the tissue to be 
pinned keeping it steady. The tray is then filled with PSS buffer and the lungs cleaned by removing as much 
of the fat and blood clots from the outside of the lungs as possible, being careful not to damage the lungs 
while doing this. A dilution, 1:10, of water soluble black writing ink in PSS is used to fill a 1ml syringe and a 
G21 needle attached to the end. The end of the needle is carefully placed into the opening of the bronchi 
and the bronchi are then filled with the ink solution. This colours the bronchi making them distinguishable 
from pulmonary vessels.  
The first order bronchi are followed into the lung and tissue is removed by lifting it away from the 
bronchial tube and cutting away from it with the lung kept steady by pinning the very edge of the lung to 
hold it in place. The bronchi branches very quickly. In this study on F1 generation, bronchi from 35 and 75 
day old rats were used. 
Once the bronchi have been removed from the lungs they are then cleaned as well as possible. This 
is essential to make it easier to mount the bronchi on to the wires of the myograph. The sections of tissue 
are cut into 2mm length pieces, as this is the length between the jaws within the myograph wells. 
 
3.3.2 Mounting of Bronchi onto the Myograph. 
 
 
Figure 23: Myograph set-up. The dissection is done using the microscope on the left. The myograph is in the middle 
with the four organ baths on the top and the computer linked to the myograph to monitor the tension on the wires is 
to the right. 
  The metal myograph wire was cut into 2cm long sections. It is important that the wire is not too long 
as there needs to be a space between the wire and the myograph well to be able to mount the bronchi. It is 
also important that the wire is not too long so that it will fit onto the screws within the wells. To make sure 
that there is enough wire, two more pieces than required were cut as the wire can bend and as it is so fine     Chapter 3  Methods 
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may also break when tightening the screws.  When the wire is cut there is a small kink where it was held taut 
when being cut. The wire is placed on the side with the kink at the bottom end nearest to the researcher to 
ensure correct orientation as it is difficult to push the kinked end through the tissue. 
  One piece of wire is then secured horizontally between the jaws within the myograph well, making 
sure that the kinked end of the wire is at the end with the screw that the tissue will be attached to first. The 
jaws can then be tightened just enough to hold the wire in place. One end of this wire, the end with the kink, 
can then be wrapped around the screw and the screw tightened but not too much as the wire may break. 
The well is then filled with 5ml of PSS buffer.  
  When this has been done the tissue can be pushed onto the wire. The jaws are opened and the 
tissue pushed into the space between them. Once this has been done the end of the wire can be secured 
onto the second screw, the same side but below the first attached screw and the wire tightened.  
  Once complete the second wire is then pushed through the bronchi tube, making sure the kinked 
end does not pass through the tissue. When the second wire has an equal distance showing on either side of 
the tissue, the jaws are gently closed to hold the wire in place as the wire is wrapped around the screws both 
top and bottom on the side. The wires are held parallel to each other and taught. As seen in figure 24. 
 
 
 
Figure 24: Bronchi tissue (pink rectangle) as positioned within the myograph bath. The two wires are secured onto the 
tension plates and passed through the bronchi lumen without being crossed/twisted together. 
 
The wells are then put back into the myograph, over slips are placed over the wells and machine is 
turned on. A mix of 95% CO2 and 5% O2 is pumped into the buffer within the wells and the solution is heated 
to around 37
oC. The resting tension on the bronchi is around 1g, which translates into 4.9mN. The tension on 
the tissue is brought up to this level and the well is left for 1 hour to get up to temperature. 
 
3.3.3 Testing of Tissue Reaction to Regents. 
Additional  PSS buffer  and PSS  with  2.5mM concentration of  CaCl2 are  warmed  up  to  37°C  and 
aerated with a mix of 95% CO2 and 5% O2, as above. At this time the myograph is turned on and the time 
marked to ensure that the tissue has achieved a stable tension. Once the tissue is stable the jaws are opened 
and the buffer is removed from the wells with a vacuum and 5ml of new KPSS is added to the wells.     Chapter 3  Methods 
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Following this, a bronchoconstrictor agent is added at the desired initial concentration and the time 
of addition is recorded on the graph. Three minutes gap is left between additional doses of drug. If  a 
different drug is to be tested, the solution is removed from the wells using the vacuum and the well is 
washed out three times with 5ml of PSS and the tissue is left to achieve a stable resting tension. 
 
Figure 25: An example of a myograph readout. Increasing concentrations of the drug are added and left for 2 minutes. 
This example is showing the effects of a bronchoconstrictor, carbachol, therefore the tension of the bronchi increases 
with each addition. The 1g scale at side is shown for reference only. 
The same process is used for the relaxation drugs but prior to the first concentration being added 
the  bronchi  are  individually  constricted  to  80%  of  the  maximum  response  to  carbachol.  This  is  done 
individually for each bronchi as an 80% constriction will differ between different bronchi due to length and 
tone of the bronchi segment. Serial dilutions are made from stock solutions for each drug of 0.01M. Dilutions 
contained 450µl of each concentration of 1x10
-3, 1x10
-4, 1x10
-5 and 1x10
-6M. These concentrations were 
added to the myograph wells as detailed in table 20. 
Table 20: Dilution series from stock concentration 1x10
-2M 
Dilution  Volume  added  per 
well (µl) 
Concentration in well 
1x10
-6  5  1nM 
1x10
-6  10  3nM 
1x10
-6  35  10nM 
1x10
-5  10  30nM 
1x10
-5  35  100nM 
1x10
-4  10  300nM 
1x10
-4  35  1µM 
1x10
-3  10  3µM 
1x10
-3  35  10µM 
1x10
-2  10  30µM 
1x10
-2  35  100µM 
     Chapter 3  Methods 
65 
 
Serial dilutions are made from stock solutions for each drug of 0.0001M. Dilutions contained 450µl 
of  each  concentration  of  1x10
-5,  1x10
-6,  1x10
-7  and  1x10
-8M.  These  concentrations  were  added  to  the 
myograph wells as detailed in table 21. 
Table 21: Dilution series from stock concentration 1x10
-4M 
Dilution  Volume  added  per 
well (µl) 
Concentration in well 
1x10
-8  5  10pM 
1x10
-8  10  30pM 
1x10
-8  35  100pM 
1x10
-7  10  300pM 
1x10
-7  35  1nM 
1x10
-6  10  3nM 
1x10
-6  35  10nM 
1x10
-5  10  30nM 
1x10
-5  35  100nM 
 
Once the experiment has been completed, the well is emptied by vacuum and the wires and tissue 
removed. The wells are washed with 5ml acetic acid for 2 minutes to remove any calcium deposits left by the 
buffer. The well is then finally washed three times with 5ml of water.  
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3.4 Methylation and Gene expression 
3.4.1 DNA, RNA and Protein Extraction  
Firstly a tissue sample of approximately 100mg in weight was snap frozen in liquid nitrogen and 
homogenised using a bio-pulveriser steel hammer. Homogenised tissue was washed into Lysing Matrix-D 
tubes with 1.0ml trizol. Tubes were ribolysed for 20 seconds on speed setting 4.0 in the ribolyser-instrument 
(Thermo Fisher Scientific). This procedure was repeated at least twice or until the tissue had been fully 
homogenised. The homogenate was transferred to a clean 1.5ml micro-centrifuge tube. 0.2ml of chloroform 
was added per 1ml of trizol, shaken vigorously by hand for 15 seconds and then centrifuged at 12,000 x g 
(11,100 RPM) for 15 minutes at 4°C.  RNA was isolated from the top aqueous layer while the bottom layer 
was kept on ice for DNA and protein isolation the following day. RNA was precipitated by mixing in 0.5ml of 
iso-propanol  (ice-cold)  per  1ml  of  TRIzol  reagent.    RNA  was  washed  twice  using  75%  ethanol  in 
Diethylpyrocarbonate (DEPC) water and the pellet was re-suspended in 20µl DNA-free master mix then 
incubated for 1 hour at 37°C. The master mix was from Ambion and consisted of 2µl 10x DNase I buffer, 1µl 
of rDNase I and 17µl of RNase-free water per tube/sample. 2µl DNase inactivation reagent was added, mixed 
and incubated for 2 minutes. Samples were centrifuged at 10,000 x g for 1.5 minutes at 4°C. The mix was 
transferred into  a  new  0.2ml  tube  and 30µl  RNase-free  water was added  before the sample  was  split 
between two screw cap tubes with 25µl in each. Tubes were stored at -80°C. 
After all of the remaining top aqueous layer was removed from the tubes, 0.3ml of 100% ethanol per 
ml of trizol was added to the DNA/protein phase left in the 1.5 ml tubes from the previous day. This was 
mixed gently via inversion and left to incubate for 3 minutes at room temperature. The top layer of phenol-
ethanol supernatant was removed to a new 2ml screw cap tube and left on ice to be used later for protein 
isolation. The DNA pellet was washed twice with 1ml 0.1M sodium citrate in 10% Ethanol per 1ml trizol. Each 
wash  step  included  a  30  minute  incubation  at  room  temperature  with  periodic  mixing  followed  by 
centrifugation at 2,000 x g for 5 minutes at 4°C. The pellet was re-suspended in 75% ethanol and incubated 
at room temperature for a further 15 minutes. It was then centrifuged as before at 2,000 x g for 5 minutes at 
4°C. The 75% ethanol was carefully removed and the pellet allowed to air dry. The pellet was then dissolved 
in 300µl TE and left overnight. The following day the tubes were centrifuged at ≥12,000 x g for 10 minutes 
before the solution was removed to a screw cap tube to be stored at -80°C. 
The phenol-ethanol supernatant was aliquoted into equal volumes into new 2ml screw top tubes. 
Tubes were then treated in parallel for the following procedures. The proteins were precipitated with 750µl 
of iso-propanol per 0.5 ml trizol. Samples were incubated at room temperature for 10 minutes before being 
centrifuged at 12,000 x g for 10 minutes at 4°C. The supernatant was removed and pellet washed three     Chapter 3  Methods 
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times with 1ml 0.3M Guanidine hydrochloride in 95% ethanol. Each wash step was incubated for 20 minutes 
at room temperature and then centrifuged at 7,500 x g for 5 minutes at 4°C. Once this was completed the 
tube was snap frozen in nitrogen and stored at -80°C. A flow diagram of this procedure can be seen in figure 
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Key: 
 
* Store at -70° C for up to one month  
† Store at -20° C for up to one year 
‡ Store at 2° C for months 
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Figure 26: Flow chart describing DNA and RNA extraction by the Trizol method. The procedure for extraction through 
trizol takes three days. The tissue disruption and RNA isolation occurs on the first day, DNA isolation occurs on the third 
day and the last day is for protein isolation. 
  The DNA concentration for each sample was quantified using a Nanodrop 1000. Samples were then 
normalised to as close to 100ng/µl as possible in 10µl volumes with RNA free water.  
 
3.4.2 Global Methylation Assay 
The  level  of  global  methylation  was  measured  using  the  Epigenetek,  Methylamp
TM  Global  DNA 
Methylation  Quantification  Ultra  Kit.  (Cat.  No.  P-1014)  A  diagrammatic  representation  of  the  assay 
methodology is shown in figure 27. 
 
Figure 27: Diagrammatic representation of the Methylamp
TM Global DNA Methylation Quantification Ultra Kit 
method. 
 
DNA samples were normalised to 100ng/µl. 28µl of the DNA binding solution was added to every 
well that was being used. 2µl of each sample was then added to these wells and the wells were always in 
duplicate. Ten wells were left with no sample to form the standard dilution curves and the negative control. 
The positive control was diluted 1:20 with the DNA binding solution. This diluted solution was used to form 
the standard curve by diluting with the DNA binding solution again, the top concentration being 100% 
methylated DNA, then 75%, 50%, 25% and 0%. The 0% in the standard curve was just the binding solution. 
2µl of each of these dilutions was added to the appropriate wells. 2µl of the negative control was added to 
the appropriate well.       Chapter 3  Methods 
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The plate was shaken gently to make sure that the entire surface of the bottom of the well was 
covered.  This  is  essential  as  the  final  measure  is  based  on  light  absorbance  that  needs  to  be  evenly 
distributed within the well to give a correct measurement. The plate was incubated at 37
oC with no humidity 
for 40 minutes to bind the DNA to the bottom of the well to stop it from being washed out during later 
stages. The plate was then incubated for a further 40 minutes at a higher temperature of 60
oC.  This was to 
remove any excess solution from the wells. If there was any non-evaporated solution left it was removed 
using a pipette.  
150µl of block solution was the added and incubated at 37°C for 30 minutes. Following this, the 
wells were washed three times with 150µl of the diluted wash buffer. The pH of this solution was between 
7.2 and 7.5. The 150µl was aspirated within the wells 10 times for each wash. 
Once the last wash had been removed the capture antibody (1000µg/ml) was diluted 1:1000 with 
the  diluted  wash  buffer.  50µl  of  this  diluted  solution  was  added  to  the  wells  and  incubated  at  room 
temperature  for 60 minutes. Once complete,  wells  were  washed four  times by aspirating  150µl  of  the 
washing buffer.  
The detection antibody (400µg/ml) was diluted 1:5000 with the diluted wash buffer and 50µl were 
added to each well. The plate was then incubated at room temperature for 30 minutes. The wells were then 
washed five times, by aspirating, with 150µl of the diluted washing buffer.  
The enhancer solution was then diluted 1:5000 with the diluted wash buffer and 50µl added to each 
well. The plate was then incubated at room temperature for 30 minutes. The wells were then washed five 
times, by aspirating, with 150µl of the diluted washing buffer.  
100µl of developer solution was added to each well and incubated at room temperature in a dark 
room for 1-5 minutes depending on the time required for the colour to change from a clear solution to a 
medium  blue  colour.  Once  this  had  happened  50µl  of  the  stop  solution  was  added.  This  stopped  the 
developer solution from becoming too dark and turned the colour from blue to yellow. The plate was then 
wrapped in foil to prevent light from degrading the colour.  
The  plate  was  then  taken  to  a  microplate  reader  (Molecular  Devices),  unwrapped  and  the 
absorbance at 450nm wavelength was measured within 2-15 minutes of the addition of stop solution.  There 
were two methods of determining the level of methylated DNA within the samples. The first method gave an 
estimate of the percentage of methylated DNA. 
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Methylation % = (Sample OD – Negative OD)/ rat GC content (42) 
                            (Positive control OD – Negative OD ) x 10 
 
A more accurate measure for both % and ng of methylated DNA within the samples. 
 
Methylated DNA (ng) = Sample OD – Negative control   x 100 
                                    Slope 
  
Methylation % = Methylated DNA amount/ rat GC content (42)    x 100 
Sample DNA amount added 
 
The  second  method  was  used  to  estimate  the  percentage  of  DNA  that  was  methylated  in  the 
samples. 
This method was used with pooled samples for each time point and treatment as well as individual 
samples for the F1 225 day old samples. 
3.4.3 cDNA Generation from Extracted Rat Lung RNA. 
The RNA concentration for each sample was quantified using a Nanodrop 1000. Samples were then 
normalised to as close to 500ng/µl as possible in 10µl volumes with RNA free water. Normalised sample 
RNAs were reverse transcribed using the Improm
TMII Kit from Promega, UK. All of these reactions contained 
negative  water,  no  template  controls,  reverse  transcription  negative,  lacking  in  the  Improm  II  reverse 
transcriptase, and positive, Kanamycin RNA, controls. Samples and primers were mixed, as detailed in table 
22. These 5µl volumes were incubated for 5 minutes at 70°C to denature double stranded RNA. 
Master mix:  Positive control (µl)  Negative control (µl)  Experimental  sample 
(x1) (µl) 
Experimental  sample 
(x25) (µl) 
Positive control  2  0  0  0 
Normalised RNA  0  0  2  2 per reaction 
Oligo primer  1  0  0  0 
Random primer  0  1  1  25 
Nuclease free water  2  4  2  50 
Final volume  5  5  5  125 
 
Table 22: Sample and primer set-up for initiation of reverse transcription reaction of RNA samples. 
  As soon as this step had been completed the samples were put on ice ready for the next stage. Each 
sample then had the remaining solutions added, as in table 22. The total volume of the reaction was now 
20µl. These volumes were then put into the thermo cycler on the following program:  
 
      Chapter 3  Methods 
72 
 
·  25°C for 5 minutes 
·  42°C for 1 hour 
·  70°C for 15 minutes 
·  Cooled to 20°C to be removed. 
 
cDNA was stored at -80°C until needed for qPCR. 
 
Master mix:  Positive control (µl)  Negative control (µl)  Experimental  sample 
(x1) (µl) 
Experimental  sample 
(x25) (µl) 
Nuclease free water  4.2  8.8  7.3  182.5 
5x ImProm II buffer  4  4  4  100 
MgCl2  4.8  1.2  1.2  30 
dNTP  1  1  1  25 
Ribonuclease 
inhibitor 
0  0  0.5  12.5 
ImProm II RTase  1  0  1  25 
Final volume  15  15  15  375 
 
Table 23: Second reaction set-up for the completion of the reverse transcription reaction. 
3.4.4 Optimisation of Primer Sets. 
  Each set of primers were designed using PrimerExpress (version 2.0; Applied Biosystems) software 
and  where  appropriate  the  online  Universal  Probe  Library  assay  design  centre  (www.roche-applied-
science.com/sis/rtpcr/upl/index.jsp). Each design was aimed to cover a splice site which was common to all 
of the known transcripts of that gene were possible. Non-specific binding sites were avoided by running the 
primer designs through a BLAST search (www.ncbi.nim.gov/blast/Blast.cgi) to ensure the primer was specific 
to the genes being targeted.   
Some primer sets had been previously optimised and validated within the laboratory (MJ Rose-
Zerilli), new primer assays were validated as described in section 3.5.5.5. Primer sets for each gene are given 
in appendix 2. 
3.4.5 qPCR Validation of Primers 
  Validation  of  primer  sets  was  performed  using  pooled  rat  lung  cDNA.  When  optimising  these 
reactions the ideal combination should produce the lowest value of crossing threshold (Ct), or crossing point 
(Cp), was  chosen. Primer  concentrations  were  set-up using three  different  final  concentrations  each  in 
combination as detailed in table 24.     Chapter 3  Methods 
73 
 
 
    Reverse Primer 
F
o
r
w
a
r
d
 
P
r
i
m
e
r
    300nM  600nM  900nM 
300nM  Reaction 1  Reaction 2  Reaction 3 
600nM  Reaction 4  Reaction 5  Reaction 6 
900nM  Reaction 7  Reaction 8  Reaction 9 
 
Table 24: Primer optimisation reaction set-ups for the differing primer concentrations. 
   The following annealing temperatures were tested 59°C, 60°C, 61°C and 62°C, as were the following 
magnesium chloride concentrations: 3, 2.5, 2, 1.5, and 1mM. Optimum primer concentrations were set at 
900nM for the forward and reverse primers for the Taqman assays and at 1µM for the forward and reverse 
primers for the SYBR green assays. The optimum magnesium chloride concentration was set at 2mM for 
both assays, and the optimum annealing temperature was set at 60°C.  
3.4.6 Quantification of Gene Expression by qPCR. 
  Alterations in the expression of different genes determine tissue type during development and can 
produce  an  altered  phenotype  in  the  organism.  One  way  to  identify  and  quantify  gene  expression 
differences is through quantitative polymerase chain reaction (qPCR).  
There are two types of assays for the genes that are used in this investigation, SYBRgreen assays and 
Taqman (hydrolysis probe) assays. The SYBR green assay uses the total fluorescence within the wells when 
the two DNA strands have been parted before the annealing process to measure the amount of DNA within 
those wells. The Taqman assay uses the fluorescence emitted by the probe as it cleaved by the 5’-3’ nuclease 
activity of the DNA polymerase as it displaces the probe from its binding site within the PCR amplicon to 
measure the amount of DNA within the well. 
SYBRgreen Master Mix: 
Reagents  X1 reaction (µl)  Concentration 
10x Buffer  2  N/A 
MgCl2 (50mM)  0.8  2mM 
dNTP mix (5mM)  0.8  0.2mM 
Forward Primer (10µM)  2  1µM 
Reverse Primer (10µM)  2  1µM 
SYBRgreen Dye  0.6  N/A 
Gold Star Taq  0.1  N/A 
dH20  12.7  N/A 
cDNA  1  N/A 
Volume  20  N/A     Chapter 3  Methods 
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3.4.7 Estimation of Relative Gene Expression of Samples. 
  The optimum conditions for the primers were used with each gene on a pooled selection of samples. 
Samples were pooled according to age and treatment and tested in duplicate for each gene. This was done 
to find out if the relative level of gene expression was different in any gene between the treatment groups 
and minimise the waste in reagents. Each gene also contained a replicate of a calibrator sample that lies on 
the standard curves to ensure that the levels of expression seen can be correlated back to the original 
standard curves. If a significant difference was found between the groups then the individual samples were 
tested to ensure it is a real difference and not an abnormal sample skewing the outcome.   
  The relative level of gene expression is compared with housekeeping genes. These are genes whose 
expression should not change between the samples as they are present at almost equal levels throughout 
the tissue being looked at. More than one house keeping gene is used, BAC, B2M and UBC are used in this 
investigation. The average expression of these genes is used to quantify the target genes expression. In this 
study the delta ct value was used to compare the expression levels.  
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3.5 Statistics 
  The same sets of statistics were used to determine the significance of the difference, if any, between 
the treatment groups. The tests used were a Students T test and an analysis of variance (ANOVA) test. The 
Students T test was chosen as there were two un-paired test variables, control or PR group, or testing of the 
same treatment group but between two time points, control group at F1 28 days against control group at F1 
225 days. The outcomes for each testing group were continuous and the raw data showed a parametric test 
would be appropriate. A two tailed test was used as the direction of effect, of the dietary challenge was 
unknown. 
The ANOVA test was chosen to for similar reasons to the T test, the data being normally distributed 
etc, but this test enabled the comparison of the data a crossed different time points while still comparing 
between the treatment groups.  
Determination of normal distribution of raw data was determined using a Shapiro-Wilk test.     Chapter 4  Results 
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4. Results 
4.1: Physiology and Morphometry   
4.1.1 The DOHAD Hypothesis and Respiratory Disease  
As previously described (see 1.1) maternal dietary challenges during pregnancy can alter offspring 
disease risk. This is due to the ability of the fetus to predict the best adaptation for its life once it is born, also 
known as the predictive adaptive response.  In humans, evidence exists that suggests, changes in maternal 
nutrition during pregnancy results in altered lung development that may lead to increased risk of respiratory 
disease in the offspring (see 1.4). For example both asthma and COPD have been linked epidemiologically 
with markers of fetal growth such as anthropometric measurements at birth (Barker 1991; Leadbitter 1999). 
Fetal growth and duration of gestation influence lung development; recent studies in the Southampton 
Women’s Survey reveal that lower rates of fetal growth are associated with impaired lung development in 
children  (Lucas  2004).  Airway  function  in  the  newborn  period,  which  is  dependant  on  fetal  lung 
development, is also a significant predictor of asthma (Dezateux 1997; Palmer 2001; Håland 2006), adult 
lung function (Stern 2007), and potentially, COPD (Håland 2006). Shaheen et al. studying the 1970 British 
Cohort Study showed that the prevalence of asthma at 26 years increased with decreasing birth weight 
(Shaheen 1999). Equally, poor adult lung function and increased risk of death from COPD are also associated 
with lower birth weight, again suggesting an effect of in utero development (Barker 1991; Lopuhäa 2000; 
Edwards 2003; Canoy 2007). For example, studies of the effects of under nutrition in pregnancy resulting 
from  the  effects of the Dutch  famine  of  1944-1945,  showed  that exposure to famine during gestation 
resulted in increased incidence of COPD at age 50 (Lopuhäa 2000). 
Studies of developmental programming in humans have limitations such as availability of tissue and 
the inherent timescale of cohort studies that need to span many decades to examine correlation between in 
utero exposures and the risk of late onset diseases such as COPD. As a consequence, a number of animal 
models have been utilised to explore the effects of developmental programming on a range of physiological 
parameters (Nathanielsz 2006). 
The Southampton PR model, described in section 2.1, uses a decrease of 50% in the protein content 
of the rat dams’ food from confirmation of pregnancy until birth of offspring. The decrease in protein is 
supplemented by an increase in carbohydrates to give an isocalorific diet. This model has been shown to 
induce a number of phenotypes that recapitulate effects of the DOHAD response in humans such as raised 
offspring blood pressure (Torrens 2008) and decreased nephron number within the kidneys (Harrison 2009). 
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4.1.2 Morphometry  
Stereology is a method of making morphological measurements that can be applied to a 3D object to 
estimate a complete value for that 3D object. This method is used, as when inflated, the lung comprises 
approximately 85-90% airspaces and therefore the internal structure is vitally important (Weibel 2007). 
There are four main considerations with this method. One is the thickness of the sections. To be 
used on a microscope the sections have to be thin which does not provide support for the tissue. This makes 
the tissue easily breakable and difficult to get accurate readings from if it is too thin. Secondly the sample 
size is small especially when compared with the entire lung organ. While for the rat this difference is not as 
accentuated as for analysis of human lung, it is still a consideration. Thirdly is consideration of specimen 
preparation. In the case of lungs, for accurate analysis it is important to ensure an equal, consistent degree 
of inflation of the lung samples when fixing. Furthermore, consideration needs to be made of the possible 
effects of unequal shrinkage and compression during sample processing (Weibel 2007). 
The most commonly used stain for overall structure in morphometric investigations in the literature 
is haematoxylin and eosin (H&E) staining. Other stains that have been cited as used for this type of study are 
Congo Red, used to look at the large airways in rats (Vanacker 2001), Mason’s trichrome, used to look at 
smooth muscle and basement membrane area of rats (Moir 2003), and alpha desmin/alpha vimentin, used 
to look at bronchiole profiles and areas of tissues in the airways of rats (Bonner 2000). H&E was used in this 
investigation as it is easier to define the areas of interest in comparison to other stains.      Chapter 4  Results 
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4.1.3 Aims 
Given that: both 1) changes in body weight and, 2) changes in body composition, as seen with a brain-
sparing effect, can be altered with maternal diet; in addition 3) increased risk of respiratory disease has been 
linked with both of these, we hypothesised that: 
i.  Maternal protein restriction will significantly alter body weight, lung weight and/or lung volume. 
ii.  Maternal protein restriction will significantly alter the fine structure of the lungs. 
iii.  These changes in lung structure will also be evident in the F2 and F3 generations. 
To test these hypotheses, we aimed to extract the lungs from rats harvested at 28, 120 and 225 days of 
F1 animals and assess body weight, lung weight and lung volume. To establish if there were changes in the 
fine structure of the lungs we used stereology to measure volume fractionation, surface area and alveolar 
wall thickness, we also aimed to harvest the lungs from 28 day F2 and 21 day F3 generations and assess 
these measures in those as well. 
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4.1.4 Materials and Method 
  For materials see section 2.1 
  Animals were culled at F1 28 days, F1 225 days, F2 28 days and F3 21 days for this part of the 
investigation. See section 3.1 for details on the animal model. Comparisons between body weights, total 
lung weights and lung volumes were preformed using the method detailed in section 3.2.1. Lung tissue from 
the F1 28 day, F1 225 day and F2 28 day, rats was embedded, see section 3.2.2, in paraffin wax, cut and 
stained with H & E, see section 3.2.3, and stereological methods such as volume fractionation, see section 
3.2.4.1, surface area, see section 3.2.4.2, and average alveolar wall thickness, see section 3.2.4.3, were used 
to compare the structure of the two treatment groups for the selected time points. 
As described previously (see section 3.5) a Students-T test was used to determine the significance of 
any differences seen between the groups. 
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4.1.5 Results 
In all graphs data is shown in box plot format with the middle line indicating the median value, the 
two edges of the box indicating the upper and lower quartile values and the tails coming from the box 
indicating the 95% values around the mean. Beyond these the circles indicate individual values that are more 
than two standard deviations from the median, and asterisks indicate individual values that are more then 
three standard deviations from the median. 
4.1.5.1:  Physical Data and Lung Volumes 
4.1.5.1.1:  Male 28 Day F1, 28 Day F2 and 21 Day F3 Rats. 
 
Figure 28: Comparison of the body weights (kg); of male rats 21-28 days old over three consecutive generations. (F1 28 
days, C=15, PR=10: F2 28 days, C=24, PR=17: F3 21 days, C= 16, PR=5) 
As can be seen in figure 28, the body weights of the animals increase with age, as expected. The F1 
and F2 groups are older, 28 days, than the F3, 21 days. The growth difference between the two age groups 
almost doubles over the week between 21 days and 28 days. With all generations there is a trend towards a 
lower body weight in the PR group when compared to C, with the F3 generation having a significantly lower 
body weight in the protein restricted group than the controls. The difference in body weight was significant 
for the F2 (p=0.001) and F3 (p=0.008) generation with the use of the ANOVA test. This trend does not extend 
into the F1 and F2 older groups, implying that the rate of growth of the PR group is faster than that of the C 
group, i.e. the PR animals exhibit catch-up growth. 
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Figure 29: Comparison of total lung weights; from male rats 21-28 days old over three consecutive generations. (F1 28 
days, C=15, PR=10: F2 28 days, C=24, PR=17: F3 21 days, C= 16, PR=5) 
  Total lung weights exhibit a similar pattern as that observed for whole body weight (figure 29). The 
difference in lung weight between either generations- or treatment groups- is not as extreme as that in body 
weight, with an increase of about 50% compared to 100% for bodyweight. There is no significant difference 
found between treatment groups for the t-test, however the F2 generation showed a p value of 0.044 when 
the ANOVA test was applied. There is a trend towards smaller lung weights in the protein restricted groups 
when compared with controls, although this is not as marked as that seen in body weight.  
 
Figure 30: Comparison of lung volume; from those male rats ranging from 21-28 days old over three consecutive 
generations. (F1 28 days, C=15, PR=10: F2 28 days, C=24, PR=17: F3 21 days, C= 16, PR=5) 
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Lung volume also follows the age related pattern observed for body and lung weight, (figure 30) 
however  the difference between the F3 groups and the other groups is much more extreme with the F1 and 
F2 volumes being approximately 4.5 times larger than those of the F3 rats reflecting the rapid postnatal 
growth in lung volume.  Although there is no significant difference (p=>0.05, t-test and ANOVA) between the 
treatment groups they all follow the same trend with the protein restricted group exhibiting a lower lung 
volume than the control group in all generations.       Chapter 4  Results 
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4.1.5.1.2:  Male and Female F1 225 Day Old Rats. 
 
Figure 31: Comparison of body weight; of male and female rats aged 225 days old across treatment groups. (F1 225 
days male, C=6, PR=6: F1 225 days female, C=6, PR=2) 
  As seen in figure 31, body weights of male and female rats at the age of 225 days is significantly 
different (p=0.003, t test) with the males being larger than the females. The body weights for male or 
females are not significantly different (p=>0.05, t test and ANOVA) between treatment groups. However 
there is a trend towards the control group weighing more than the protein restricted group in the male data, 
whereas this trend is reversed in the female data. 
 
Figure 32: Comparison of total lung weight; from male and female rats aged 225 days old across treatment groups. (F1 
225 days male, C=6, PR=6: F1 225 days female, C=6, PR=2) 
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  There is almost no difference (p=>0.05, t test and ANOVA) between the total lung weights of the 
male 225 day old treatment groups, figure 32.  There is a no significant difference (p=>0.05, t test and 
ANOVA) between the treatment groups in the female data with the controls being smaller than the protein 
restricted group. The females have a significantly lower total lung weight than the males (p=0.004, t test and 
ANOVA) which is as expected as the females are smaller in size than the males. 
 
Figure 33: Comparison of lung volumes; from male and female rats aged 225 days old across treatment groups. (F1225 
days male, C=6, PR=6: F1 225 days female, C=6, PR=2) 
The lung volume data, figure 33, is more evenly spread with no significant difference (p=>0.05, t test 
and ANOVA) seen between treatment groups or sex. However the control group have a trend towards a 
smaller volume than the protein restricted group in the males, with this trend reversed in the females. 
Overall the lung volume of the females is lower than that of males, again as expected given the relative size 
of females compared to males.  
4.1.5.2 Morphometry Results 
Previous work on 120 day old male rats has established that maternal protein restriction results in 
clear  changes  in  physiological  parameters  such  as  blood  pressure  (Brawley  2003)  and  altered  gene 
expression in the lung (MJ Rose-Zerilli, personal communication and (Rose-Zerilli 2010)). Using the F1 28 day 
and the F1 225 day old offspring of the control and protein restricted mothers, the morphometric analysis of 
the lungs was undertaken to determine if there were differences between the two treatment groups. A third 
group was also analysed, F2 28 day old offspring, to assess the possibility of effects of maternal protein 
restriction manifesting in the F2 (grandchild) generation.     Chapter 4  Results 
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4.1.5.2.1: Volume Fractionation 
 
Figure 34: Rat lung H&E stain. Airspaces are highlighted by yellow rings. Magnification x10. 
 
 
Figure 35: Box plot showing the total % airspaces of the entire lung; from PR and C groups for all age groups and 
generations of rats tested. There is a trend for increased airspaces in the C lungs but the range of data is larger in the PR 
group. The p value for the difference between the two groups is 0.146.  (F1 28 days, C=13, PR=13; F1 225 days, C=6, 
PR=6; F2 28 days, C=15, PR=15)  
No significant differences were found between the two treatment groups in the F1 28 day, F1 225 
day or F2 28 day old offspring for percentage air spaces within the lung.     Chapter 4  Results 
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Figure 36: Rat lung H&E stained, A) shows the entire airway, B) shows the lumen of the airway in blue, C) shows the 
epithelium around the airway in blue and D) shows the smooth muscle around the airway in blue. Each of these airway 
components was compared between the treatment groups for all generations and age groups. Magnification x10. 
 
 
Figure 37: Box plot showing the total % airways, and their components, from both PR and C groups for the F1 28 day 
old rats. (F1 28 days, C=13, PR=13) 
  There was no significant difference seen between the treatment groups for any component of the 
airways in the F1 28 day old rats.     Chapter 4  Results 
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Figure 38: Box plot showing the total % airways of the entire lung, for the different airway components analysed, from 
both PR and C groups for the 225 day old rats. (F1 225 days, C=6, PR=6) 
There was no significant difference seen between the treatment groups for any component of the 
airways in the F1 225 day old rats. 
 
Figure 39: Box plot showing the total percentage of airways of the entire lung, for the different airway components 
analysed, from both PR and C groups for the 225 day old rats. (F2 28 days, C=15, PR=15)  
There was no significant difference seen between the treatment groups for any component of the 
airways in the F2 28 day old rats.     Chapter 4  Results 
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Figure 40: Rat lung H&E stained.  A) The yellow ring with internal yellow lines shows the entire blood vessel, B) shows 
the vessel lumen in blue and D) shows the vessel muscle in blue. Magnification x10. 
 
Figure 41: Box plot showing the percentage of vessel of the entire lung, from both PR and C groups for the F1 28 day 
old rats. (F1 28 days, C=13, PR=13) 
There was no significant difference seen between the treatment groups for any component of the 
vessels in the F1 28 day old rats.     Chapter 4  Results 
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Figure 42: Box plot showing the percentage of vessel of the entire lung, from both PR and C groups for the F2 28 day 
old rats. (F2 28 days, C=15, PR=15) from both PR and C groups for the F1 225 day old rats. (F1 225 days, C=6, PR=6) 
  There was no significant difference between the treatment groups for the entire vessel or vessel 
lumen for the F1 225 day old rats, but there is a significant difference between the amounts of muscle 
around the vessels in these rats. The muscle around the PR rats is increased when compared with the C rats 
(p=0.046, t-test; p=0.024, ANOVA). 
 
Figure 43: Box plot showing the percentage of vessel of the entire lung, for the different vessel components analysed, 
from both PR and C groups for the 225 day old rats. (F2 28 days, C=15, PR=15) 
There was no significant difference between the treatment groups for the vessel lumen for the F2 28 
day old rats, but there is a significant difference between the entire vessel and the amount of muscle around 
the vessels in these rats when described using an ANOVA test. The entire vessels and the amount muscle 
around the vessels in PR rats is increased when compared with the C rats (vessel, p=0.038; vessel muscle, 
p=0.005; ANOVA). This significance was not found when using a t-test.     Chapter 4  Results 
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4.1.5.2.2 Surface Area. 
 
Figure 44: Overview of H and E images from the offspring rat lungs culled at 225 days old. These mature lungs show 
an offspring lung from the control in utero diet on the left and from the protein restricted diet on the right. 
Magnification x10. 
 
Figure 45: Box plot of average internal surface area, for all the age groups and generations of rats tested. (F1 28 days, 
C=13, PR=13; F1 225 days, C=6, PR=6; F2 28 days, C=15, PR=15) 
 
There was no significant difference found between the two treatment groups when looking at the 
lung surface area for any of the F1 28 day old offspring, the F1 225 day old offspring or the F2 28 day old 
offspring. There is a trend towards a reduction in surface area in the PR lungs for both age groups. This 
difference is more pronounced in the adult, F1 225 day, age group.     Chapter 4  Results 
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4.1.5.2.3  Alveolar Wall Thickness.  
 
Figure 46: Overview of H and E images from the offspring rat lungs culled at 225 days old. These mature lungs show 
an offspring lung from the control in utero diet on the left and from the protein restricted diet on the right, of the 
alveolar walls. Magnification x63. 
 
Figure 47: Box plot of average alveolar wall thickness, for all the age groups and generations of rats tested. (F1 28 
days, C=13, PR=13; F1 225 days, C=6, PR=6; F2 28 days, C=15, PR=15) 
There was no significant difference found between the two treatment groups when looking at the 
average alveolar wall thickness for the F1 28 day old, the F1 225 day old offspring or the f2 28 day old 
offspring. There is a trend towards a reduction in average alveolar wall thickness in the protein restricted 
group lungs for the 28 day F1 age group, which was then reversed in the adult 225 day F1 age group.      Chapter 4  Results 
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4.1.6 Discussion 
4.1.6.1 Physiology Discussion 
4.1.6.1.1  Body Weights 
As expected, body weights increased with the age of the rats. There was no significant difference 
between body weights between the two treatment groups in any of the F1, F2, or F3 generations. However, 
there was a trend towards a lower body weight in the protein restricted groups in all generations. This was 
inline  with  previous  observation  of  the  effect  of  protein  restriction  (Torrens 2002;  Rodford  2008),  and 
although the difference is not significant between groups, this is likely to reflect the severity of dietary 
restriction in this model when compared with others in the literature where a significant difference in the 
body weights of the two groups has been observed (Chen 2004). 
Body  weight  measurements  from  the  225  day  old  F1  rats  showed  that  there  was  a  significant 
difference  between  the  male  and  female  measurements.    In  the  interests  of  efficiency  only  the  male 
offspring were used for further analysis. The reasons for using the male animals instead of the females were, 
1) Physiological measurements in females are known to alter with respect to their ovulation, therefore 
culling would have to be timed to match these cycles to reduce measurement variability if females were 
utilised; 2) some studies have shown that protein restriction induces changes in physiological phenotypes in 
males that are not reproduced in the female offspring, and as this is a preliminary study it is preferable to 
use the group that has previously exhibited physiological changes in response to PR (Woods 2003); and 3) 
the female offspring can be utilised to breed subsequent generations (F2, F3 etc) to study the effect of 
epigenetic inheritance.  
Previously, there have been two significant studies that have utilised this precise model of Wistar 
rats with a 50% reduction in protein of maternal diet. A study of F1 offspring found a significant difference 
(p=<0.01, two-way ANOVA) in the birth weights of offspring, with the PR group (n=9) having a lower birth 
weight than controls (n=12) (Torrens 2002). A second study however, did not observe a significant difference 
in birth weights between groups (C=13, PR=15) (Torrens 2008). In this study the numbers for the F1 offspring 
at 28 days (C=5, PR=7) and 225 days (C= 6, PR=6) was lower than these studies, which may account for the 
lack of significant difference in birth weights between groups.  
4.1.6.1.2  Lung Measurements 
  Total lung weight was found to be lower in younger rats, as expected, however the difference in the 
lung weights as the offspring age does not follow the same trajectory as observed for body weights. A larger 
difference in lung weight was observed between the 21 and 28 day old rats than between the 28 and 225 
day old rats. This implies that the although the lung is still growing for part of the time between 28 days and 
225  days,  this  growth  is  less  than  that  seen  between  21  and  28  days.  This  is  in  line  with  previous     Chapter 4  Results 
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observations suggesting the lung develops to maturity before the body does. (Powell 1980) This earlier 
maturation of the lung in the rat model is also seen in the human. The rat lung grows for 13.5% of a rat’s 
total life span (Powell 1980; Goodrick 1982), whereas the human lung grows for 5.6% of a human’s total life 
span (Burri 1984; Sowell 2003). 
No significant difference in lung volumes between the two treatment groups at any age was seen. 
However there was a trend towards reduced volume in the protein restricted group compared to controls. 
Lung volumes followed a similar pattern to that of total lung weight, although there is a more marked 
difference between the younger age groups with the volume of the F3, 21 day old rat lungs, being half that 
of the 28 day old groups. 
4.1.6.1.3 Summary 
Several problems were identified in the method utilised to estimate lung volume. One of these was 
back flow of formalin around the needle inserted into the bronchi due to poor fit of the needle with the 
bronchi of these lungs, this was reduced by tying the needle into the bronchi but some fluid still escaped in 
some cases.  A loss of formalin through small nicks in the lungs caused during dissection was also observed in 
some instances, and these lungs were removed from analysis. Partial inflation of the lung was also seen. It is 
assumed that because a non-flexible needle was used to introduce the formalin in to the lungs any deviation 
from the main path of the bronchi may have caused the needle to enter into a single branch of the lung. This 
resulted in only a single lobe inflating and not the entire lung. Over inflation of the lung was also observed. 
To try and remove these problems an altered method was developed.  
By inserting the cannular needle into the trachea through the wall of this organ, with only the needle 
causing the breach, the hole was the correct size and no formalin was lost from the lung. As the needle was 
cannular, the steel needle could be removed and only the flexible sheath was left in the lung. This meant 
that the fluid was able to fill the lung completely with no partial inflation of a single lobe. The lungs were also 
inflated in situ, reducing the chance of cuts in the lung during dissection, and by leaving the rib cage and 
diaphragm as intact as possible, preventing over inflation.   
4.1.6.2 Morphometry Discussion 
  A  summary  of  the  results  found  for  each  age  group  allows  for  a  better  understanding  of  the 
interpretation of the results. The F1 28 day old rats and the F2 28 day old rats were found to have no 
significantly different alterations in their lung structure between control and PR groups.  
4.1.6.2.1 Volume Fractionation 
The percentage of the lung that was found to be airspaces was slightly reduced in the PR rats. There 
was also a small difference in the percentage of the lung that constituted the total airways, with the PR rats     Chapter 4  Results 
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having a slightly higher value that that of the C group. The percentage of total airways was created using a 
measure of the lumen, epithelium and the muscle. It is interesting to note that the within this data, only the 
airway lumen was increased in the PR group when compared to the C group. As the other differences 
showed opposite direction of effect it implies that although the total airways were found to be slightly 
increased in the PR rats this is mainly due to the lumen of the airway. The percentage of the lung that 
comprised blood vessels was found to be increased in the PR rats and when broken down this appeared to 
be due to the increased amount of muscle that was found around the vessels.  
No significant difference was found between treatment groups for the components of the lung 
structure for the 225 day old rats. The percentage of the lung that was found to be airspaces was slightly 
reduced in the PR rats. There was also a small difference in the percentage of the lung that constituted the 
total airways, with the PR rats have a slightly higher value that that of the control group. The percentage of 
total airways was created using a measure of the lumen, epithelium and the muscle. It is interesting to note 
that the within this data set only the airway lumen was increased in the PR group when compared to the 
control group. As the other differences were against the total airway result it implies that although the 
percentage of the lung that comprised total airways was found to be slightly increased in the PR rats this is 
mainly due to the lumen of the airway. The percentage of the lung that comprised blood vessels was found 
to be increased in the PR rats and when broken down this appeared to be due to the increased amount of 
muscle that was found around the vessels. 
The amount of smooth muscle found around the vessels of the F1 225 day PR group of rats was 
significantly increased (p=0.046). This remodelling of the muscle around the vessels could potentially explain 
the previous observation of increased blood pressure in the PR F1 treatment group previously observed with 
this  model  (Torrens 2002;  Torrens  2008). This  increase  in  blood  pressure  was  also  observed  in  the  F2 
generation, however there was no alteration in the internal diameter of the vessels. Vessels from the PR 
group were found to have enhanced vasoconstriction. The finding that there is more muscle around the 
vessels in the PR lung means that they are able to constrict more than those in the control group and exert 
more pressure on the blood inside those vessels. However this does not provide an exact mechanism for the 
hypertension seen as the blood branches off into smaller vessels. If these vessels were seen to have more 
muscle around them then this would indeed explain the results as the smaller the vessels the higher the 
pressure the blood is already under. If the muscle surrounding the smaller arterioles in the lung was found to 
be also increased, then the effect of that muscle on the blood pressure would be magnified.  
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4.1.6.2.2 Surface Area 
  The surface area was decreased in the PR when compared to the control group for all time points 
and generations. When comparing between the age groups the surface area of the lung increased in the 
oldest 225 day rats. This implied that the lungs are still maturing in the 28 day old rats and a difference may 
be seen at an older age in the F2 generation. 
4.1.6.2.3 Alveolar Wall Thickness 
The control alveolar walls were thicker than those seen in the PR for the F1 28 day old rats, although 
not significantly. This trend is still apparent in the 225 day old rats but the difference between the two 
treatment groups is less. This trend is reversed in the F2 28 day rats with the PR group having thicker 
alveolar walls when compared with the control group.  
4.1.6.2.4 Summary 
All the trends in differences between percentages of total lung for the various airway components 
found in the 28 day old rats were the same direction in both the F1 and F2 generations for both treatment 
groups. However, these trends appeared to reverse in the older 225 day old treatment groups. This could 
indicate that a period of catch-up growth occurs in the PR group, resulting in a reversal of the trends in 
airway structure. Previous studies using more severe dietary changes have seen significant changes in airway 
structure in younger animals that resemble those observed between the 28 day old control and PR groups in 
this study(Chen 2004; Maritz 2004). 
 The results of the morphometric analysis of the F2 generation lungs showed changes in structure 
between  control  and  PR  similar  to  those  observed  in  the  F1  generation,  however  although  still  not 
significant, these effects appear to be more pronounced. A study by Maloney et al. (2011) examined the 
effect of a maternal diet low in methyl-donors on the development of diabetes through both decreased 
insulin production and insulin resistance in rats (Maloney 2011). In this model, the dietary challenge was 
started three weeks before the females were mated up until confirmation of pregnancy, plugging, at around 
5 days post mating. In this study a low methyl-donor maternal diet for this time resulted in offspring that 
were more resistant to insulin. However this phenotype was only observed in male offspring and was more 
pronounced at the older time point of 51 weeks than at 26 weeks of age. This has similarities with humans, 
where development of type II diabetes, featuring insulin resistance, tends to occur later in life.  
The timing of the dietary challenge here is of interest as the effect on offspring insulin resistance 
occurred  despite  the  maternal  dietary  challenge  being  restricted  to  approximately  the  first  5  days  of 
development. In contrast, the dietary challenge in the current study is only initiated on confirmation of 
pregnancy. However, while for the F1 generation, this means that the developing embryo is not exposed     Chapter 4  Results 
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during this critical early window, for the F2 generation, the eggs that will go on to form the F2 generation are 
being made during this time in the female F1 embryos. During the act of fertilisation gametes are stripped of 
all their methylation patterns and then these are reinstated early in blastocyst development (Cirio 2008). 
This  may  account  for  the  apparently  stronger  effect  of  dietary  challenges  that  occur  in  this  early 
developmental window. It may also explain why there is an apparently stronger effect on lung morphometry 
in the F2 rats of maternal PR, in comparison to the effects seen in the F1 offspring. 
4.1.6.2.4.1 Sample Size 
A posthoc power calculation for a 5% difference between the two treatment groups, for airway 
muscle, indicated that a sample size of 60 would have been required to achieve statistical significance with 
an α=0.05 and 80% power. This means that the size of groups being using would have to be increased ten 
times and there were not enough animals in the study to accomplish this. 
4.1.6.2.4.2 Vessel Smooth Muscle 
The observed increase in smooth muscle, surrounding blood vessels in the lung, suggests a potential 
mechanism to explain the observation of hypertension in F1 and F2 offspring in the maternal PR model. 
Future studies could extent the analysis to smaller resistance arterioles and to blood vessels in other organs. 
This effect is not seen in the younger 28 day old rats. As such this effect could be due to natural aging, as 
with humans it is unusual to see problems such as hypertension in the young. If this is the case then the 
build-up of muscle around the vessels must be driven by an underlying reason such as an alteration in gene 
expression. This could be due to a failure to stop a gene from being expressed at the correct time, or it could 
be due to an increase in the expression of that gene at some point, possibly due to some altered epigenetic 
effect. To see if this is the case gene expression for this set of lungs will be the next step in this investigation.  
4.1.6.2.5 Future Directions 
  If resources, time and money, had been inexhaustible, an investigation into the morphometry of the 
F3 lungs would have been of interest. In addition, the input of a challenge, either an allergen challenge or a 
straight  forward  forced  constriction  of  the  bronchi,  with  methacholine  for  example,  would  likely  have 
resulted in a more pronounced alteration within the lungs.     Chapter 4  Results 
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4.2 Bronchial Hyperresponsiveness (BHR) 
4.2.1 Introduction 
A characteristic of asthmatic airways is reduced lung function. This is due to both the number and 
frequency of bronchoconstriction events that occur with asthma exacerbations, and the development of a 
degree of fixed airway obstruction as a result of airway remodelling. See section 1.2.7. 
BHR is exaggerated bronchial constriction in response to nonspecific provocation, whether that is 
inhalation of various bronchoconstrictors, or due to environmental stimuli, e.g. exercise, dry or cold air, 
hypertonic or hypotonic aerosols (see section 1.2.2.2). Such hyperresponsiveness is characteristic of asthma, 
and is commonly used for clinical diagnosis, as asthmatics exhibit exaggerated bronchoconstrictor responses, 
to  a  methacholine  or  histamine,  challenge.  An  increased  airway  responsiveness to stimuli  results in  an 
increase in the number of these types of events, which in turn, may lead to increased airway remodelling 
and disease progression. 
  Direct evidence  for  BHR  being linked with  developmental  programming has not been reported. 
However,  there  is  evidence  for  susceptibility  to  asthma  per  se  being  influenced  by  developmental 
programming. For example maternal exposure to a range of environmental exposures results in increased 
risk of developing asthma in childhood (Bertelsen 2010; Kozyrskyj 2011). Furthermore a number of studies 
have  linked  anthropomorphic  measurements  at  birth  (e.g.  birth  weight,  head  circumference  and  body 
length) to altered susceptibility to asthma in childhood (Barker 1991; Lopuhäa 2000; Edwards 2003; Canoy 
2007; Hancox 2009; Walter 2009). One of the first studies to link low birth weight with BHR was undertaken 
in 1988. This study was interested in the link between asthma and premature birth, because of this the 
babies  in  the  study  were low  birth  weight  due to  premature  delivery  not low  birth  weight for normal 
gestational age, however the prevalence of BHR to histamine was significantly increased in the low birth 
weight group of children compared to the reference group (Chan 1988). 
  Exploration of the effect of any developmental challenge on rat airways has not been reported in the 
literature.  There  is  a  large  body  of  evidence  that  has  noted  a  hypertension  phenotype,  with  altered 
vasoconstriction within offspring rats whose mothers were exposed to the low protein diet during their 
pregnancy (Rodford 2008; Torrens 2008). This effect has also been found to be transgenerational (Torrens 
2008). This chapter will examine the effect of bronchoconstrictors: carbachol (an acetylcholine mimetic); 
U46619  (a  thromboxane  mimetic);  angiotensin  II  and  histamine,  and  bronchodilators:  isoprenaline; 
salbutamol;  BRL37344  and  papaverine,  on  the  rat  bronchi  to  try  and  validate  this  model,  and  assess 
differences in responses for the protein restricted versus control treatment groups.     Chapter 4  Results 
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4.2.2 Aims 
Given that 1) BHR is a key diagnostic measure for asthma and, 2) changes in asthma risk have been seen 
in response to maternal protein restriction and 3) this alteration in asthma risk is linked with BHR, we 
hypothesised that: 
iv.  Base-line readings from the rat bronchi will be similar to those found in humans. 
v.  Increased BHR will be present in the offspring from protein restricted mothers compared to controls. 
vi.  These changes in BHR will result in significantly different reaction of the bronchi to bronchodilators. 
To test these hypotheses, we aimed to extract primary bronchi from lung samples harvested at 35 and 
75 days of F1 animals and assess the reaction of these bronchi to a panel of both bronchoconstrictors and 
bronchodilators in order to establish if potential changes in BHR have been induced by maternal PR and if so 
does this alter the reaction of the bronchi to bronchodilators.     Chapter 4  Results 
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4.2.3 Materials and Methods 
For materials see section 2.1. 
4.2.3.1 Bronchial Responsiveness Testing 
  Animals were culled at F1 35 days, and F1 75 days for this part of the investigation. See section 3.1 
for details on the animal model.  
Following post mortem lungs were excised and placed in cold PSS (4°C). To better visualise the 
bronchi,  the  airways  were  flushed  with  PSS  containing  a  few  drops  of  ink.  Segments  of  bronchi  were 
dissected out, cleaned of surrounding tissue, cut into 2mm segments and mounted on the wire myograph. 
Segments of bronchi were maintained in PSS heated to 37°C and continually gassed with 95% O2 and 5% CO2. 
More detail for these methods is given in sections 3.3.1 and 3.3.2. 
The optimal resting tension for rat bronchi was calculated by measuring the KPSS contraction at 
increasing resting tensions. The optimal resting tension for rat bronchi was found to be 1.5g of tension. 
Subsequently mounted bronchi were placed under 1.5g of tension and cumulative concentration response 
curves (CRCs) to the various agonists were constructed. 
Bronchoconstriction  was  assessed  by  the  construction  of  CRCs  to  the  acetylcholine  mimetic, 
carbachol (CCh, 1nM-100µM), the thromboxane mimetic, U46619 (1pM-1µM), angiotensin II (Ang II, 1pM-
1µM) and  histamine (1nM-100µM).  Bronchi were  then  preconstricted  with  a sub-maximal dose  of CCh 
equivalent to pEC80 (the concentration which produced 80% of the maximal CCh response) and relaxation 
was assessed to the non-selective β-adrenoceptor agonist isoprenaline, (ISO, 0.1nM - 100µM), the selective 
β2-adrenoceptor agonist salbutamol (SAL, 0.1nM - 100µM), the selective β3-adrenoceptor agonist BRL37344 
(BRL, 0.1nM - 100µM), and the PDE inhibitor papaverine (PAP,  0.1nM - 100µM). 
4.2.3.2 Statistics 
As described previously (see section 3.5) a Students-T test was used to determine the significance of 
any differences in area under the curve (AUC) seen between the groups. 
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4.2.4 Results 
  Animals were used from the F1 generation at 35 and 75 days of age for this investigation. These 
animals were produced as detailed in section 3.1. 
4.2.4.1 Resting Tension 
  Stepwise increases in resting tension produced greater constriction to KPSS up to a resting tension of 
1.5g. At resting tensions greater than this, KPSS-induced constriction was reduced (see figure 48). All data is 
displayed with errors bars showing one standard deviation from the mean. 
 
Figure 48: Response of 125mM KPSS to isolated bronchi at various resting tensions. (n=10)     Chapter 4  Results 
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4.2.4.2 Base-line Effects of Bronchoconstrictors on Rat Bronchi. 
Initially the effects of four bronchoconstrictor agents were tested on bronchi obtained from the 
lungs  of  rats  whose  body  weights  were  between  200  and  250g.  The  classical  stimulator  of 
bronchoconstriction in humans, histamine, failed to produce any response in a rat bronchi (see figure 49). 
Similarly the vasoactive peptide angiotensin II produced only a very modest constriction of isolated rat 
bronchi (see figure 50). 
 
Figure 49: Cumulative addition of histamine to isolated rat bronchi (•, n=8) 
 
 
Figure 50: Cumulative additions of angiotensin II to isolated rat bronchi (•, n=8) 
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4.2.4.3 Base-line Effects of Dilators on Rat Bronchi 
  The non-selective adrenoceptor agonist isoprenaline produced a modest bronchodilation of isolated 
rat  bronchi  that  was  attenuated  at  higher  concentrations  (figure  51).  To  counter  any  α-adrenoceptor 
mediated constriction of the bronchi, responses where repeated in the presence of the α1-adrenoceptor 
agonist, Prazosin (10µM) which abolished the biphasic response (figure 52). 
 
Figure 51: Cumulative addition of adrenoceptor agonist isoprenaline to isolated rat bronchi (ο, n=8) 
 
Figure 52: Cumulative addition of the non-selective adrenoceptor agonist isoprenaline to isolated rat bronchi in the 
absence (ο, n=8) or presence of the α1-adrenoceptor antagonist, prazosin (10µM; ￿, n=3)     Chapter 4  Results 
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Similarly  to isoprenaline, the selective β2-adrenoceptor agonist salbutamol and  the  selective  β3-
adrenoceptor agonist BRL37344 produced a modest dilation of isolated bronchi (figure 53 and 54). The 
cAMP  activator  papaverine  had  little  response  until  the  very  top  dose  where  it  produced  a  complete 
abolition of the carbachol-induced tone (figure 55). 
 
Figure 53: Cumulative addition of the selective β2-adrenoceptor agonist salbutamol to isolated rat bronchi (•, n=8) 
 
Figure 54: Cumulative addition of the selective β3-adrenoceptor agonist BRL37344 to isolated rat bronchi (•, n=8)     Chapter 4  Results 
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Figure 55: Cumulative addition of the cAMP activator papaverine to isolated rat bronchi (ο, n=8)     Chapter 4  Results 
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4.2.4.4 Comparison of Protein Restricted and Control  
4.2.4.4.1 Bronchoconstrictor Responses at Age 35 Days 
  In isolated bronchi from day 35 old rats, CCh produced a dose dependent constriction that was 
similar between PR and C groups (figure 56) 
 
Figure 56: Cumulative addition of CCh to isolated bronchi from 35 day old male offspring from C (ο, n=6) or PR (•, 
n=5) dams. 
  Similar to CCh, the thromboxane mimetic U46619 produced a concentration dependent constriction 
in isolated rat bronchi. There was a no difference in the constriction between the PR group and the control 
(figure 57; p=>0.05). 
 
Figure 57: Cumulative addition of thromboxane mimetic U46619 to isolated bronchi from 35 day old male offspring 
from C (ο, n=6) or PR (•, n=5) dams.     Chapter 4  Results 
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4.2.4.4.2 Bronchodilator Responses at Age 35 Days 
The 35 day old bronchi relaxed to the isoprenaline in a concentration-dependent manner that was 
similar in both groups (figure 58). As seen previously, papaverine did fully abolish CCh-induced tone but only 
at  the  highest  concentrations.  There  was  no  real  difference  seen  between  the  two  treatment  groups 
(p=<0.05) (figure 59). 
 
Figure 58: Cumulative addition of isoprenaline to 80% CCh constricted isolated bronchi from 35 day old male 
offspring from C (ο, n=6) or PR (•, n=5) dams. 
 
Figure 59: Cumulative addition of papaverine to 80% CCh constricted isolated bronchi from 35 day old male offspring 
from C (ο, n=6) or PR (•, n=5) dams. 
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4.2.4.4.3 Bronchoconstrictor Responses at Age 75 Days 
In isolated bronchi from day 75 old rats, CCh produced a dose dependent constriction that was 
significantly increased in PR compared to C groups (Figure 60; p=<0.0001).  
 
Figure 60: Cumulative addition of CCh to isolated bronchi from 75 day old male offspring from C (ο, n=6) or PR (•, 
n=4) dams. *** indicates p<0.001 % max response C vs PR. 
Similar to CCh, the thromboxane mimetic U46619 produced a concentration dependent constriction 
in isolated rat bronchi. There was a significant increase in the constriction in the PR group compared to C. 
(figure 61; p<0.001). 
 
Figure 61: Cumulative addition of U46619 to isolated bronchi from 75 day old male offspring from C (ο, n=6) or PR (•, 
n=4) dams. *** indicates p<0.001 % max response C vs PR. 
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4.2.4.4.4 Bronchodilator Responses at Age 75 Days  
The 75 day old bronchi relaxed to the isoprenaline in a concentration-dependent manner that was 
similar in both groups (figure 62). As seen previously papaverine did fully abolish CCh-induced tone but only 
at the highest concentrations (figure 63). There was no difference seen between the two treatment groups 
(p=>0.05). 
 
Figure 62: Cumulative addition of isoprenaline to 80% CCh constricted isolated bronchi from 75 day old male 
offspring from C (ο, n=6) or PR (•, n=4) dams. 
 
Figure 63: Cumulative addition of papaverine to 80% CCh constricted isolated bronchi from 75 day old male offspring 
from C (ο, n=6) or PR (•, n=4) dams.     Chapter 4  Results 
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4.2.5 Discussion 
4.2.5.1 Base-Line Bronchoconstrictors 
As described in section 1.2.2.2, a number of bronchoconstrictors are used to assess the degree of 
bronchial hyperresponsiveness of airways in humans. Methacholine, an acetylcholine mimetic, is used most 
commonly  for  bronchial  hyperresponsiveness  testing  in  humans.  Another  acetylcholine  mimetic,  is 
carbachol, that also induces bronchial smooth muscle contraction (Forster 1993). Within the rat bronchi, the 
addition of carbachol to the wells caused a concentration-dependent constriction. Due to the constant, and 
concentration-dependant nature, of the constriction to this drug, it was chosen to achieve 80% maximum 
constriction of bronchi before assessment of bronchodilator responses. 
Histamine is an alternative bronchoconstrictor often utilised in BHR testing in humans. Histamine 
induces bronchoconstriction by activating specific H1 histamine receptors within the human lung (Bryce 
2006). It causes an inflammatory response and also constriction of bronchial smooth muscle (Melgarejo 
2010). However it has been established that within the rat lung the presence of histamine is immediately 
reduced/eliminated  by  histaminase  (Rose  1940;  Zeller  1942;  Cotzias  1952),  with  the  rate  of  histamine 
degradation  dependent  on  the  amount  of  lung  tissue  present  (Zeller  1942).  Thus  the  lack  of  response 
observed in the rat bronchi to histamine was expected. 
Angiotensin II is found in all tissues of the human body but is present in the highest concentration in 
the capillaries of the human lung, and is a known vasoconstrictor (Nishioka 2011). In this investigation, 
angiotensin had no effect on bronchi, in line with previous observations by others (Sakai 2010). For example, 
a two week course of angiotensin treatment, 200ng/min/kg via subcutaneous infusion in the rat, results in 
remodelling of the arteries but has no effect on the airway (Ramsay 2000). Angiotensin receptors have been 
found to be expressed within the rat lung through RT-PCR methods. This may suggest that although the 
receptors are present, they may not be functional (Sakai 2010). 
The  effects  of  thromboxane  can  be  mimicked  by  U46619,  a  stable  synthetic  analogue  of 
prostaglandin PGH, by activation of phospholipase C. A previous study has shown that U46619 caused a 
bronchoconstriction effect 178x more potent than methacholine in humans (Jones 1992).  
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4.2.5.2 Bronchodilators 
In humans constriction of the bronchi is treated with broncho-dilators such as selective β2-adrenergic 
receptor agonists, e.g. salbutamol. Several different broncho-dilators were tested for their effectiveness in 
rat lungs. Almost all of these reagents affect α and β-adrenergic receptors that are found within the lungs of 
both humans and rats. None of the dilatory agents used in the rat lung worked with any great efficacy. 
Salbutamol is a mainstay of asthma therapy. It is a selective β2-adrenergic receptor agonist (see 
section1.2.3) that is used to relieve broncho-spasm. When this drug was used to study vasodilation in the 
vasculature of the rat the only effect seen was in the hind-quarters (Gardiner 1991). The use of salbutamol 
(either aerosolised or by intravenous injection) to induce bronchodilation as assessed by lung function in a 
live  rat,  has  shown  that  salbutamol  is  effective  in  improving  airway  function  after  bronchoconstriction 
induced by methacholine (Petak 1999). In the current study, treatment with salbutamol in the dose range 
1nM-100µM did result in a slight relaxation of tension, but only by ~20%, conflicting with these previous 
observations. The difference between the studies is that in the study by Petak et al. the salbutamol was 
administered both orally and via IV injection and the lungs were still in situ within the rat. This could imply 
that relaxation of the bronchi in response to salbutamol requires a factor to be present that is in the lung 
tissue  surrounding  the  bronchi  but  not  in  the  bronchi  themselves.  Alternatively,  this  could  also  reflect 
differences  in  bronchodilator  responsiveness  between  large  and  small  airways,  as  the  use  of  dissected 
bronchi to assess airway smooth muscle responses is restricted to large 1
st generation bronchi. 
Isoprenaline has been used as an asthma therapy in the past but is no longer used clinically as it is a 
non-selective β-adrenergic receptor agonist, activating both β1- and β2-adrenergic receptors. While this will 
induce bronchoconstriction, in the heart this will induce increased rate and force of cardiac smooth muscle 
contractions via its action on β1-adrenergic receptors (de Monte 1993). Isoprenaline was expected to induce 
bronchodilation as it has previously been shown to induce bronchodilation in the rat (Mahajan 2010), and it 
did relax the bronchi slightly at a lower dose than salbutamol. However, as higher concentrations were 
added  to the  bath  the bronchi  constricted again  to  give no  overall  relaxation. It  was  thought that  the 
isoprenaline may have been acting on the β-receptors to relax the bronchi, but then began to activate the α-
receptors which caused the bronchi to re-constrict. To test this an α-receptor blocker was added to the 
bronchi bath before the isoprenaline dilution. The α-blocker used was prazosin, which was added to the 
wells at a final concentration of 10mM, before the Isoprenaline dilution series was started. This caused the 
bronchi to relax and the relaxation continued, supporting the initial suggestion that activation of α-receptors 
due to reduced selectivity at higher concentrations of isoprenaline underlies the constriction observed.  
Papaverine is an opium alkaloid antispasmodic drug, that is a known vasodilator and is used as such 
to treat a number of conditions such as migraine (Victor 2003), erectile dysfunction (Yildiz 2011), and during     Chapter 4  Results 
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cardiac surgery to aid with heart catheterisation (Osman 2008). It has also been linked with the reduction of 
ACE inhibitor (enalapril) induced cough in guinea pigs (Ebrahimi 2006). Papaverine was expected to produce 
a positive control for the relaxation of the bronchi as it increases intercellular cAMP, through inhibition of 
phosphodiesterases (Rang 2007) leading to protein kinase A activation and decreased free [Ca
2+]. However, 
although papaverine did relax the bronchi completely, this was not in a dose dependent manner, and it was 
only with the addition of the top concentration (100µM) that relaxation was observed. The reason for 
relaxation at only the highest concentration of papaverine added could be due to the amount of free calcium 
within the bath. The PSS that is in the well surrounding the bronchial tissue has a calcium concentration of 
2.5mM. That concentration may need the highest dose of papaverine to be effective. 
BRL37344  is  an  agonist  of  an  additional  β-adrenergic  receptor  subtype  present  in  the  body,  β3-
adrenergic receptors (Hodis 2011). The β3-adrenergic receptor has been found within the rat lung and linked 
with the clearance of alveolar fluid (Li 2010). β3-adenergic receptors have also been previously shown to 
mediate  bronchodilation in  canine airways  (Tamaoki  1993). The  bronchi did  relax in  a  dose  dependent 
manner although not completely. This is of interest as this indicated that β3 receptors may be a potential 
therapeutic target for possible use in humans. Activation of β3 receptors to produce a dilation of the bronchi 
would circumvent the problems with the use of β2 receptors, such as salbutamol, as it would not affect the 
other organs within the body. However a previous study of isolated human bronchi showed that while 
BRL37344 did appear to exhibit weak bronchodilator effects, this was mediated by β2-adrenergic agonist 
action (Martin 1994), suggesting that β3-adernergic receptors do not  mediate bronchial smooth muscle 
relaxation in humans. 
4.2.5.3 Effects of Maternal Protein Restriction on Bronchoconstrictor and Bronchodilator 
Responses of Isolated Rat Bronchi 
Both carbachol and thromboxane constricted the rat bronchi in a dose dependent manner. The 
younger time point (35 days) did not show any difference in their response between the two treatment 
groups. However in the older, 75 day, in PR rats a bronchial hyper-responsive phenotype was observed. A 
recent  study  has  suggested  that  the  asthmatic  remodelling  seen  in  the  bronchi  could  be  caused  by 
mechanical stress responses in the airways induced by repeated constrictions, as this phenotype was seen in 
non-allergic  inflammation  in  asthmatic  individuals  that  underwent  repeated  methacholine  challenge 
(Grainge 2011). In this study, individuals were exposed to three challenges 48 hours apart of either allergen 
challenge  (bronchoconstriction  with  eosinophillic  inflammation)  or  methacholine  challenge 
(bronchoconstriction without inflammation). Remodelling of the airways was seen in both sets of challenged 
airways and not in control groups exposed to methacholine together with a bronchodilator or saline alone. 
This  would  suggest  that  if  individuals  exhibited  increased  bronchial  hyperresponsiveness  as  a  result  of     Chapter 4  Results 
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developmental  programming,  this  could  lead  to  airway  remodelling  and  predispose  to  development  of 
asthma in childhood (Grainge 2011). 
This is the first report of bronchial hyperresponsiveness following maternal protein restriction in the 
absence of any post-natal stimuli. The mechanism behind the contraction of smooth muscle, such as that 
surrounding the airways, is the phosphorylation of the myosin light chain which activates actin-activated 
myosin ATPase which is required for muscle contraction. The kinase responsible for this is the myosin light 
chain kinase, a calcium-calmodulin-activated kinase, and it is essential as it cannot be replaced by another 
kinase  (Hong  2011).  Due  to  its  method  of  activation  the  calcium-calmodulin-binding  site  is  the  most 
important regulator for smooth muscle contraction. It is possible that maternal exposure to a low protein 
diet  has  altered  the  expression  level  of  the  myosin  light  chain  kinase  which  has  resulted  in  the  BHR 
phenotype, or it may be that there are other structural changes that are making the calcium-calmodulin-
binding site more accessible.  
4.2.5.4 Future Work 
Having seen a bronchial hyper-responsive phenotype in the 70 day old F1 rats it would be of interest 
to see if the same phenotype can be observed in F2 and F3 generations, as this would suggest that the effect 
may be transmitted transgenerationally, and in the case of an F3 effect, imply that this is epigenetic in 
nature (see section 1.1.5). 
The ability to observe the effect of these drugs in vivo would give a better understanding of the 
reaction within the bronchi as they would be within their natural environment. The dissection of the bronchi 
from the surrounding lung tissue alters its biology as other mediators are not present and the structural 
support is also absent. To do this in vivo a lung function measure would have to be taken. There are a 
number of ways to assess lung function in and bronchial hyperresponsiveness in the rat. For example a 
common  asthma  inducing  challenge  for  small  mammals,  such  as  rodents,  includes  inhalation,  under 
anaesthesia, of with isoflurane with a low percentage of Ovalbumin, e.g. 2% (Nabe 2005). 
 In  humans,  asthma  results  from  the  interaction  between  inherited  susceptibility  and  postnatal 
environmental  exposure.  To  determine  whether  the  observed  effect  of  maternal  protein  restriction  on 
bronchial hyperresponsiveness had relevance to human asthma, the observation of the effects of maternal 
protein restriction on lung function, and inflammatory, responses in an allergen challenge model such as 
that utilised by Raemdonck et al. would be of interest (Raemdonck 2011). 
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4.3 Methylation and Gene Expression 
4.3.1 Methylation Introduction 
  As described in section 1.1.5, epigenetic mechanisms can alter the expression of genes reversibly. 
One such mechanism is the addition of methyl groups to the cytosine residue of a cytosine-guanine pair of 
bases. In a number of animal models, changes in offspring DNA methylation in a range of tissues have been 
observed in response to alterations in maternal diet. In the Agouti mouse (a(vy/a)), expression of the yellow 
coat colour is dependent on changes in DNA methylation of six CpG sites in a retrotransposon upstream of 
the  transcription  start  site  of  the  Agouti  gene.  The  offspring  of  pregnant  Agouti  mice  fed  a  diet 
supplemented with the phytoestrogen genistein shifted coat colour from yellow towards a pseudoagouti 
brown coat as a result of changes in methylation (Dolinoy 2006). The extent of this DNA methylation was 
similar in endodermal, mesodermal and ectodermal tissues, suggesting the exposure acted during early 
embryonic development. Furthermore, this genistein-induced hypermethylation persisted into adulthood, 
altering other common features of the Agouti phenotype, such as obesity. Supplementation of maternal diet 
with methyl donors has also been shown to alter methylation of a number of genes in inflammatory cells 
and lead to increased airway inflammation in a mouse model of asthma (Hollingsworth 2008). In the lung, 
exposure of pregnant females to a restricted diet (65% of ad libitum) has been shown to result in impaired 
endothelium-dependent  pulmonary  artery  vasodilatation,  and  exaggerated  hypoxia-induced  pulmonary 
hypertension and subsequent right ventricular hypertrophy all associated with increased global lung DNA 
methylation (Rexhaj 2011). 
In the rat, changes in maternal diet have also been shown to alter DNA methylation both globally, 
and in a gene specific manner. For example, increased folic acid coupled with reduced vitamin B12 in the 
maternal  diet  has  been  shown  to  reduce  global  DNA  methylation  in  placental  tissue  (Kulkarni  2011). 
Maternal  protein  restriction  has  also  been  shown  to  result  in  altered  renal  structure  accompanied  by 
changes  in  methylation  of  the  promoter  for  the  gene  encoding  11β-hydroxysteroid  dehydrogenase 
(Mesquita 2010). 
4.3.2 Gene Expression  
As described above, there is evidence that maternal dietary exposures during pregnancy, such as 
protein restriction, can lead to altered DNA methylation and consequently changes in gene expression. A 
number of candidate genes were selected to assess changes in gene expression in response to maternal PR. 
These can be classified into four main groups: 1) histone deacetylases; 2) lung development; 3) asthma 
susceptibility genes and 4) COPD susceptibility genes.     Chapter 4  Results 
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4.3.2.1 Histone Deacetylase 
Histone deacetylases (HDAC) such as the class II HDAC family members HDAC2, HDAC3 and HDAC8 
remove acetyl groups (O=C-CH3) from ε-N-acetyl lysine amino acids on histones which the DNA is coiled 
around. Acetylation of lysine residues increases the positive charge of histone tails, encouraging high-affinity 
binding between histones and the DNA phosphate backbone. This increased DNA binding results in a more 
condensed  DNA  structure,  preventing  access  of  transcription  factors  to  DNA  binding  sites  and  hence 
reducing transcription. 
HDAC2 is expressed as a single isoform from a gene encoded on chromosome 20q21 in the rat and is 
associated with the core histones H2a, H2B, H3 and H4 (Hollenbach 2002). In the lung HDAC2 has been 
shown  to  be  reduced  in  COPD  patients  (Ito  2005)  and  in  cystic  fibrosis  patients  the  transmembrane 
conductance regulator protein excreting cells are also effected by HDAC2 (Bartling 2009). 
HDAC3 is highly involved in the regulation of cellular mitosis. It has been linked with microtubule 
attachment,  centromeric  deacetylation  and  sister  chromatid  cohesion  (Li  2006;  Eot-Houllier  2008;  Ishii 
2008). Similar to HDAC2, HDAC3 mRNA levels have been shown to be decreased in lung biopsies from COPD 
patients (Ito 2005) . 
HDAC8 is known to be phosphorylated by the cyclic AMP-dependent protein kinase A and that the 
increase in phosphorylation inhibits HDAC8 resulting in the acetylation of the histones H3 and H4 (Lee 2004). 
HDAC8 has been used as a marker of smooth muscle differentiation and its distribution within the cell, 
following the stress fibre distribution in alpha-smooth muscle actin, implies some association with smooth 
muscle  function,  possibly  through  regulation  of  the  contractile  capacity  of  the  smooth  muscle  cells 
independent of its function in regulation gene expression in the nucleus (Waltregny 2005). As with HDAC2 
and HDAC3, HDAC8 has also been found to be decreased in COPD patients (Ito 2005). 
  Analysis of the HDAC8 gene in the rat is problematic as there is no annotated gene sequence, but 
using homology there is a sequence similar to that in humans. 
4.3.2.2 Developmental Genes 
The  insulin-like  growth  factors  1  (IGF-1)  and  2  (IGF-2)  are  key  regulators  of  fetal  growth  and 
development. IGF1 is formed as a precursor that is bound by a receptor and then secreted. There are several 
known transcripts of this protein. In the rat, serum levels of IGF1 in the serum fluctuate, with a decrease 
leading up to birth, a dramatic increase in levels at day 8 which is then reversed back to previous level, day1, 
by post-partum day 15. IGF1 levels then continue to steadily decrease as the rat ages (Werner 1989). IGF-2 
expression is controlled through maternal imprinting, with the paternally inherited allele being expressed 
(Reik 2000; Sasaki 2000; Arney 2003). Overall IGF-2 levels are reduced in the adult, when compared to fetal,     Chapter 4  Results 
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rat tissues (Lund 1986). A reduction in maternal food intake by 50% has been shown to lead to intrauterine 
growth restriction (IUGR) and an increase of both IGF-1 and IGF-2 mRNA levels in the lung  (Chen 2007). 
Tp53 is a well known essential protein that responds to diverse cellular stress resulting in cell cycle 
arrest, apoptosis and senescence. It is also involved in DNA repair and reacts to changes in metabolism. The 
importance of Tp53 in the cell cycle means that expression levels within cells must be carefully regulated 
(Lehnert 2001). This protein can be  DNA bound and contains transcription activation,  DNA-binding and 
oligomerisation domains. There are multiple variants due to alternative promoters and multiple splicing 
variants. These variants encode two distinct isoforms which can regulate activity. Tp53 expression levels 
have been linked with COPD, with increased pro-apoptotic Tp53 protein expression in lung tissue specimens 
from COPD patients in comparison to non-COPD smoking subjects (O'Brien 2007; Siganaki 2010) . 
Uncoupling  protein  (UCP)  is  a  mitochondrial  uncoupling  protein  that  separates  the  oxidative 
phosphate from ATP and dissipates the energy as heat. It is also known as the mitochondrial proton leak. 
UCP helps to facilitate the transfer of anions from the inner to the outer membrane. This reduces the 
membrane potential in mammals (Divakaruni 2011). 
In sheep, gene expression levels of UCP in the lung peak at postnatal day 1 of age and then decline 
with age. The effect of total maternal nutritional reduction induced IUGR is to give rise to increased levels of 
UCP gene expression both prenatally and postnatally and the increased expression persisted until the last 
postnatal sampling point of 6 months (Gnanalingham 2005). 
The role of this protein in the rat is similar as that seen in humans (Cassard-Doulcier 1998). The 
expression levels of UCP within the rat lung, increase at the point of birth and continue to increase up to 
three fold from day 1 until adulthood (Xiao 2004). 
4.3.2.3 Asthma Genes 
As described in section 1.2.8, A Disintergrin Metalloprotease 33 (ADAM33), is a membrane anchored 
protein and is structurally related to snake venom disintergrins. It has been implicated in cell-cell and cell-
matrix  interactions,  including  fertilisation,  muscle  development  and  neurogenesis.  This  type  one 
transmembrane protein has been identified as an asthma susceptibility gene, with polymorphisms in the 
gene  being  associated  with  increased  susceptibility  to  asthma  and  specifically,  bronchial 
hyperresponsiveness  (van  Eerdewegh  2002;  Schedel 2006),  also to lung function  decline  in  the general 
population  (van  Deimen  2011)  and  COPD  (Sadeghnejad  2009;  Xiao  2010).  Tissue  specific  regulation  of 
ADAM33 expression has been shown to be regulated by methylation of a CpG island within the promoter 
(Yang 2008).     Chapter 4  Results 
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Protocadherin 1 (PCDH1) is a membrane bound protein that is a member of the δ-protocadherin 
subgroup of non-clustered protocadherins and is found at all cell-cell boundaries. It is involved in neural cell 
adhesion and so may play an important role in the development of the neuronal system. The protein itself 
includes an extra-cellular region that contains seven cadherin-like domains, a transmembrane region and a C 
terminal cytoplasmic region. Any cells that express this protein are prone to aggregation activity. Genetic 
studies have shown association between variants in the PCDH1 gene and susceptibility to asthma and BHR in 
several  Caucasian  populations  (Koppelmann  2009).  Furthermore,  these  studies  showed  a  potential 
interaction between these PCDH1 variants and maternal smoking during pregnancy, suggesting a role for this 
protein  in  early  lung  development  (Koppelmann  2009).  In  the  mouse,  PCDH1  is  expressed  both  in  the 
developing and adult lung epithelium and the tight spatial and temporal regulation of PCDH1 expression 
suggests that it plays multiple roles not only during development, but also in mature tissues and organs 
(Redies 2008). 
The glucocorticoid receptors (GR) allow glucocorticoid to bind to them in the cytoplasm and when 
bound they are translocated into the nucleus, once there they can bind to glucocorticoid response elements. 
These elements increase the transcription of certain genes. Most of these genes encode anti-inflammatory 
proteins, as seen in asthmatic inflammation. The GR response elements also have a secondary function 
which blocks the transcription of inflammatory encoding genes (Barnes 1998). The Southampton model of 
protein  restriction  found  that  the  expression  of  the  GR  gene  was  increased  within  the  liver  of  the  PR 
offspring when compared to controls. This was found to be linked with a reduction of methylation in the GR 
promoter, these alterations were prevented by the addition of increased folic acid within the diet (Lillycrop 
2005), this alterations was also found to be transmitted to the F2 generation without any further dietary 
challenge  (Burdge  2007).  A  later  study  linked  the  decrease  in  methylation  with  a  decrease  in 
methyltransferase-1 expression (Lillycrop 2007). 
When the animal model in this investigation was used to study hypertension, GR levels were found 
to be elevated in response to maternal PR (Bertram 2001). The importance of GR to lung development is 
highlighted by GR deficient mice that are embryonic lethal with under developed lungs partially filled with 
fluid  (Cole  1995).  This  is  unsurprising  as  cortisol  is  hugely  important  in  the  maturation  of  cells  during 
development. It is given to premature babies to start the development of surfactant and single doses during 
specific windows have some particular long term consequences (Halliday 2010). 
4.3.2.4 COPD Genes 
Beta-Hydroxysteroid  Dehydrogenase  1  (11β-HSD1),  is  a  microsomal  enzyme  that  catalyses  the 
conversion of the stress hormone cortisol into its inactive metabolite cortisone. This protein is also able to 
catalyse this reaction in reverse, to produce cortisol from cortisone. This is essential as too much cortisol     Chapter 4  Results 
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results in central obesity. Variation within this gene has been linked with obesity and insulin resistance. This 
protein also has an equally high affinity for aldosterone (Tannin 1991). The level of cortisol within the lung is 
implicated in the maturation of the lung tissue (Suzuki 1998).  
The protein has a similar effect within the rat and it has also been linked with blood pressure 
regulation (Lloyd-MacGilp 1999). As for GR and UCP2, IUGR in sheep has been shown to result in persistent 
increased 11β-HSD1 mRNA expression in the rat lung (Gnanalingham 2005). The rat homologue is around 
77% identical to that found in humans (Tannin 1991). Beta-Hydroxysteroid dehydrogenase 2 (11β-HSD2), has 
a similar effect as 11β-HSD1, although it cannot reverse the reaction, going from cortisone back to cortisol. It 
is expressed predominantly in epithelial tissues, especially in the kidney and lung and is thought to prevently 
illicit activation of mineral corticoid receptors (MR). The 11β-HSD2 enzyme has been found to co-localise in 
rat lung tissue with both MR and GR receptors (Hirasawa 1997; Suzuki 1998). Within cells that have no MR 
involvement, 11β-HSD2 protects the cell from the growth inhibiting effects of cortisol. (Suzuki 1998) This is 
especially true during embryonic development.   
The  role  of  this  protein  in  the  rat  is  slightly  different  as  it  catalyses  the  transformation  of 
corticosterone into 11-dehydrocorticosterone. This enzyme has been found in the terminal alveolar sacs of 
the rat lung at 21 days of age (Suzuki 1998). Bertram used the same rat model of maternal protein restriction 
and found that levels of 11β-HSD2 were reduced in protein restricted animals which inversely correlated 
with the levels of GR also present in relation to hypertension. These readings were taken over a large time 
span running from 2-20 weeks (Bertram 2001). Work looking at the early life origins of adult disease found 
that placental levels of 11β-HSD2 were linked with birth weight. It was also found that by inhibiting 11β-
HSD2 the birth weight of the rat is also reduced and the adults developed hypertension and hyperglycaemia 
(Seckl 1997). The impact of this alteration in levels implies a link between early life origins and development 
of disease in both rat and human models.  
The mineralocorticoid receptor (MR) protein, also known as NR3C2 (nuclear receptor subfamily 3, 
group C member 2), mediates the actions of aldosterone, including the increased reabsorption of sodium 
and consequently blood volume and pressure. It is a ligand dependent transcription factor which, upon 
ligand binding, dimerises and translocates to the nucleus where it binds to MR response elements and 
transcriptionally activates target genes (Strachan 2011). The ligands for MR include mineralcorticoids, such 
as aldosterone and deoxycorticoids, as well as glucocorticoids, like cortisol. Normally, the MR is “protected” 
from glucocorticoids by co-localisation of 11β-HSD2 that converts cortisol to inactive cortisone. In the lung, 
11β-HSD2 co-localises with MR in airway epithelium, suggesting that 11β-HSD2 may play an important role 
in pulmonary mineralocorticoid activity, such as sodium and fluid transport (Suzuki 1998).      Chapter 4  Results 
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4.3.3 Aims 
  Given that 1) DNA methylation can be altered globally by changes in maternal diet, 2) changes in 
DNA  methylation  have  been  seen  in  response  to  maternal  protein  restriction  and  3)  this  alteration  in 
methylation can affect the phenotype of the individual, we hypothesised that: 
vii.  Maternal protein restriction will significantly alter global DNA methylation in lung tissue of the F1 
offspring. 
viii.  These changes in global DNA methylation will also be evident in the F2 and F3 generations. 
ix.  These changes in DNA methylation will result in significantly different gene expression providing a 
mechanistic basis for the observation that maternal PR leads to altered lung physiology. 
To test these hypotheses, we aimed to extract DNA and RNA from lung samples harvested at 28, 120 and 
225 days of F1 offspring and assess the global DNA methylation and expression levels of candidate genes. To 
establish if potential changes in global methylation and/or gene expression induced by maternal PR were 
transgenerational in nature, we also aimed to harvest lung tissue from 28 day F2 and F3 generations and 
assess global DNA methylation and gene expression.     Chapter 4  Results 
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4.3.4 Materials and Methods 
For materials see section 2.3 
  Rat dams were allocated either C or PR diet from confirmation of pregnancy until term, and resulting 
male offspring were culled at F1 28 days, F1 120 days, F1 225 days, F2 28 days and F3 21 days for this part of 
the investigation. See section 3.1 for details on the animal model. Extraction of the DNA, RNA and Protein 
has been detailed in section 3.4.1. The global methylation assay was in kit form and is detailed in 
section 3.4.2. Once the RNA had been extracted it was used to generate cDNA ready for use with the 
primer sets (See section 3.4.3.). Each set of primers used was optimised and validated using pooled rat cDNA 
from  all  lung  samples  (See  section  3.4.4  and  3.4.5).  Gene  expression  was  compared  between  the  two 
treatment groups for all time points (See sections 3.4.6 and 3.4.7.). As described previously (see section 3.5) 
a Students-T test was used to determine the significance of any differences seen between the groups, with 
p<0.05 considered significant. 
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4.3.5 Results 
4.3.5.1 Pooled Global Methylation Results 
  Methylation of lung DNA was assessed in pooled samples for each treatment group from F1 28 day 
old, F1 120 day old, F1 225 day old, F2 28 day old and F3 21 day old rats. 
 
Figure 64: Pooled data for global methylation percentage at each time point for the different treatment groups. (F1, 
28 days, n=25; F1, 120 days, n=18; F1, 225 days, n=12; F2, 28 days, n=41; F3, 21 days, n=21) 
 
  No significant differences  were observed between treatment groups at the same time point or 
between time points for the same treatment group.  
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4.3.5.2 F1 225 Day Old Global Methylation Results 
Methylation of lung DNA was assessed in individual lung samples from the F1 225 day old rat group. 
 
Figure 65: Individual sample data for the 225 day old rats. X axis gives individual animal ID and indicate allocation to 
control and protein restricted groups. (C, n=6; PR, n=6) 
The F1 225 day old samples were chosen as the ones that were looked at individually as they 
showed the only significant difference in their lung structure. Each sample was measured in triplicate. The 
mean value for the methylation of the control group is 85.54, and the mean for the protein restricted group 
is higher, at 94.26 but not significantly different. There is a large variation in methylation levels between 
individuals within a treatment group and also between the triplicate samples from a single rat. 
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4.3.5.3 Sample Number and Type for Gene Expression 
Table 25 below indicates the number of samples that were pooled into their separate generation, 
age  group  and  treatment.  The  pooled  samples  were  used  for  acquisition  of  gene  expression  data.  To 
generate pools, 2µl of each pre-prepared cDNA samples were collected in fresh tubes dependent on age and 
treatment group allocation.  
Table 25: Table shows the number of samples that was used in each pooled sample for gene expression. 
Generation 
Age (days)  Treatment  Number of samples 
F1  28  Control  15 
Protein Restricted  10 
F1  120  Control  11 
Protein Restricted  7 
F1  225  Control  6 
Protein Restricted  6 
F2  28  Control  24 
Protein Restricted  17 
F3  21  Control  16 
Protein Restricted  5 
4.3.5.4 Reference Genes. 
When trying to quantify the relative expression of a gene it is important to make sure that the 
reference genes to which their expression is being compared are correct. A study by Cai et al. (2007) looked 
at the reference genes with a stable expression, within the different rat tissues, for use within low density 
arrays. The study looked at the best genes to use for several different tissues, including the lung. From this 
study the top five genes were, in order of preference, Rpl10a, Mapk14, FLJ20445, Taf91 and Map2k5 (Cai 
2007). 
The primer sets for these genes were obtained, however the genes proved difficult to optimise and 
were eventually replaced with other primer sets for other more recognised reference genes, β-actin, β-2-
microglobulin and ubiquitin C. These were optimised and used to produce standard curves for the entire 
pooled sample of rat lung cDNA.  
4.3.5.5 Standard Curves. 
A standard curve was created for all the gene sets. The dilution series was created 1 in 4 with 5 
dilutions giving the following concentrations. 
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Dilution  4
0  4
-1  4
-2  4
-3  4
-4  4
-5 
Concentration  1  0.25  0.0625  0.0156  0.0039  0.00098 
 
Standard curves were formed for the following genes: 
·  B2M  ·  BAC  ·  UBC  ·  ATP11α1 
·  HDAC2  ·  HDAC3  ·  HSD11β1  ·  HSD11β2 
·  IGF1  ·  IGF2  ·  MR  ·  Tp53 
 
A successful standard curve had an error of less than 0.2 and an efficiency of between 1.5 and 2.5. 
The duplicated samples should appear close together on the graph, with the samples points sometimes 
touch or over-laying another. The error value gives an idea of how close the replicated samples are. The 
efficiency value is ideally 2. This is because every time there is an amplification cycle the strands of cDNA 
should be copied by primers annealing on each strand, doubling the total amount of DNA in the reaction.  
 
Figure 66: Example of a standard curve found for UBC on 04-05-2010. The error for this curve was 0.0482 and the 
efficiency was 2.039. 
  There  was  no  amplification  of  the  no  template  control  samples,  indicating  that  there  was  no 
contamination in the samples from other sources. 
4.3.5.6 Comparison of Gene Expression. 
Pooled samples for each treatment at each time point were then tested for their relative gene 
expression for each of the genes that had satisfactory standard curve data.  
Each gene was compared to the expression of the reference genes for the same time point and 
expressed as a ratio of that reference gene’s expression. Using the expression level data obtained from the 
reference genes a minimum detectable difference for the genes was calculated as shown in the example for 
BAC and UBC below: 
=   (concentration of reference gene 1/concentration of reference gene 2) control group 
    (Concentration of reference gene 1/concentration of reference gene 2)treatment group 
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=  (23.13377/27.62174) 
   (22.95467/27.99596) 
 
=  0.837520373/0.820000457 
 
=  1.021365739 
 
This  indicates  that  any  difference  being  tested  that  is  above  1.022  is  not  due  to  experimental 
variability and could be real difference.   
4.3.5.7 Gene Expression Levels Compared Between Treatment Groups. 
4.3.5.7.1 Histone Deacetylases 
HDAC2 expression within the lung was assessed in pooled samples for each treatment group from F1 28 
day old, F1 120 day old, F1 225 day old, F2 28 day old and F3 21 day old rats. 
 
Figure 67: Gene expression data for HDAC2, showing the difference in expression between treatment groups at each 
time point using pooled samples. There were no significant differences (p=>0.05) between the expression levels of each 
treatment group or between each time point. (F1, 28 days, C, n=15, PR, n=18; F1, 120 days, C, n=11, PR, n=7; F1, 225 
days, C, n=6, PR, n=6; F2, 28 days, C, n=24, PR, n=17; F3, 21 days, C, n=16, PR, n=5) 
 
HDAC3 expression within the lung was assessed in pooled samples for each treatment group from F1 28 
day old, F1 120 day old, F1 225 day old, F2 28 day old and F3 21 day old rats.     Chapter 4  Results 
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Figure 68: Gene expression data for HDAC3, showing the difference in expression between treatment groups at each 
time point using pooled samples. There were no significant differences (p=>0.05) between the expression levels of each 
treatment group or between each time point. (F1, 28 days, C, n=15, PR, n=18; F1, 120 days, C, n=11, PR, n=7; F1, 225 
days, C, n=6, PR, n=6; F2, 28 days, C, n=24, PR, n=17; F3, 21 days, C, n=16, PR, n=5) 
4.3.5.7.2 Developmental Genes 
IGF1 expression within the lung was assessed in pooled samples for each treatment group from F1 28 
day old, F1 120 day old, F1 225 day old, F2 28 day old and F3 21 day old rats. 
 
Figure 69: Gene expression data for IGF1, showing the difference in expression between treatment groups at each time 
point using pooled samples. There were no significant differences (p=>0.05) between the expression levels of each 
treatment group or between each time point. (F1, 28 days, C, n=15, PR, n=18; F1, 120 days, C, n=11, PR, n=7; F1, 225 
days, C, n=6, PR, n=6; F2, 28 days, C, n=24, PR, n=17; F3, 21 days, C, n=16, PR, n=5) 
IGF2 expression within the lung was assessed in pooled samples for each treatment group from F1 28 
day old, F1 120 day old, F1 225 day old, F2 28 day old and F3 21 day old rats.     Chapter 4  Results 
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Figure 70: Gene expression data for IGF2, showing the difference in expression between treatment groups at each time 
point using pooled samples. There were no significant differences (p=>0.05) between the expression levels of each 
treatment group or between each time point. (F1, 28 days, C, n=15, PR, n=18; F1, 120 days, C, n=11, PR, n=7; F1, 225 
days, C, n=6, PR, n=6; F2, 28 days, C, n=24, PR, n=17; F3, 21 days, C, n=16, PR, n=5) 
Tp53 expression within the lung was assessed in pooled samples for each treatment group from F1 28 
day old, F1 120 day old, F1 225 day old, F2 28 day old and F3 21 day old rats. 
 
Figure 71: Gene expression data for Tp53, showing the difference in expression between treatment groups at each 
time point using pooled samples. There were no significant differences (p=>0.05) between the expression levels of each 
treatment group or between each time point. (F1, 28 days, C, n=15, PR, n=18; F1, 120 days, C, n=11, PR, n=7; F1, 225 
days, C, n=6, PR, n=6; F2, 28 days, C, n=24, PR, n=17; F3, 21 days, C, n=16, PR, n=5) 
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4.3.5.7.3 COPD Genes 
HSD11B1 expression within the lung was assessed in pooled samples for each treatment group from F1 
28 day old, F1 120 day old, F1 225 day old, F2 28 day old and F3 21 day old rats. 
 
Figure 72: Gene expression data for HSD11B1, showing the difference in expression between treatment groups at each 
time point using pooled samples. There were no significant differences (p=>0.05) between the expression levels of each 
treatment group or between each time point. (F1, 28 days, C, n=15, PR, n=18; F1, 120 days, C, n=11, PR, n=7; F1, 225 
days, C, n=6, PR, n=6; F2, 28 days, C, n=24, PR, n=17; F3, 21 days, C, n=16, PR, n=5) 
MR expression within the lung was assessed in pooled samples for each treatment group from F1 28 day 
old, F1 120 day old, F1 225 day old, F2 28 day old and F3 21 day old rats. 
 
Figure 73: Gene expression data for MR showing the difference in expression between treatment groups at each time 
point using pooled samples. There were no significant differences (p=>0.05) between the expression levels of each 
treatment group or between each time point. (F1, 28 days, C, n=15, PR, n=18; F1, 120 days, C, n=11, PR, n=7; F1, 225 
days, C, n=6, PR, n=6; F2, 28 days, C, n=24, PR, n=17; F3, 21 days, C, n=16, PR, n=5)     Chapter 4  Results 
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Table 26: Exact p values for the difference between each treatment group for each time point. 
Sample  HDAC 2  HDAC 3  HSD 1  IGF 1  IGF 2  Mr  Tp53 
F1 28d  0.306  0.611  0.539  0.431  0.899  0.891  0.291 
F2 28d  0.879  0.393  0.951  0.906  0.567  0.718  0.461 
F3 21d  0.669  0.115  0.376  0.480  0.241  0.446  0.270 
F1 120d  0.766  0.214  0.873  0.681  0.892  0.850  0.208 
F1 225d  0.278  0.551  0.609  0.434  0.722  0.647  0.439     Chapter 4  Results 
131 
 
4.3.6 Discussion 
4.3.6.1 Methylation 
  No difference in the global methylation levels between the two treatment groups was shown and 
the level of methylation did not change with the age of the rat either. This does not mean that there is no 
difference in the methylation levels for certain genes that are involved in the process of development or 
disease within the lungs. It may be that there are a set of genes that have been differentially-methylated in 
the PR group when compared with the controls, but this is off-set by an increase in methylation in another 
set resulting in no overall change in global methylation.   
There is also the possibility that there is an individual sample within the pooled rat samples that has 
an extremely altered level of methylation that has altered the position of the mean readings giving a false 
negative result, masking a real difference that could be observed if that individual was removed. To see if 
this was the case individual rat samples were assayed for their methylation levels within the F1 225 day old 
age group.  
The F1 225 day old group was chosen as it showed the only significantly different result in the 
structural analysis. Again no difference was seen between the two treatment groups and there was no 
obvious outlier from a single individual that could have skewed the pooled results. It could be that the levels 
of methylation are altered only at the gene level and off-set by an opposite effect on another gene. To see if 
this was the case individual genes were selected to see if their expression levels had been altered.  
Other studies have observed changes in methylation but these have either been with the addition of 
substances to induce a phenotype in an F0 animal, or the dietary challenges were more severe, such as high 
and low methyl-donor diets specifically tailored for the experiment. As such, results between this study and 
those are not directly comparable. It could be that the PR dietary challenge is not severe enough to produce 
an alteration in the global methylation profile. 
There is also the possibility that DNA methylation changes are not involved but another form of 
epigenetic regulation such as histone modification is. For example, exposure to a maternal low protein diet 
has been shown to result in reduced p 16 mRNA expression in the mammary glands of F1 offspring which 
was due to histone modifications and not DNA methylation changes (Zheng 2011). 
Any changes in global methylation are more likely to be due to alterations in Long Interspersed 
Nuclear Elements, LINE (Ohka 2011). These are repetitive elements in the DNA that can be methylated but 
do not have a specific function of related protein that is derived from them. Because of this it may be better 
to look at specific genes that are known to be involved in the process of interest.  Therefore the purpose of     Chapter 4  Results 
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the  gene  expression  analysis  was  to  identify  genes  that  were  differentially  expressed  so  gene  specific 
methylation could be assessed. 
4.3.6.2 Gene Expression  
Some genes and the top five reference genes did not produce a valid standard curve. This may be 
because the cDNA was not of a high enough quality, although the RNA was put through a DNAse treatment 
twice to ensure that there was little or no DNA contamination within the samples. The RNA absorbance 
curves and ratios also suggested that these samples were not contaminated, but this could still be the cause 
of the lack of standard curve.  
It  could  be  that  the  primers  for  the  sections  of  cDNA  were  not  completely  binding,  and  so  a 
disruption of the copying was observed. The RT-PCR kit was used as per the kit instructions and so this stage 
of the procedure should have worked correctly. It may also have been that the cDNA samples had been 
freeze thawed too often and the lengths of cDNA had been broken down into smaller pieces that were not 
of a long enough length to give an accurate estimation of gene expression.  
4.3.6.2.1 HDACs 
There was no difference in the expression of the HDACs between the two treatment groups. This 
could mean that the process of histone acetylation is not involved in the mechanism behind the disease 
processes within the lung. However it may be that we are looking at the wrong gene. It may be that another 
gene that is involved in the regulation of HDACs has an altered expression. As the expression of these 
proteins has been shown to be altered in human disease (COPD) it may just be that this mechanism is not as 
important in baseline lung physiology in the rat.  
4.3.6.2.2 Developmental Genes 
  Genes that are involved in the developmental process were of interest as if a gene that is meant to 
be switched off is still being expressed, or has an increased expression, this could lead to the alteration of 
the structure of the lungs or a more severe, or repressed, reaction to certain stimuli. No genes within this 
class were found to be differentially expressed between the two groups.  
The lack of a difference in these could indicate that there is not a difference seen, or it could be due 
to the same factors as those discussed in relation to the HDACs above; wrong genes being looked at, other 
unlinked genes are regulating the process, or they are not the important genes within the mechanism being 
looked at. Alteration in the expression levels of developmental genes usually involve a difference in the 
structure of the tissue, in this case the lung, that is involved, even with complex disorders (Courchesne 
2001). As there was no structural differences found in the morphometry section it was unlikely that these     Chapter 4  Results 
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genes were the ones whose expression was altered. The only difference that was noted was a difference in 
the expression profile of IGF2 between time points. As the rats age increased the expression level of this 
gene decreased, however due to the variance of the results this finding was not statistically significant. 
4.3.6.2.3 Asthma Genes 
  There were no differentially expressed genes identified in this class of genes for this investigation. 
This could be due to a lack of challenge that is used in humans to activate these genes before initiation of 
the phenotype. It may be that the focus is on the wrong gene, with another being the cause of the disease 
outcome.  
4.3.6.2.4 COPD Genes 
  As with the asthma genes there was no difference in expression within this group of genes either.  It 
could be that the alteration of these genes is done through exposure to tobacco smoke, as it is the biggest 
risk  factor  for  developing  COPD.  It  may  be  that  if  these  animals  had  been  exposed  to  tobacco  smoke 
alterations in gene expression would have been seen.  
Association studies that have linked some of these genes with respiratory disease could have been 
picking up the association of another gene in which polymorphism predisposed to these diseases that was in 
linkage disequilibrium with the genes mentioned. This means that a gene very close in physical location was 
actually linked with the disease but that gene was not the one highlighted as it had less reason to be linked. 
It could also be that the genes being looked at are not affected but another that is in that genes functional 
pathway has been altered making it the regulatory step for the process.  
In contrast with results seen previously from the gene expression of these rats the Hsd11β2, IGF1, 
IGF2, Pcdh1 and Tp53 genes were found to have significantly increased expression in the protein restricted 
rats, and the ADAM33, Atp1α1, Atp1α2 and GR genes were found to have a decreased expression in the 
protein restricted rats (Rose-Zerilli 2010). These results were only found between the 120 day old treatment 
groups as these were the only ones investigated. However, these results could not then be replicated in later 
samples. This could have been due fragile cDNA from these samples breaking down into small fragments 
that could then not be used as a template.  
The difference between these results and those found in this investigation could be due to the age 
of the samples. The same lung tissue was used to extract the RNA and so it had been thawed again between 
the two extraction time points. It could also be that the primers used were older for this investigation.     Chapter 4  Results 
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4.3.6.3 Future Directions 
Future  work  from  this  investigation  could  be  to  look  at  unique  cell  types  using  laser  capture 
microdissection. This would give the gene expression profile from these individual cells. It could be that an 
increase in one gene in one type of cell is counteracted by a decrease in another cell type. By individually 
selecting a single cell type the unique gene expression profile will be revealed.  
 As the gene expression looked at within this investigation was targeted to look at specific genes the 
use of global gene expression profiles using microarrays could point us towards other genes that are either 
up or down steam of the ones looked at, that are the regulating step in the pathway. As asthma and COPD 
are complex diseases there are many more than one specific gene regulating their phenotype and so a global 
gene expression array gives a wider view point. For example one study used this approach to look at the 
gene expression profile of different parts of the rat brain to identify new pathways of degradation. This was 
done by extracting and purifying the RNA, from the isolated cell types of interest, and hybridising it to a rat 
genome 230 2.0 array (Affymetrix). The raw data was analysed and any differences in gene expression levels 
across the entire genome were discovered (Hedlund 2010). 
An allergen exposure, asthma challenge, or a tobacco smoke exposure, COPD challenge, may have 
activated alterations in gene expression that are not seen before the animals have been challenged. There 
are models involving postnatal challenge that recapitulate features of asthma and COPD in the rat. For 
example repeated exposures to inhalation of 10g/L of either saline (control) or ovalbumin (challenge) for a 
period of 30 minutes will cause remodelling in rat airways (Birrell 2005). 
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5. General Discussion 
5.1 Summary of Findings 
5.1.1 Physiology and Morphometry 
  In response to a 50% reduction in protein content (in an otherwise isocalorific diet) of maternal diet 
from confirmation of pregnancy until birth, comprehensive morphometric analysis of the lungs found no 
significant differences between the control and PR groups in F1 28 day old, F1 225 day old or F2 28 day old 
male  offspring  in  any  morphometric  measurements  of  lung  structure.  This  contrasts  with  previous 
observations of the effect of maternal calorific restriction within the rat. Chen et al. (2004) found that body 
weight, lung volume and alveolar surface area were reduced in response to maternal nutritional restriction. 
However, there are significant differences between the study of Chen et al. and the current study in both the 
type  and  timing  of  the  nutritional  challenge.  In  the  study  of  Chen  et  al.,  mothers  experienced  a  50% 
reduction in total food given, but only during the last trimester of gestation, from day 15-21 of gestation. 
This could account for the difference seen between studies in the effect of maternal nutritional restriction 
on lung development. As discussed in section 4.1 the Southampton protein restriction model reduces the 
protein content of the diet but the diet is isocalorific, through increasing the carbohydrate content, and no 
effects are seen on offspring bodyweight.  
Equally, studies of the effects of reduced nutritional intake on offspring lung development in sheep 
have  shown  alterations  within  the  lung.  Reduced  nutritional  intake  induced  by  umbilico-placental 
embolisation during late gestation, 120 days to term (147 days) has been shown to result in increased 
alveolar wall thickness, small number of alveoli and a greater volume density within the lungs of offspring. 
These alterations are more significant in animals at 8 weeks postpartum than those of a younger age (Maritz 
2001).  A  later  study  undertaken  using  the  same  exposure  found  that  the  alterations  seen  at  8  weeks 
postpartum persisted at age 2 years, indicating that the effects of in utero diet can lead to changes in lung 
structure that persist into adult life (Maritz 2004). 
5.1.1.1 Sample Size 
One of the biggest limiting factors of this study was the number of samples that were included. In a 
post-hoc power calculation an estimated 60 animals would be required to accurately observe a significant 
difference between the two groups with respect to the smallest of the airways components, the airway 
muscle, with a power of 80% and α=0.05. The most likely reason for this large number of required animals is 
the amount of variation that is seen between rats.     Chapter 5  General Discussion 
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Within this study the actual numbers of animals used was much lower, with sample groups selected 
based on previous observable differences in blood pressure between groups (Torrens 2008). However, it is 
interesting  to  note  (while  bearing  in  mind  the  differences  between  the  studies  noted  above),  that 
morphometric differences were seen in the study by Chen et al. (2004) with group sizes of 6-8. Undertaking 
a retrospective power calculation using the data from Chen et al. to observe the size difference noted with 
80% power and α=0.05 would require a minimum group size of 8, if the PR model induced the same degree 
of effect as the 50% total nutrient restriction exposure. This implies that the difference between the two 
diets results in a difference in the size of effect seen. 
5.1.1.2 Timing of Exposure 
Changes in timing of diet given are also of importance as developmental windows alter during the 
progression of pregnancy. As evidenced by the study of the Dutch Hunger Winter cohort, exposure to famine 
during early and mid gestation had an effect on respiratory disease outcome in the offspring, but not late 
gestational exposure. If dietary restriction was started before conception, a reduction in protein could have 
a greater effect on the methylation profile of the offspring. This is due to the fact that the methylation 
patterns on the maternal and paternal gametes are stripped and then replaced as soon as fertilisation 
occurs.  With  a  reduction  in  available  protein  providing  fewer  methyl  groups,  less  methylation  of  the 
offspring genome could be a resulting effect.  
Starting restriction at an earlier time point may also have an effect on the methylation patterns laid 
down in the gametes of the parents and hence alter the methylation pattern in the offspring. A study that 
reduced the amount of methyl donors given to rat dams, from 3 weeks prior to conception until 5 days after 
the birth of the offspring, observed a type II diabetes phenotype in the male, but not female, adult offspring 
(Maloney 2011).  
In the rat a larger majority of the lung is developed after birth in comparison to humans (see section 
1.5.2), and so increasing the time the diet is given, such as continuing on until weaning, could have a greater 
effect on the lung, as with the current dietary challenge plan the mothers are back onto a normal diet once 
the offspring have been born. 
5.1.1.3 Type of Nutrient Restriction Exposure 
Other alterations that could be included in this model are changes in the composition of diet given. 
As discussed above, other more severe diets, such as 50% total reduction in nutrition during the mothers’ 
pregnancy, have been shown to alter the structure of the lungs (Chen 2004; Chen 2007). A more severe 
challenge  is  less  likely  to  occur  within  normal  conditions  in  the  general  population,  but  could  give  an 
indication of the types of effects that could be seen, and the mechanisms involved, in prenatal programming     Chapter 5  General Discussion 
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of lung development. These could be then followed up in a more targeted approach in a model more 
reminiscent  of  normal  exposure  variation  in  the  general  population  such  as  maternal  PR.  The  other 
possibility is that although the airways appear normal they are more prone to damage when challenged with 
a post-natal stimulus and so they are ‘primed’ for respiratory disease. 
5.1.1.4 Parent of Origin Effects 
  In  humans  transgenerational  effects  have  been  shown  to  be  inherited  in  a  sex  linked  manner, 
grandfather to grandson, and grandmother to granddaughter (Kaati 2007). This has also been observed in 
animal models where paternal (father’s) diet exposure has been shown to result in epigenetic programming 
and phenotype changes. The use of a high fat diet given to rat sires, from weaning until sexual maturity, 
resulted in β-cell dysfunction in the daughters, which was found to be linked with the differential expression 
of several genes involved in the related pathways (Ng 2010). Another study, in mice, observed a paternal low 
protein diet, from weaning until sexual maturity, caused an increase in the expression of genes involved in 
lipid and cholesterol biosynthesis within the livers of the offspring; this was linked with an alteration in the 
methylation  of  the  cytosines  in  this  tissue  (Carone  2010).  Therefore  it  may  be  possible  that  paternal 
exposure may result in bigger phenotypic/methylation/gene expression changes than maternal exposure in 
male offspring as assessed in this study. Alternatively, larger differences in female offspring phenotype may 
be induced in response to maternal PR than those observed in male offspring in this study. 
5.1.2 Bronchial Hyperresponsiveness   
As previously mentioned (section 1.2.2), BHR is one of the defining characteristics of human asthma. This 
study observed increased BHR in the 75 day old F1 rats in response to maternal PR. However, a significant 
difference was not seen in the younger 35 day old rats. This effect, of alterations in lung phenotype being 
larger in older offspring, has also been seen in sheep (Maritz 2004). A possible explanation for this could be 
that the offspring sacrifice another system in order to achieve maturity in peak condition and this then 
declines as they age, and they can no longer stave off the effects of the in utero diet causing BHR. It could 
also be that the exposure of the rats to normal air currents and/or mechanical effects of stretch in postnatal 
life makes the BHR phenotype apparent, and that this takes time for the effects to develop.  
The increase in BHR observed could be linked with the increase in smooth muscle that has been seen in 
the morphometric analysis of the F1 225 day old rats. In this group the PR rats had significantly increased 
smooth muscle (p=0.046) around the vessels within the lung. Although there was no difference seen in the 
airways components, the sample size could have been too low to identify this morphometrically, but was 
enough to result in the BHR phenotype seen in the offspring. Alternatively, as these rats have not been 
exposed to any stimuli, the bronchi have become hypersensitive to CCh due to epigenetic alterations and     Chapter 5  General Discussion 
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that this would lead to increased bouts of constriction in a normal environment due to exposure to inhaled 
allergens. 
However, while significant alteration in the reaction of the protein restricted group compared with the 
control  groups  to  bronchoconstriction agents  was  observed, this  does  not  imply  that these phenotypic 
changes result from epigenetic differences induced by maternal PR, as hypothesised at the start of the 
investigation. Differences in the BHR phenotype may result from a direct effect of the in utero environment 
on lung development. To confirm if the BHR effect is indeed a result of epigenetic programming, a number of 
additional  investigations  would  need  to  be  made.  Firstly,  assessment  of  CpG  specific  DNA  methylation 
differences in bronchial smooth muscle between groups. Secondly, if an observable difference in smooth 
muscle cell function in vitro between groups could be observed, then methylation marks could be removed 
by culturing cells in 5-deaza-Cytidine to assess whether this alters cellular phenotype. Thirdly, if the BHR 
phenotype could be shown to be transgenerational, with observable effects in the F2 and F3 generations, 
this  would  also  imply  that  the  phenotype  was  the  result  of  epigenetic  programming,  specifically  DNA 
methylation which is the only epigenetic mark known to be transmitted between generations. 
With respect to the use of a rat model to assess lung physiology, a number of reagents that cause the 
human bronchi to constrict are not effective in the rat. These include histamine, which is broken down as 
soon as it enters the rat lung by histaminases (Rose 1940), and angiotensin II. However the rat bronchi did 
constrict  in  a  concentration-dependent  manner  to  the  thromboxane  mimetic  U46619  and  carbachol, 
mimicking the response seen in the human bronchi. The bronchodilators that were used did not result in 
significant  relaxation  of  the  bronchi  once they  had been constricted.  A  slight  relaxation  to  salbutamol, 
isoprenaline and BRL37344 was observed and a total relaxation to the last dose of papaverine was also 
observed. These reagents do not seem to mimic the responses seen in the human lung. It could be that the 
receptors which cause the relaxation in the humans lung are not present in the rat, or that although they are 
present they are at low concentrations and so do not result in the same strength of reaction.  
There is evidence of developmental programming of asthma in humans with several studies having 
linked  a  low  birth  weight,  from  both  premature  babies  and  those  who  suffered  undernutrition,  with 
increased risk of developing asthma in later life and BHR (Chan 1988). Thus the results of this study are 
significant, as they provide confirmatory evidence to support the concept that asthma susceptibility is, at 
least  in  part,  determined  by  in  utero  environmental  exposure.  This  raises  the  possibility  of  dietary 
intervention in pregnant women to reduce the risk of developing asthma in their children. As parental 
asthma is a significant risk factor for the development of asthma in the child (Arshad 2011), this would allow 
targeting of such intervention to those at highest risk.     Chapter 5  General Discussion 
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5.1.3 Methylation and Gene Expression 
  In the antenatal period, it has been clearly demonstrated that maternal environmental exposures 
have the capacity to influence lung development. There is very strong evidence that maternal smoking in 
pregnancy has adverse effects on fetal lung development and asthma risk (Gilliland 2000; Hylkema 2009). 
This  includes  increased  responsiveness  to  methacholine,  smooth  muscle  layer  thickness,  and  collagen 
deposition. Altered DNA methylation patterns have been observed in several genes in buccal cells from 
children exposed in utero to tobacco smoke, which may be a likely mechanism for increased risk of diseases 
(Hylkema 2009). Similarly, and perhaps more closely related with altered immune system development, 
maternal infections and the use of antibiotics have been associated with an increased risk for allergic airways 
disease (McKeever 2002), as have the level of specific micronutrients within the maternal diet (Chatzi 2008; 
Hollingsworth 2008), maternal stress levels (Gheorghe 2010), and exposure to pollutants (Liu 2008), all of 
which have been associated with epigenetic changes in a range of cell types and tissues (Martino 2011). 
Given the observation that surrogate markers of exposure to nutrient restriction in humans, e.g. birth weight 
and early growth, had been observed to be associated with asthma susceptibility in humans (Lopuhäa 2000) 
and that the Southampton PR model had previously been shown to result in changes in DNA methylation at 
specific gene promoters (Lillycrop 2007) we hypothesised that exposure to maternal PR would result in 
altered DNA methylation in the lungs of offspring exposed to maternal PR in utero. 
This study found no difference in the global levels of methylation in DNA from the lungs or in the gene 
expression levels of the individual transcripts that were targeted. Previous investigation into this area using 
the PR model observed, in lungs from 120 day old rats, a difference in expression of Hsd11β2, IGF1, IGF2, 
Pcdh1 and Tp53 genes (increased expression levels) between PR and control groups (Rose-Zerilli 2010). This 
study did not find these alterations in gene expression levels. As previously stated, in section 4.3.6.2.4, this 
could be due to the age of the samples. The same lung tissue was used to extract the RNA and so it had been 
thawed again between the two extraction time points. This could have degraded the RNA, which is plausible 
as these results could not be replicated. Alternatively, the previous observation could have been the result 
of type I error (false positive). 
  Alteration  of  methylation  and  specific  gene  expression  levels  could  be  primed  by  the  dietary 
challenge but, as asthma is a complex disease, require a postnatal environmental stimulus to initiate these 
changes. In animal studies, an asthma like phenotype can be induced by sensitisation to allergens, such as 
ovalbumin  or  the  house  dust  mite  allergen  Der  p  1  (either  by  intra-peritoneal  injection  with  alum  or 
repeated  aerosol  exposure),  followed  by  allergen  challenge  by  an  inhaled  route  (intranasal  or  aerosol 
exposure) (Nabe 2005).     Chapter 5  General Discussion 
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  With assessment of global methylation levels, it is the methylation of repeated elements of DNA that 
dominate the measurement. This means that the individual methylation within the promoters of the gene 
involved in diseases processes are not closely examined. To do this candidate genes can be selected and 
their expression levels analysed, as done within this study. However, targeting of individual gene is difficult 
due to the many different genes that make up either A) a certain pathway of interest within a disease or B) a 
mechanism of regulation within the disease. There are other methods that could have been used such as 
whole genome gene expression, which can then mapped back to the gene involved to ascertain if there 
could be a link with the disease, or gene expression of entire pathways that are involved within the disease. 
5.1.4 Southampton Model of Protein Restriction 
The nutritional challenge that the mothers are exposed to during their pregnancy has been detailed in 
section 3.1. This challenge has no overall altered calorific intake; as a result no significant difference in the 
body weights of the offspring should occur. A non-significant difference in the body weights was seen that 
followed the same trend has been seen previously in other studies using this model (Torrens 2002; Rodford 
2008). However several studies have shown that a more severe nutritional challenge can alter the body 
weights of the offspring (Chen 2004). These challenges almost always involve an extreme dietary challenge 
such as a total reduction in nutritional intake by 50%.  
  The Southampton model has been shown to have effects that are similar to those seen in a human 
population.  The dietary  exposure is also  more  common place in  the  human  population  as  exhibited  in 
mothers who are vegetarian and do not take the appropriate supplements to counter act the effect of a 
reduced level of protein within the diet.  A complete reduction of 50% of nutritional intake during pregnancy 
is only seen in extreme famine conditions for which there is no comparable data and is unlikely to be seen in 
the general population.      Chapter 5  General Discussion 
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5.2 Future Directions. 
5.2.1 Protein Restriction Model 
  In the current study, a nutritional exposure involving a reduction in protein content of 50% in the 
maternal diet that is made up with carbohydrates making it a very mild restriction that has no overall calorie 
difference. This is a model that mimics exposures more commonly seen within a human population not 
exposed to extreme starvation. 
  The  protein  restriction  model  has  been  shown  to  have  an  effect  on  the  responsiveness  of  the 
bronchi. In humans, repeated contraction of the bronchi in response to either methacholine or inflammation 
induced bronchoconstriction can cause airway remodelling to occur in non-asthmatic individual’s bronchi 
(Grainge 2011). However, no remodelling was observed in the F1 or F2 offspring lungs in this study.  It could 
be that the maternal dietary challenge has primed the asthmatic phenotype, but that due to a lack of 
postnatal exposure this phenotype has not been expressed. The introduction of number of challenges, such 
as those utilised in animal models of asthma, could shift the phenotype from one that is primed to one that 
is expressed within the structure of the lungs.  The most commonly used asthmatic challenge within animal 
models is sensitisation with an interpreitoeal injection of ovalbumin, followed by aerosol challenge (Nabe 
2005). It would be interesting to observe whether BHR responses in vivo using whole animal measurement 
of lung function would show an enhanced BHR phenotype in response to allergen challenge in the PR group 
in comparison to control and whether this results in increased airway remodelling. Alterations in the timing 
and type of dietary challenge could also be considered, see sections 5.1.1.2 and 5.1.1.3. 
5.2.2 Humans 
  The use of animals models give an idea of what could be happening due to an alteration in the level 
of protein intake during pregnancy. However, a normal human diet would not suddenly have a reduction in a 
single  food  group,  and  data  derived  from  animal  models  does  not  always  fit  when  compared  back  to 
humans. The use of detailed dietary data during pregnancy and a closely followed up birth and life of a 
human child could either prove, or disprove, the ideas suggested within this thesis. Several cohorts have 
collected the data required to start an investigation into this area. A correlation between dietary intake of 
specific nutrients during pregnancy and bronchial hyperresponsiveness has already been identified in the 
Southampton  Women’s  Survey  cohort  (Pike  2011).  Other  studies  into  the  exact  dietary  program  could 
highlight the more important food groups to be included for a reduction in the offspring risk of developing 
respiratory diseases later in life.   
Other  studies  that  have  examined  maternal  diet  during  pregnancy  have  been  undertaken 
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pregnancy. There are several problems with this, mainly the effect of misreporting of food consumption. A 
nine month period is a long time to remember the information needed and the consumption of foods that 
are perceived to be bad may be under-reported by the mother concerned. Due to this fact, most studies 
have focused on a certain food group or a certain, regional, type of diet. For example, a study by Chatzi et al. 
looked at the effect of a Mediterranean diet. This diet is high in fruit and vegetables, as well as wholegrain 
bread and cereals, and low in dairy, eggs and red meat. This results in decreased levels of fatty acids and 
increased levels of carbohydrates, fibre and anti-oxidants. Children of mothers who consumed this diet 
during pregnancy were found to have a decreased risk of developing asthma and allergy (Chatzi 2007; Chatzi 
2008). However, it is possible that this observation is confounded by high similarities between maternal diet 
during pregnancy and the child’s diet postnatally. 
5.2.3 Methodology 
Alterations in DNA methylation, and the subsequent change in gene expression levels, could be 
investigated  in  a  different  manner  that  would  allow  a  hypothesis  independent  approach.    The  use  of 
genome-wide expression arrays could be used to identify differentially expressed genes followed by targeted 
DNA methylation analysis of those genes or an array based method to identify differentially methylated 
sections of DNA and the gene involved in those sections could then be assessed for expression levels. For 
example, a study by Weinhouse et al. of supplemental increase of 50mg bisphenol A (BPA), during gestation 
and  continued  through  until  weaning,  utilised  genome-wide  gene  expression  analysis  to  identify 
differentially expressed genes in the liver of 22 day old male mouse offspring. In this study, 2 genes (Glcci1 
repeat 1 and Glcci repeat 2) were identified as having metastable epialleles that are differentially expressed 
as  a  result  of  maternal  BPA  exposure  and  the  authors  went  on  to  show  that  the  differences  in  gene 
expression  were  due  to  alterations  in  DNA  methylation  of  specific  CpG  sites  in  both  of  these  genes 
(Weinhouse 2011). 
This  study  has  linked  maternal  diet  during  pregnancy  with  increased  risk  of  BHR,  a  defining 
phenotype for asthma. Although there have been no other altered results in the offspring lungs this could be 
due  to  the  lack  of  allergen  challenge/environmental  exposure  needed  by  most  respiratory  diseases  to 
express the disease phenotype.   
Other questions that need to be considered in further work would be: 
·  Is the BHR observed sex specific or would it also be observed in female offspring? 
·  Would this also be shown in F2 and F3 generations, as has previously been observed for blood 
pressure?     Chapter 5  General Discussion 
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·  Would  an  allergen  challenge  produce  a  BHR  phenotype  at  a  younger  time  point  or  result  in 
enhanced airway remodelling in PR offspring? 
·  Does an identical biochemical mechanism resulting in altered smooth muscle functionality underlie 
the observation of BHR in airways and raised blood pressure in vessels in response to maternal PR? 
·  Does  the  increased  smooth  muscle  surrounding  pulmonary  vasculature  lead  to  pulmonary 
hypertension  as  has  been  previously  observed  in  rats  in  response  to  a  more  severe  maternal 
nutritional restriction?      
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Appendix 1: Nugget Effect for Smooth Muscle. 
Sample data for the first grid trialled for used in stereology analysis. 
  Pi  Pi x Pi  Pi x Pi(+1)  Pi x Pi(+2) 
1  0  0  0  0 
2  0  0  0  0 
3  0  0  0  0 
4  55  3025  0  0 
5  0  0  0  0 
6  0  0  0  0 
7  77  5929  231  0 
8  3  9  0  0 
9  0  0  0  0 
10  0  0  0  0 
11  13  169  0  26 
12  0  0  0  0 
13  2  4  0  2 
14  0  0  0  0 
15  1  1  16  - 
16  16  256  -  - 
Total  167  9393  247  28 
    A  B  C 
 
A(p) = 8x9 
         = 72mm 
Correct for magnification = 72/30000 
                                             = 0.72 
T = thickness of sections = 5um 
Variance  = ∑Pi x A(p) x t 
  = 167 x 0.72 x 5 
  = 6.68 x 10
-5 mm
3 
Nug = 0.0724 x 10 x √(n x ∑Pi) 
        = 37.4 
Variance of sum of total area = (3(A-Nug)-4B+C)/12 
        = (3(9393-37.4)-(4x247)+28)/12 
        = 2258.9 
Nug + Variance of total area = 37.8 + 2258.9 = 2296.3      
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CE = (√2296.3/167) x 100 
  = 28% (As this is above 10% a grid with closer points will have to be used) 
Nug = (100 x 37.8) / 2296.3 
         = 1.63% (As this is below 5% the grid is fine for this effect) 
As both the percentages were not below their respective values a smaller grid will be trialled to see 
if it is appropriate for this investigation. 
 
Nugget effect for smooth muscle with second grid 
Sample data for the second grid trialled for used in stereology analysis. 
  Pi  Pi x Pi  Pi x Pi(+1)  Pi x Pi(+2) 
1  61  3712  1952  12566 
2  32  1024  6592  5888 
3  206  42436  37904  3502 
4  184  33856  1972  21344 
5  17  289  1472  1564 
6  116  13456  17940  22620 
7  92  8464  23790  11224 
8  195  38025  10248  16380 
9  122  14884  9744  1952 
10  84  7056  20416  14784 
11  116  13456  2816  14268 
12  176  30976  21648  4576 
13  123  15129  3198  13653 
14  26  676  2886  6344 
15  111  12321  27084  - 
16  244  59536  -  - 
Total  1905  295305  189662  150665 
    A  B  C 
 
A(p) and t are the same as above as the magnification  and thickness of sections has not been 
altered. 
Variance  = ∑Pi x A(p) x t 
  = 1905 x 0.72 x 5 
  = 6858 mm
3 
Nug = 0.0724 x 10 x √(n x ∑Pi) 
        = 126.4 
Variance of sum of total area = (3(A-Nug)-4B+C)/12      
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        = (3(295305-126.4)-(4x189662)+150665)/12 
        = 23129.4 
Nug + Variance of total area = 126.4 + 23129.4 = 23255.8 
CE = (√23255.8/1905) x 100 
  = 8% (As this is below 10% the grid is fine for this effect) 
Nug = (100 x 126.4) / 23255.8 
         = 0.5% (As this is below 5% the grid is fine for this effect) 
As both the percentages were below their respective values this grid is appropriate for this 
investigation and so will be used. 
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Appendix 2: Primer Sets 
 Appendix 2: Primer sets for gene expression assays 
Gene 
name 
Target or reference  Assay 
type 
Intron spanning  Forward primer   Reverse primer 
Adam33  Target (IUGR marker)  UPL  Yes  TAGTGGCCCTGCACAGTCT  TGGTAGTAGCACCAGGCTAGG 
Atp1a1  Target (IUGR marker)  SYBR 
green 
Yes  TGGATCAATGATGTGGAGGA  CAATATTCCTCTGCTCGTAGG 
Atp1a2  Target (IUGR marker)  SYBR 
green 
Yes  GACCTCATCATTTGCAAGACC  CTAGCAGCCCAAAAATCAGG 
Gr  Target (IUGR marker)  TaqMan  Yes  TGCATGTATGACCAATGTAAACACA  CCTTCCTTAGGAACTGAGGAGAGAA 
Hsd11b1  Target (IUGR marker)  SYBR 
green 
Yes  TGTCCTCGGCTTCATAGACA  GCGCAGAACTGTGCCTTT 
Hsd11b2  Target (IUGR marker)  SYBR 
green 
Yes  GGGGTATCAAGGTCAGCATC  TCCCAGAGGTTCACATTAGTCA 
Igf1  Target (IUGR marker)  SYBR 
green 
Yes  CGGCCTCATAATACCCACTC  AAGACGACATGATGTGTATCTTTATTG 
Igf2  Target (IUGR marker)  SYBR 
green 
Yes  CGCTTCAGTTTGTCTGTTCG  GCAGCAACTCTTCCACGATG 
MR  Target (IUGR marker)  SYBR 
green 
Yes  CAAATACCCCAGCAAGCAGT  CTGTGCTGTGATGGATCCTG 
Pcdh1  Target (IUGR marker)  UPL  Yes  GAGAGCACTGCCCACCAG  AACATCTCGAAGCGCTCAC 
Tp53  Target (IUGR marker)  SYBR 
green 
Yes  GACTCTGTAAAGCAGTTCTACACCAA  GGGCACCTGTGGTGCTAC 
Ucp2  Target (IUGR marker)  SYBR 
green 
Yes  TAGTGGCCCTGCACAGTCT  TGGTAGTAGCACCAGGCTAGG 
HDAC2  Target (methylation 
marker) 
SYBR 
green 
Yes  ATGCTGAAGAGAGGGGTCCT  TCATAGAATTCATTGGGTGCTTC 
HDAC3  Target (methylation 
marker) 
 
 
SYBR 
green 
Yes 
 
 
CGCTGACTCCCTCTCTGGT  TCACTACTTCTACACATTTAGCGTGA      
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Gene 
name 
Target or reference  Assay 
type 
Intron spanning  Forward primer   Reverse primer 
HDAC8  Target (methylation 
marker) 
SYBR 
green 
Yes  GTGGGAATTGGCAAGTGTCT  CCGTGTTGGCAAGGTTGTA 
Actb  Reference 
(endogenous 
control) 
TaqMan  Yes 
CGTGAAAAGATGACCCAGATCA  CACAGCCTGGATGGCTACGT 
B2m  Reference 
(endogenous 
control) 
TaqMan  Yes 
ACTCTGAAGGAGCCCAAAACC  TCCAGATGATTCAGAGCTCCATAG 
Ubc  Reference 
(endogenous 
control) 
TaqMan  No 
CGTACCTTTCTCACCACAGTATCTAGA  GAAAACTAAGACACCTCCCCATCA 
           
 
 
 
 
 
 
 
 
 
 
 